Custom Report with Litter-Based Statistics

NTP Study Number:	C20105B		
Lock Date:	12/29/2015		
Cage Range:	ALL		
Date Range:	ALL		
Reasons For Removal:	25022 ACCK	25021 TSAC	25020 NATD
	25019 MSAC		
Removal Date Range:	ALL		
Treatment Groups:	Include ALL		
Study Gender:	Both		
TDMSE Version:	2.5.0.0_sfh		
PWG Approval Date:	NONE		

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF CELL PHONE RADIATION: CDMA

MALE RATS

Organ	Morphology
Adrenal Cortex	Hypertrophy
	Necrosis
	Vacuolation, Cytoplasmic
Adrenal Medulla	Hyperplasia
Aorta	Dilation
	Mineral
Bone Marrow	Hemorrhage
Bone	Fibrous Osteodystrophy
Brain	Compression
	Necrosis
Brain: Choroid Plexus	Mineral
Brain: Pineal Gland	Vacuolation, Cytoplasmic
Epididymis	Exfoliated Germ Cell
	Hypospermia
Eye: Cornea	Inflammation Acute
	Neovascularization
	Ulcer
Eye: Cornea, Epithelium	Hyperplasia
Eye: Retina	Atrophy
Harderian Gland	Hyperplasia
	Inflammation Granulomatous
Heart: Artery	Mineral
Heart: Endocardium (All)	Hyperplasia Schwann Cell
Heart: Endocardium or Mycardium	Hyperplasia Schwann Cell
Heart: Endocardium	Hyperplasia Schwann Cell
Heart: Myocardium	Mineral
Heart: Ventricle Right	Cardiomyopathy
Intestine Large, Cecum	Edema
	Erosion
	Inflammation Acute
	Ulcer
Intestine Large, Cecum: Artery	Inflammation Chronic

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF CELL PHONE RADIATION: CDMA

Intestine Large, Cecum: Epithelium	Regeneration
Intestine Large, Colon: Artery	Inflammation Chronic
Intestine Large, Colon: Epithelium	Regeneration
Intestine Large, Rectum: Epithelium	Regeneration
Kidney: Renal Tubule	Cyst
Liver	Eosinophilic Focus
	Mixed Cell Focus
Liver: Bile Duct	Hyperplasia
Lung	Congestion
	Inflammation Granulomatous
Lung: Artery	Inflammation Chronic
Lung: Interstitium	Inflammation Chronic
Lymph Node, Mandibular: Lymphatic Sinus	Ectasia
Lymph Node, Mesenteric	Erythrophagocytosis
Lymph Node: Iliac, Lymphatic Sinus	Ectasia
Lymph Node: Renal	Erythrophagocytosis
Lymph Node: Renal, Lymphatic Sinus	Ectasia
Mesentery: Artery	Inflammation Chronic
	Mineral
Nerve Trigeminal	Degeneration
Nose	Inflammation
	Inflammation Chronic
Nose: Olfactory Epithelium	Accumulation, Hyaline Droplet
Pancreas: Acinus	Hyperplasia
Pancreas: Artery	Inflammation Chronic
	Mineral
Parathyroid Gland	Hyperplasia
Pituitary Gland: Pars Distalis	Cyst
Pituitary Gland: Pars Intermedia	Cyst
Prostate	Inflammation Acute
Prostate: Epithelium	Hyperplasia
Salivary Glands: Artery	Inflammation Chronic
Salivary Glands: Duct, Parotid Gland	Dilation
Salivary Glands: Parotid Gland	Atrophy
Seminal Vesicle	Decreased Secretory Fluid
Skin	Cyst Epithelial Inclusion

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF CELL PHONE RADIATION: CDMA

Spinal Cord, Cervical	Degeneration
Spinal Cord, Lumbar	Degeneration
Spinal Cord, Thoracic	Degeneration
Spleen	Extramedullary Hematopoiesis
	Hyperplasia Lymphocyte
	Pigment
Spleen: Red Pulp	Atrophy
Spleen: White Pulp	Atrophy
Stomach, Forestomach	Edema
	Ulcer
Stomach, Forestomach: Epithelium	Hyperplasia
Stomach, Glandular	Mineral
Stomach, Glandular: Artery	Inflammation Chronic
Testis: Artery	Inflammation Chronic
Testis: Germ Cell	Degeneration
Thymus	Cyst
	Hemorrhage
Thymus: Artery	Inflammation Chronic
Trigeminal Ganglion	Degeneration

FEMALE RATS

Organ	Morphology
Adrenal Cortex	Hyperplasia
Bone Marrow	Hypercellularity
Brain	Compression
Clitoral Gland	Inflammation Chronic
Clitoral Gland: Duct	Dilation
Harderian Gland	Inflammation Chronic
Kidney	Nephropathy Chronic Progressive
Kidney: Renal Tubule	Cyst
Liver	Mixed Cell Focus
Liver: Hepatocyte	Vacuolation, Cytoplasmic
Lung	Congestion
Lung: Alveolus	Infiltration Cellular Histiocyte
Lymph Node, Mandibular	Proliferation Plasma Cell

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF CELL PHONE RADIATION: CDMA

Lymph Node: Iliac	Hyperplasia Lymphocyte
Lymph Node: Iliac, Lymphatic Sinus	Ectasia
Lymph Node: Mediastinal	Erythrophagocytosis
Mammary Gland	Galactocele
	Hyperplasia
Mammary Gland: Duct	Dilation
Nose: Olfactory Epithelium	Accumulation, Hyaline Droplet
Nose: Respiratory Epithelium	Accumulation, Hyaline Droplet
	Hyperplasia
Ovary	Atrophy
	Cyst
Pancreas: Artery	Inflammation Chronic
Peripheral Nerve, Sciatic	Degeneration
Peripheral Nerve, Tibial	Degeneration
Pituitary Gland: Pars Distalis	Cyst
Salivary Glands: Parotid Gland	Fibrosis
Skeletal Muscle	Degeneration
Spinal Cord, Cervical	Degeneration
Thymus	Atrophy
	Hyperplasia Epithelial
Tissue NOS: Abdominal, Fat	Necrosis
Trigeminal Ganglion	Degeneration
Urinary Bladder	Inflammation Acute
Uterus	Hemorrhage
	Inflammation
Uterus: Epithelium	Metaplasia

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex				
Accessory Adrenal Cortical Nodule				
LESION RATES				
OVERALL (a)	6/90 (7%)	4/90 (4%)	7/90 (8%)	7/89 (8%)
LITTERS (b)	6/35 (17%)	4/35 (11%)	7/35 (20%)	6/35 (17%)
POLY-3 RATE (c)	6/66.57	4/74.05	7/78.40	7/66.13
POLY-3 PERCENT (g)	9%	5.4%	8.9%	10.6%
TERMINAL (d)	3/25 (12%)	4/43 (9%)	6/56 (11%)	7/43 (16%)
FIRST INCIDENCE	610	730 (T)	717	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.306	P=0.308N	P=0.607N	P=0.495
POLY 1.5	P=0.307	P=0.334N	P=0.567	P=0.486
POLY 6	P=0.320	P=0.267N	P=0.522N	P=0.530
RAO-SCOTT	P=0.311	P=0.302N	P=0.590N	P=0.476
LITTER C-A/FISHERS	P=0.454	P=0.367N	P=0.500	P=0.624

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex **Atrophy**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	1/89 (1%)
LITTERS (b)	0/35 (0%)	1/35 (3%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/65.47	1/74.05	0/78.35	1/66.59
POLY-3 PERCENT (g)	0%	1.4%	0%	1.5%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	730 (T)	---	594
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex Degeneration				
LESION RATES				
OVERALL (a)	3/90 (3%)	1/90 (1%)	1/90 (1%)	2/89 (2%)
LITTERS (b)	3/35 (9%)	1/35 (3%)	1/35 (3%)	2/35 (6%)
POLY-3 RATE (c)	3/66.37	1/74.05	1/78.35	2/66.13
POLY-3 PERCENT (g)	4.5%	1.4%	1.3%	3%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	1/56 (2%)	2/43 (5%)
FIRST INCIDENCE	496	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.484N	P=0.268N	P=0.251N	P=0.502N
POLY 1.5	P=0.485N	P=0.284N	P=0.275N	P=0.508N
POLY 6	P=0.483N	P=0.244N	P=0.214N	P=0.478N
RAO-SCOTT	P=0.475N	P=0.285N	P=0.271N	P=0.489N
LITTER C-A/FISHERS	P=0.474N	P=0.307N	P=0.307N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex **Degeneration Cystic**				
LESION RATES				
OVERALL (a)	0/90 (0%)	3/90 (3%)	0/90 (0%)	1/89 (1%)
LITTERS (b)	0/35 (0%)	3/35 (9%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/65.47	3/74.13	0/78.35	1/66.13
POLY-3 PERCENT (g)	0%	4.1%	0%	1.5%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	0/56 (0%)	1/43 (2%)
FIRST INCIDENCE	---	710	---	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.603N	P=0.144	(e)	P=0.502
POLY 1.5	P=0.621N	P=0.134	(e)	P=0.498
POLY 6	P=0.570N	P=0.163	(e)	P=0.514
RAO-SCOTT	P=0.618	P=0.205	(e)	P=0.524
LITTER C-A/FISHERS	P=0.634	P=0.120	(e)	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex Hyperplasia				
LESION RATES				
OVERALL (a)	47/90 (52%)	42/90 (47%)	45/90 (50%)	44/89 (49%)
LITTERS (b)	29/35 (83%)	29/35 (83%)	27/35 (77%)	26/35 (74%)
POLY-3 RATE (c)	47/76.79	42/81.86	45/80.67	44/73.32
POLY-3 PERCENT (g)	61.2%	51.3%	55.8%	60%
TERMINAL (d)	15/25 (60%)	17/43 (40%)	35/56 (63%)	28/43 (65%)
FIRST INCIDENCE	496	388	577	425
STATISTICAL TESTS				
POLY 3	P=0.447	P=0.127N	P=0.291N	P=0.507N
POLY 1.5	P=0.490	P=0.174N	P=0.353N	P=0.481N
POLY 6	P=0.432	P=0.077N	P=0.200N	P=0.499N
RAO-SCOTT	P=0.450	P=0.145N	P=0.303N	P=0.501N
LITTER C-A/FISHERS	P=0.189N	P=0.624	P=0.383N	P=0.281N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex Hypertrophy				
LESION RATES				
OVERALL (a)	35/90 (39%)	42/90 (47%)	55/90 (61%)	44/89 (49%)
LITTERS (b)	28/35 (80%)	30/35 (86%)	31/35 (89%)	27/35 (77%)
POLY-3 RATE (c)	35/71.88	42/80.07	55/81.25	44/70.19
POLY-3 PERCENT (g)	48.7%	52.5%	67.7%	62.7%
TERMINAL (d)	15/25 (60%)	27/43 (63%)	43/56 (77%)	32/43 (74%)
FIRST INCIDENCE	498	404	495	510
STATISTICAL TESTS				
POLY 3	P=0.022*	P=0.377	P=0.009**	P=0.052
POLY 1.5	P=0.032*	P=0.292	P=0.004**	P=0.063
POLY 6	P=0.022*	P=0.509	P=0.029*	P=0.059
RAO-SCOTT	P=0.028*	P=0.373	P=0.013*	P=0.062
LITTER C-A/FISHERS	P=0.381N	P=0.376	P=0.256	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex **Necrosis**				
LESION RATES				
OVERALL (a)	5/90 (6%)	5/90 (6%)	1/90 (1%)	1/89 (1%)
LITTERS (b)	5/35 (14%)	4/35 (11%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	5/66.47	5/75.74	1/78.36	1/66.38
POLY-3 PERCENT (g)	7.5%	6.6%	1.3%	1.5%
TERMINAL (d)	1/25 (4%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	577	517	728	665
STATISTICAL TESTS				
POLY 3	P=0.035N*	P=0.545N	P=0.072N	P=0.104N
POLY 1.5	P=0.037N*	P=0.581N	P=0.086N	P=0.108N
POLY 6	P=0.031N*	P=0.489N	P=0.054N	P=0.092N
RAO-SCOTT	P=0.066N	P=0.552N	P=0.123N	P=0.155N
LITTER C-A/FISHERS	P=0.040N*	P=0.500N	P=0.099N	P=0.099N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex **Thrombus**				
LESION RATES				
OVERALL (a)	2/90 (2%)	2/90 (2%)	1/90 (1%)	0/89 (0%)
LITTERS (b)	2/35 (6%)	2/35 (6%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	2/65.75	2/74.32	1/78.47	0/66.13
POLY-3 PERCENT (g)	3%	2.7%	1.3%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	666	695	698	---
STATISTICAL TESTS				
POLY 3	P=0.125N	P=0.648N	P=0.439N	P=0.237N
POLY 1.5	P=0.128N	P=0.668N	P=0.467N	P=0.241N
POLY 6	P=0.118N	P=0.616N	P=0.396N	P=0.224N
RAO-SCOTT	P=0.149N	P=0.633N	P=0.451N	P=0.256N
LITTER C-A/FISHERS	P=0.124N	P=0.693	P=0.500N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex **Vacuolation, Cytoplasmic**				
LESION RATES				
OVERALL (a)	20/90 (22%)	18/90 (20%)	21/90 (23%)	12/89 (13%)
LITTERS (b)	17/35 (49%)	15/35 (43%)	18/35 (51%)	9/35 (26%)
POLY-3 RATE (c)	20/69.49	18/76.64	21/80.06	12/66.99
POLY-3 PERCENT (g)	28.8%	23.5%	26.2%	17.9%
TERMINAL (d)	5/25 (20%)	8/43 (19%)	13/56 (23%)	10/43 (23%)
FIRST INCIDENCE	510	582	614	531
STATISTICAL TESTS				
POLY 3	P=0.112N	P=0.292N	P=0.434N	P=0.093N
POLY 1.5	P=0.109N	P=0.346N	P=0.527N	P=0.096N
POLY 6	P=0.103N	P=0.219N	P=0.298N	P=0.079N
RAO-SCOTT	P=0.111N	P=0.296N	P=0.430N	P=0.102N
LITTER C-A/FISHERS	P=0.039N*	P=0.405N	P=0.500	P=0.041N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Medulla **Hyperplasia**				
LESION RATES				
OVERALL (a)	42/88 (48%)	34/90 (38%)	32/90 (36%)	21/90 (23%)
LITTERS (b)	27/35 (77%)	20/35 (57%)	25/35 (71%)	16/35 (46%)
POLY-3 RATE (c)	42/74.57	34/78.51	32/81.61	21/67.23
POLY-3 PERCENT (g)	56.3%	43.3%	39.2%	31.2%
TERMINAL (d)	9/23 (39%)	17/43 (40%)	21/56 (38%)	18/43 (42%)
FIRST INCIDENCE	440	550	595	580
STATISTICAL TESTS				
POLY 3	P=0.002N**	P=0.066N	P=0.020N*	P<0.001N**
POLY 1.5	P<0.001N**	P=0.081N	P=0.034N*	P<0.001N**
POLY 6	P=0.003N**	P=0.050N*	P=0.009N**	P=0.002N**
RAO-SCOTT	P=0.003N**	P=0.085N	P=0.031N*	P=0.004N**
LITTER C-A/FISHERS	P=0.012N*	P=0.063N	P=0.393N	P=0.007N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Aorta **Dilation**				
LESION RATES				
OVERALL (a)	0/90 (0%)	5/90 (6%)	1/90 (1%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	5/35 (14%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	5/75.08	1/78.55	0/66.24
POLY-3 PERCENT (g)	0%	6.7%	1.3%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	615	677	---
STATISTICAL TESTS				
POLY 3	P=0.210N	P=0.047*	P=0.536	(e)
POLY 1.5	P=0.228N	P=0.040*	P=0.520	(e)
POLY 6	P=0.175N	P=0.059	P=0.562	(e)
RAO-SCOTT	P=0.284N	P=0.092	P=0.581	(e)
LITTER C-A/FISHERS	P=0.240N	P=0.027*	P=0.500	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Aorta **Mineral**				
LESION RATES				
OVERALL (a)	30/90 (33%)	8/90 (9%)	6/90 (7%)	2/90 (2%)
LITTERS (b)	20/35 (57%)	7/35 (20%)	6/35 (17%)	2/35 (6%)
POLY-3 RATE (c)	30/76.21	8/76.06	6/79.61	2/66.87
POLY-3 PERCENT (g)	39.4%	10.5%	7.5%	3%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	496	568	614	621
STATISTICAL TESTS				
POLY 3	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
POLY 6	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Bone Marrow **Fibrosis**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	0/74.05	0/78.35	0/66.24
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Bone Marrow Hemorrhage				
LESION RATES				
OVERALL (a)	0/90 (0%)	5/90 (6%)	3/90 (3%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	5/35 (14%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	5/74.50	3/78.53	0/66.24
POLY-3 PERCENT (g)	0%	6.7%	3.8%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	695	698	---
STATISTICAL TESTS				
POLY 3	P=0.293N	P=0.046*	P=0.157	(e)
POLY 1.5	P=0.309N	P=0.040*	P=0.140	(e)
POLY 6	P=0.253N	P=0.057	P=0.188	(e)
RAO-SCOTT	P=0.361N	P=0.107	P=0.249	(e)
LITTER C-A/FISHERS	P=0.278N	P=0.027*	P=0.246	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Bone Marrow Hypercellularity				
LESION RATES				
OVERALL (a)	15/90 (17%)	25/90 (28%)	18/90 (20%)	13/90 (14%)
LITTERS (b)	13/35 (37%)	16/35 (46%)	13/35 (37%)	11/35 (31%)
POLY-3 RATE (c)	15/70.25	25/81.30	18/80.22	13/69.71
POLY-3 PERCENT (g)	21.4%	30.8%	22.4%	18.7%
TERMINAL (d)	5/25 (20%)	8/43 (19%)	12/56 (21%)	6/43 (14%)
FIRST INCIDENCE	440	404	353	201
STATISTICAL TESTS				
POLY 3	P=0.196N	P=0.128	P=0.515	P=0.425N
POLY 1.5	P=0.194N	P=0.090	P=0.441	P=0.429N
POLY 6	P=0.178N	P=0.206	P=0.527N	P=0.390N
RAO-SCOTT	P=0.240N	P=0.168	P=0.519	P=0.437N
LITTER C-A/FISHERS	P=0.249N	P=0.314	P=0.598	P=0.401N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Bone **Fibrous Osteodystrophy**				
LESION RATES				
OVERALL (a)	46/90 (51%)	20/90 (22%)	15/90 (17%)	5/90 (6%)
LITTERS (b)	26/35 (74%)	15/35 (43%)	12/35 (34%)	5/35 (14%)
POLY-3 RATE (c)	46/79.83	20/78.40	15/80.63	5/67.49
POLY-3 PERCENT (g)	57.6%	25.5%	18.6%	7.4%
TERMINAL (d)	4/25 (16%)	3/43 (7%)	3/56 (5%)	2/43 (5%)
FIRST INCIDENCE	496	568	614	529
STATISTICAL TESTS				
POLY 3	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
POLY 6	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P=0.007N**	P<0.001N**	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain **Compression**				
LESION RATES				
OVERALL (a)	7/90 (8%)	12/90 (13%)	6/90 (7%)	3/90 (3%)
LITTERS (b)	7/35 (20%)	9/35 (26%)	6/35 (17%)	3/35 (9%)
POLY-3 RATE (c)	7/67.18	12/75.57	6/78.78	3/67.18
POLY-3 PERCENT (g)	10.4%	15.9%	7.6%	4.5%
TERMINAL (d)	2/25 (8%)	5/43 (12%)	4/56 (7%)	1/43 (2%)
FIRST INCIDENCE	541	608	652	590
STATISTICAL TESTS				
POLY 3	P=0.051N	P=0.238	P=0.382N	P=0.161N
POLY 1.5	P=0.055N	P=0.205	P=0.435N	P=0.167N
POLY 6	P=0.040N*	P=0.297	P=0.304N	P=0.140N
RAO-SCOTT	P=0.076N	P=0.267	P=0.399N	P=0.190N
LITTER C-A/FISHERS	P=0.073N	P=0.388	P=0.500N	P=0.153N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain				
Edema				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/35 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	1/74.11	0/78.35	0/66.24
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	717	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain **Hemorrhage**				
LESION RATES				
OVERALL (a)	2/90 (2%)	3/90 (3%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	3/35 (9%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/66.00	3/75.57	0/78.35	0/66.24
POLY-3 PERCENT (g)	3%	4%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	657	388	---	---
STATISTICAL TESTS				
POLY 3	P=0.067N	P=0.561	P=0.203N	P=0.237N
POLY 1.5	P=0.071N	P=0.536	P=0.218N	P=0.240N
POLY 6	P=0.060N	P=0.599	P=0.180N	P=0.225N
RAO-SCOTT	P=0.112N	P=0.571	P=0.272N	P=0.290N
LITTER C-A/FISHERS	P=0.072N	P=0.500	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain **Mineral**				
LESION RATES				
OVERALL (a)	5/90 (6%)	3/90 (3%)	4/90 (4%)	4/90 (4%)
LITTERS (b)	5/35 (14%)	3/35 (9%)	4/35 (11%)	4/35 (11%)
POLY-3 RATE (c)	5/66.34	3/74.31	4/78.35	4/66.29
POLY-3 PERCENT (g)	7.5%	4%	5.1%	6%
TERMINAL (d)	1/25 (4%)	2/43 (5%)	4/56 (7%)	3/43 (7%)
FIRST INCIDENCE	527	662	730 (T)	717
STATISTICAL TESTS				
POLY 3	P=0.516N	P=0.299N	P=0.399N	P=0.500N
POLY 1.5	P=0.516N	P=0.324N	P=0.444N	P=0.508N
POLY 6	P=0.504N	P=0.260N	P=0.330N	P=0.469N
RAO-SCOTT	P=0.495N	P=0.280N	P=0.379N	P=0.470N
LITTER C-A/FISHERS	P=0.500N	P=0.355N	P=0.500N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain **Necrosis**				
LESION RATES				
OVERALL (a)	7/90 (8%)	7/90 (8%)	3/90 (3%)	0/90 (0%)
LITTERS (b)	7/35 (20%)	6/35 (17%)	3/35 (9%)	0/35 (0%)
POLY-3 RATE (c)	7/67.91	7/76.74	3/79.29	0/66.24
POLY-3 PERCENT (g)	10.3%	9.1%	3.8%	0%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	580	388	577	---
STATISTICAL TESTS				
POLY 3	P=0.004N**	P=0.516N	P=0.108N	P=0.010N**
POLY 1.5	P=0.004N**	P=0.555N	P=0.131N	P=0.010N**
POLY 6	P=0.003N**	P=0.459N	P=0.079N	P=0.008N**
RAO-SCOTT	P=0.011N*	P=0.522N	P=0.151N	P=0.025N*
LITTER C-A/FISHERS	P=0.004N**	P=0.500N	P=0.153N	P=0.006N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain: Choroid Plexus Mineral				
LESION RATES				
OVERALL (a)	3/90 (3%)	1/90 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	3/35 (9%)	1/35 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	3/66.48	1/74.16	0/78.35	0/66.24
POLY-3 PERCENT (g)	4.5%	1.4%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	541	704	---	---
STATISTICAL TESTS				
POLY 3	P=0.044N*	P=0.269N	P=0.095N	P=0.121N
POLY 1.5	P=0.044N*	P=0.284N	P=0.106N	P=0.123N
POLY 6	P=0.044N*	P=0.244N	P=0.079N	P=0.112N
RAO-SCOTT	P=0.084N	P=0.336N	P=0.168N	P=0.189N
LITTER C-A/FISHERS	P=0.043N*	P=0.307N	P=0.120N	P=0.120N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain: Glial Cell Hyperplasia				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/90 (2%)	0/90 (0%)	2/90 (2%)
LITTERS (b)	0/35 (0%)	2/35 (6%)	0/35 (0%)	2/35 (6%)
POLY-3 RATE (c)	0/65.47	2/75.13	0/78.35	2/66.66
POLY-3 PERCENT (g)	0%	2.7%	0%	3%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	1/43 (2%)
FIRST INCIDENCE	---	404	---	608
STATISTICAL TESTS				
POLY 3	P=0.262	P=0.270	(e)	P=0.242
POLY 1.5	P=0.253	P=0.256	(e)	P=0.237
POLY 6	P=0.284	P=0.293	(e)	P=0.257
RAO-SCOTT	P=0.287	P=0.337	(e)	P=0.300
LITTER C-A/FISHERS	P=0.246	P=0.246	(e)	P=0.246

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain: Hypothalamus **Cyst**				
LESION RATES				
OVERALL (a)	0/90 (0%)	3/90 (3%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	3/35 (9%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	3/74.05	0/78.35	0/66.24
POLY-3 PERCENT (g)	0%	4.1%	0%	0%
TERMINAL (d)	0/25 (0%)	3/43 (7%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	730 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.277N	P=0.144	(e)	(e)
POLY 1.5	P=0.294N	P=0.134	(e)	(e)
POLY 6	P=0.246N	P=0.162	(e)	(e)
RAO-SCOTT	P=0.371N	P=0.242	(e)	(e)
LITTER C-A/FISHERS	P=0.311N	P=0.120	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain: Pineal Gland Mineral				
LESION RATES				
OVERALL (a)	3/90 (3%)	3/90 (3%)	2/90 (2%)	0/90 (0%)
LITTERS (b)	3/35 (9%)	3/35 (9%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	3/65.82	3/74.71	2/78.47	0/66.24
POLY-3 PERCENT (g)	4.6%	4%	2.6%	0%
TERMINAL (d)	1/25 (4%)	1/43 (2%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	663	615	698	---
STATISTICAL TESTS				
POLY 3	P=0.073N	P=0.602N	P=0.421N	P=0.119N
POLY 1.5	P=0.075N	P=0.627N	P=0.457N	P=0.122N
POLY 6	P=0.067N	P=0.560N	P=0.367N	P=0.109N
RAO-SCOTT	P=0.087N	P=0.586N	P=0.425N	P=0.135N
LITTER C-A/FISHERS	P=0.070N	P=0.663	P=0.500N	P=0.120N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain: Pineal Gland **Vacuolation, Cytoplasmic**				
LESION RATES				
OVERALL (a)	12/90 (13%)	6/90 (7%)	9/90 (10%)	4/90 (4%)
LITTERS (b)	12/35 (34%)	6/35 (17%)	6/35 (17%)	4/35 (11%)
POLY-3 RATE (c)	12/68.69	6/75.44	9/79.95	4/66.24
POLY-3 PERCENT (g)	17.5%	8%	11.3%	6%
TERMINAL (d)	3/25 (12%)	1/43 (2%)	4/56 (7%)	4/43 (9%)
FIRST INCIDENCE	248	615	393	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.057N	P=0.068N	P=0.198N	P=0.035N*
POLY 1.5	P=0.055N	P=0.084N	P=0.251N	P=0.036N*
POLY 6	P=0.054N	P=0.048N*	P=0.131N	P=0.029N*
RAO-SCOTT	P=0.071N	P=0.098N	P=0.231N	P=0.057N
LITTER C-A/FISHERS	P=0.023N*	P=0.085N	P=0.085N	P=0.022N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Coagulating Gland Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/0 (0%)	2/2 (100%)	2/3 (67%)	0/0 (0%)
LITTERS (b)	0/0 (0%)	2/2 (100%)	2/3 (67%)	0/0 (0%)
POLY-3 RATE (c)	0/0.00	2/2.00	2/2.84	0/0.00
POLY-3 PERCENT (g)	0%	100%	70.5%	0%
TERMINAL (d)	0/0 (0%)	2/2 (100%)	2/2 (100%)	0/0 (0%)
FIRST INCIDENCE	---	730 (T)	730 (T)	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
RAO-SCOTT	(e)	(e)	(e)	(e)
LITTER C-A/FISHERS	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Epididymis **Exfoliated Germ Cell**				
LESION RATES				
OVERALL (a)	51/90 (57%)	33/90 (37%)	33/90 (37%)	17/90 (19%)
LITTERS (b)	28/35 (80%)	24/35 (69%)	27/35 (77%)	14/35 (40%)
POLY-3 RATE (c)	51/81.72	33/79.54	33/83.05	17/69.61
POLY-3 PERCENT (g)	62.4%	41.5%	39.7%	24.4%
TERMINAL (d)	6/25 (24%)	16/43 (37%)	14/56 (25%)	8/43 (19%)
FIRST INCIDENCE	496	388	393	433
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.004N**	P=0.002N**	P<0.001N**
POLY 1.5	P<0.001N**	P=0.004N**	P=0.003N**	P<0.001N**
POLY 6	P<0.001N**	P=0.006N**	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.009N**	P=0.004N**	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P=0.206N	P=0.500N	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Epididymis **Hypospermia**				
LESION RATES				
OVERALL (a)	28/90 (31%)	24/90 (27%)	13/90 (14%)	13/90 (14%)
LITTERS (b)	21/35 (60%)	18/35 (51%)	10/35 (29%)	11/35 (31%)
POLY-3 RATE (c)	28/72.06	24/78.00	13/78.65	13/67.05
POLY-3 PERCENT (g)	38.9%	30.8%	16.5%	19.4%
TERMINAL (d)	6/25 (24%)	7/43 (16%)	9/56 (16%)	9/43 (21%)
FIRST INCIDENCE	498	550	677	594
STATISTICAL TESTS				
POLY 3	P=0.002N**	P=0.188N	P<0.001N**	P=0.008N**
POLY 1.5	P=0.002N**	P=0.233N	P=0.003N**	P=0.007N**
POLY 6	P=0.002N**	P=0.131N	P<0.001N**	P=0.007N**
RAO-SCOTT	P=0.005N**	P=0.206N	P=0.003N**	P=0.014N*
LITTER C-A/FISHERS	P=0.006N**	P=0.315N	P=0.008N**	P=0.015N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Epididymis: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	2/90 (2%)	3/90 (3%)	3/90 (3%)	3/90 (3%)
LITTERS (b)	2/35 (6%)	3/35 (9%)	3/35 (9%)	3/35 (9%)
POLY-3 RATE (c)	2/65.95	3/74.05	3/78.35	3/66.24
POLY-3 PERCENT (g)	3%	4.1%	3.8%	4.5%
TERMINAL (d)	1/25 (4%)	3/43 (7%)	3/56 (5%)	3/43 (7%)
FIRST INCIDENCE	590	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.431	P=0.552	P=0.577	P=0.502
POLY 1.5	P=0.427	P=0.530	P=0.542	P=0.495
POLY 6	P=0.452	P=0.588	P=0.631	P=0.527
RAO-SCOTT	P=0.409	P=0.517	P=0.545	P=0.460
LITTER C-A/FISHERS	P=0.437	P=0.500	P=0.500	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Esophagus **Dilation**				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/65.84	0/74.05	0/78.35	0/66.24
POLY-3 PERCENT (g)	3%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	645	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.118N	P=0.213N	P=0.202N	P=0.236N
POLY 1.5	P=0.116N	P=0.224N	P=0.218N	P=0.240N
POLY 6	P=0.125N	P=0.197N	P=0.179N	P=0.224N
RAO-SCOTT	P=0.211N	P=0.351N	P=0.346N	P=0.360N
LITTER C-A/FISHERS	P=0.114N	P=0.246N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Anterior Chamber Inflammation Acute				
LESION RATES				
OVERALL (a)	4/85 (5%)	8/83 (10%)	5/81 (6%)	1/72 (1%)
LITTERS (b)	4/35 (11%)	7/35 (20%)	5/34 (15%)	1/35 (3%)
POLY-3 RATE (c)	4/64.47	8/71.29	5/71.75	1/59.32
POLY-3 PERCENT (g)	6.2%	11.2%	7%	1.7%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	2/55 (4%)	0/43 (0%)
FIRST INCIDENCE	555	568	664	621
STATISTICAL TESTS				
POLY 3	P=0.092N	P=0.234	P=0.566	P=0.206N
POLY 1.5	P=0.109N	P=0.205	P=0.520	P=0.222N
POLY 6	P=0.069N	P=0.288	P=0.630N	P=0.178N
RAO-SCOTT	P=0.122N	P=0.253	P=0.559	P=0.225N
LITTER C-A/FISHERS	P=0.089N	P=0.256	P=0.481	P=0.178N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Cornea				
Fibrosis				
LESION RATES				
OVERALL (a)	1/85 (1%)	2/83 (2%)	2/81 (2%)	4/72 (6%)
LITTERS (b)	1/35 (3%)	2/35 (6%)	2/34 (6%)	4/35 (11%)
POLY-3 RATE (c)	1/63.26	2/69.37	2/71.45	4/58.93
POLY-3 PERCENT (g)	1.6%	2.9%	2.8%	6.8%
TERMINAL (d)	1/25 (4%)	2/43 (5%)	2/55 (4%)	4/43 (9%)
FIRST INCIDENCE	730 (T)	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.093	P=0.532	P=0.542	P=0.159
POLY 1.5	P=0.085	P=0.514	P=0.514	P=0.145
POLY 6	P=0.108	P=0.563	P=0.587	P=0.188
RAO-SCOTT	P=0.105	P=0.513	P=0.527	P=0.170
LITTER C-A/FISHERS	P=0.111	P=0.500	P=0.489	P=0.178

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Cornea **Inflammation Acute**				
LESION RATES				
OVERALL (a)	28/85 (33%)	18/83 (22%)	19/81 (23%)	17/72 (24%)
LITTERS (b)	20/35 (57%)	15/35 (43%)	14/34 (41%)	13/35 (37%)
POLY-3 RATE (c)	28/70.59	18/72.11	19/72.85	17/61.67
POLY-3 PERCENT (g)	39.7%	25%	26.1%	27.6%
TERMINAL (d)	3/25 (12%)	7/43 (16%)	11/55 (20%)	8/43 (19%)
FIRST INCIDENCE	555	568	614	531
STATISTICAL TESTS				
POLY 3	P=0.131N	P=0.041N*	P=0.056N	P=0.095N
POLY 1.5	P=0.150N	P=0.051N	P=0.080N	P=0.115N
POLY 6	P=0.103N	P=0.029N*	P=0.031N*	P=0.067N
RAO-SCOTT	P=0.149N	P=0.060N	P=0.078N	P=0.120N
LITTER C-A/FISHERS	P=0.077N	P=0.170N	P=0.139N	P=0.075N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Cornea **Neovascularization**				
LESION RATES				
OVERALL (a)	10/85 (12%)	14/83 (17%)	14/81 (17%)	21/72 (29%)
LITTERS (b)	9/35 (26%)	11/35 (31%)	11/34 (32%)	17/35 (49%)
POLY-3 RATE (c)	10/64.83	14/69.44	14/71.65	21/60.24
POLY-3 PERCENT (g)	15.4%	20.2%	19.5%	34.9%
TERMINAL (d)	4/25 (16%)	13/43 (30%)	12/55 (22%)	16/43 (37%)
FIRST INCIDENCE	577	711	688	531
STATISTICAL TESTS				
POLY 3	P=0.005**	P=0.311	P=0.342	P=0.008**
POLY 1.5	P=0.004**	P=0.275	P=0.277	P=0.006**
POLY 6	P=0.010**	P=0.376	P=0.461	P=0.017*
RAO-SCOTT	P=0.009**	P=0.317	P=0.347	P=0.015*
LITTER C-A/FISHERS	P=0.027*	P=0.396	P=0.366	P=0.041*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Cornea				
Ulcer				
LESION RATES				
OVERALL (a)	6/85 (7%)	1/83 (1%)	0/81 (0%)	0/72 (0%)
LITTERS (b)	5/35 (14%)	1/35 (3%)	0/34 (0%)	0/35 (0%)
POLY-3 RATE (c)	6/64.90	1/69.42	0/71.45	0/58.93
POLY-3 PERCENT (g)	9.3%	1.4%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/55 (0%)	0/43 (0%)
FIRST INCIDENCE	555	717	---	---
STATISTICAL TESTS				
POLY 3	P=0.005N**	P=0.049N*	P=0.012N*	P=0.022N*
POLY 1.5	P=0.005N**	P=0.055N	P=0.016N*	P=0.026N*
POLY 6	P=0.005N**	P=0.039N*	P=0.009N**	P=0.017N*
RAO-SCOTT	P=0.029N*	P=0.131N	P=0.064N	P=0.087N
LITTER C-A/FISHERS	P=0.008N**	P=0.099N	P=0.029N*	P=0.027N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Cornea, Epithelium Degeneration				
LESION RATES				
OVERALL (a)	0/85 (0%)	0/83 (0%)	1/81 (1%)	2/72 (3%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	1/34 (3%)	2/35 (6%)
POLY-3 RATE (c)	0/63.26	0/69.37	1/71.45	2/58.93
POLY-3 PERCENT (g)	0%	0%	1.4%	3.4%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	1/55 (2%)	2/43 (5%)
FIRST INCIDENCE	---	---	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.058	(e)	P=0.524	P=0.222
POLY 1.5	P=0.055	(e)	P=0.508	P=0.211
POLY 6	P=0.064	(e)	P=0.550	P=0.244
RAO-SCOTT	P=0.108	(e)	P=0.582	P=0.296
LITTER C-A/FISHERS	P=0.070	(e)	P=0.493	P=0.246

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Cornea, Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	13/85 (15%)	15/83 (18%)	17/81 (21%)	20/72 (28%)
LITTERS (b)	11/35 (31%)	13/35 (37%)	12/34 (35%)	16/35 (46%)
POLY-3 RATE (c)	13/66.76	15/70.90	17/72.35	20/61.41
POLY-3 PERCENT (g)	19.5%	21.2%	23.5%	32.6%
TERMINAL (d)	3/25 (12%)	9/43 (21%)	12/55 (22%)	14/43 (33%)
FIRST INCIDENCE	577	568	614	531
STATISTICAL TESTS				
POLY 3	P=0.040*	P=0.487	P=0.355	P=0.064
POLY 1.5	P=0.031*	P=0.444	P=0.290	P=0.049*
POLY 6	P=0.061	P=0.556	P=0.471	P=0.100
RAO-SCOTT	P=0.055	P=0.485	P=0.366	P=0.084
LITTER C-A/FISHERS	P=0.141	P=0.401	P=0.466	P=0.163

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Eye: Lens				
Cataract				
LESION RATES				
OVERALL (a)	0/85 (0%)	1/83 (1%)	0/81 (0%)	0/72 (0%)
LITTERS (b)	0/35 (0%)	1/35 (3%)	0/34 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/63.26	1/69.37	0/71.45	0/58.93
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	0/55 (0%)	0/43 (0%)
FIRST INCIDENCE	---	730 (T)	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Retina **Atrophy**				
LESION RATES				
OVERALL (a)	6/85 (7%)	17/83 (20%)	17/81 (21%)	8/72 (11%)
LITTERS (b)	5/35 (14%)	15/35 (43%)	15/34 (44%)	8/35 (23%)
POLY-3 RATE (c)	6/63.26	17/70.87	17/71.45	8/59.04
POLY-3 PERCENT (g)	9.5%	24%	23.8%	13.6%
TERMINAL (d)	6/25 (24%)	12/43 (28%)	17/55 (31%)	6/43 (14%)
FIRST INCIDENCE	730 (T)	404	730 (T)	717
STATISTICAL TESTS				
POLY 3	P=0.524	P=0.021*	P=0.023*	P=0.336
POLY 1.5	P=0.454	P=0.015*	P=0.014*	P=0.299
POLY 6	P=0.442N	P=0.037*	P=0.049*	P=0.412
RAO-SCOTT	P=0.480	P=0.029*	P=0.030*	P=0.334
LITTER C-A/FISHERS	P=0.459	P=0.008**	P=0.006**	P=0.270

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Retina **Dysplasia**				
LESION RATES				
OVERALL (a)	0/85 (0%)	0/83 (0%)	0/81 (0%)	1/72 (1%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/34 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/63.26	0/69.37	0/71.45	1/59.39
POLY-3 PERCENT (g)	0%	0%	0%	1.7%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/55 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	594
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Harderian Gland **Atrophy**				
LESION RATES				
OVERALL (a)	1/90 (1%)	4/90 (4%)	2/90 (2%)	3/89 (3%)
LITTERS (b)	1/35 (3%)	4/35 (11%)	2/35 (6%)	3/35 (9%)
POLY-3 RATE (c)	1/65.47	4/74.20	2/78.56	3/65.48
POLY-3 PERCENT (g)	1.5%	5.4%	2.6%	4.6%
TERMINAL (d)	1/25 (4%)	3/43 (7%)	0/56 (0%)	3/43 (7%)
FIRST INCIDENCE	730 (T)	693	694	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.376	P=0.221	P=0.563	P=0.306
POLY 1.5	P=0.365	P=0.204	P=0.534	P=0.300
POLY 6	P=0.409	P=0.252	P=0.607	P=0.328
RAO-SCOTT	P=0.352	P=0.220	P=0.537	P=0.290
LITTER C-A/FISHERS	P=0.370	P=0.178	P=0.500	P=0.307

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Harderian Gland **Degeneration Cystic**				
LESION RATES				
OVERALL (a)	2/90 (2%)	4/90 (4%)	1/90 (1%)	0/89 (0%)
LITTERS (b)	2/35 (6%)	4/35 (11%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	2/65.47	4/74.05	1/78.35	0/65.48
POLY-3 PERCENT (g)	3.1%	5.4%	1.3%	0%
TERMINAL (d)	2/25 (8%)	4/43 (9%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	730 (T)	730 (T)	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.080N	P=0.396	P=0.438N	P=0.238N
POLY 1.5	P=0.086N	P=0.372	P=0.466N	P=0.242N
POLY 6	P=0.069N	P=0.438	P=0.394N	P=0.224N
RAO-SCOTT	P=0.107N	P=0.405	P=0.445N	P=0.251N
LITTER C-A/FISHERS	P=0.084N	P=0.337	P=0.500N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Harderian Gland Hyperplasia				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	2/89 (2%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	2/35 (6%)
POLY-3 RATE (c)	0/65.47	0/74.05	0/78.35	2/65.48
POLY-3 PERCENT (g)	0%	0%	0%	3.1%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	2/43 (5%)
FIRST INCIDENCE	---	---	---	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.044*	(e)	(e)	P=0.238
POLY 1.5	P=0.044*	(e)	(e)	P=0.234
POLY 6	P=0.045*	(e)	(e)	P=0.252
RAO-SCOTT	P=0.117	(e)	(e)	P=0.361
LITTER C-A/FISHERS	P=0.046*	(e)	(e)	P=0.246

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Harderian Gland **Infiltration Cellular Lymphocyte**				
LESION RATES				
OVERALL (a)	0/90 (0%)	3/90 (3%)	0/90 (0%)	3/89 (3%)
LITTERS (b)	0/35 (0%)	3/35 (9%)	0/35 (0%)	3/35 (9%)
POLY-3 RATE (c)	0/65.47	3/75.05	0/78.35	3/66.42
POLY-3 PERCENT (g)	0%	4%	0%	4.5%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	0/56 (0%)	2/43 (5%)
FIRST INCIDENCE	---	542	---	289
STATISTICAL TESTS				
POLY 3	P=0.177	P=0.147	(e)	P=0.123
POLY 1.5	P=0.167	P=0.135	(e)	P=0.119
POLY 6	P=0.198	P=0.168	(e)	P=0.135
RAO-SCOTT	P=0.206	P=0.214	(e)	P=0.182
LITTER C-A/FISHERS	P=0.162	P=0.120	(e)	P=0.120

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Harderian Gland Inflammation Acute				
LESION RATES				
OVERALL (a)	2/90 (2%)	1/90 (1%)	0/90 (0%)	0/89 (0%)
LITTERS (b)	2/35 (6%)	1/35 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/65.74	1/74.31	0/78.35	0/65.48
POLY-3 PERCENT (g)	3%	1.4%	0%	0%
TERMINAL (d)	1/25 (4%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	657	662	---	---
STATISTICAL TESTS				
POLY 3	P=0.100N	P=0.458N	P=0.202N	P=0.239N
POLY 1.5	P=0.101N	P=0.476N	P=0.218N	P=0.243N
POLY 6	P=0.099N	P=0.429N	P=0.179N	P=0.226N
RAO-SCOTT	P=0.152N	P=0.499N	P=0.286N	P=0.306N
LITTER C-A/FISHERS	P=0.100N	P=0.500N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Harderian Gland **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	2/90 (2%)	3/90 (3%)	1/90 (1%)	2/89 (2%)
LITTERS (b)	2/35 (6%)	3/35 (9%)	1/35 (3%)	2/35 (6%)
POLY-3 RATE (c)	2/66.07	3/74.83	1/78.35	2/65.78
POLY-3 PERCENT (g)	3%	4%	1.3%	3%
TERMINAL (d)	1/25 (4%)	1/43 (2%)	1/56 (2%)	1/43 (2%)
FIRST INCIDENCE	541	614	730 (T)	650
STATISTICAL TESTS				
POLY 3	P=0.496N	P=0.556	P=0.441N	P=0.692
POLY 1.5	P=0.504N	P=0.532	P=0.468N	P=0.686
POLY 6	P=0.476N	P=0.595	P=0.399N	P=0.674N
RAO-SCOTT	P=0.494N	P=0.533	P=0.422N	P=0.653
LITTER C-A/FISHERS	P=0.500N	P=0.500	P=0.500N	P=0.693

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Harderian Gland				
Inflammation Granulomatous				
LESION RATES				
OVERALL (a)	0/90 (0%)	5/90 (6%)	2/90 (2%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	5/35 (14%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	5/74.98	2/78.35	0/65.48
POLY-3 PERCENT (g)	0%	6.7%	2.6%	0%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	2/56 (4%)	0/43 (0%)
FIRST INCIDENCE	---	552	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.257N	P=0.046*	P=0.280	(e)
POLY 1.5	P=0.274N	P=0.040*	P=0.261	(e)
POLY 6	P=0.218N	P=0.058	P=0.313	(e)
RAO-SCOTT	P=0.334N	P=0.106	P=0.372	(e)
LITTER C-A/FISHERS	P=0.240N	P=0.027*	P=0.500	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart **Cardiomyopathy**				
LESION RATES				
OVERALL (a)	79/90 (88%)	84/90 (93%)	83/90 (92%)	85/90 (94%)
LITTERS (b)	35/35 (100%)	35/35 (100%)	34/35 (97%)	35/35 (100%)
POLY-3 RATE (c)	79/86.22	84/86.93	83/86.91	85/88.30
POLY-3 PERCENT (g)	91.6%	96.6%	95.5%	96.3%
TERMINAL (d)	20/25 (80%)	42/43 (98%)	55/56 (98%)	41/43 (95%)
FIRST INCIDENCE	248	447	317	153
STATISTICAL TESTS				
POLY 3	P=0.146	P=0.115	P=0.207	P=0.145
POLY 1.5	P=0.134	P=0.132	P=0.229	P=0.130
POLY 6	P=0.154	P=0.103	P=0.170	P=0.162
RAO-SCOTT	P=0.183	P=0.149	P=0.241	P=0.176
LITTER C-A/FISHERS	P=0.695N	(e)	P=0.500N	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart **Thrombus**				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	3/90 (3%)	0/90 (0%)
LITTERS (b)	1/35 (3%)	0/35 (0%)	3/35 (9%)	0/35 (0%)
POLY-3 RATE (c)	1/65.51	0/74.05	3/78.57	0/66.24
POLY-3 PERCENT (g)	1.5%	0%	3.8%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	722	---	698	---
STATISTICAL TESTS				
POLY 3	P=0.525N	P=0.476N	P=0.374	P=0.498N
POLY 1.5	P=0.519N	P=0.486N	P=0.343	P=0.501N
POLY 6	P=0.520N	P=0.459N	P=0.426	P=0.486N
RAO-SCOTT	P=0.506N	P=0.513N	P=0.414	P=0.514N
LITTER C-A/FISHERS	P=0.500N	P=0.500N	P=0.307	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: All Sites **Cardiomyopathy**				
LESION RATES				
OVERALL (a)	79/90 (88%)	85/90 (94%)	85/90 (94%)	85/90 (94%)
LITTERS (b)	35/35 (100%)	35/35 (100%)	35/35 (100%)	35/35 (100%)
POLY-3 RATE (c)	79/86.22	85/87.76	85/87.65	85/88.30
POLY-3 PERCENT (g)	91.6%	96.9%	97%	96.3%
TERMINAL (d)	20/25 (80%)	42/43 (98%)	55/56 (98%)	41/43 (95%)
FIRST INCIDENCE	248	404	317	153
STATISTICAL TESTS				
POLY 3	P=0.133	P=0.100	P=0.092	P=0.145
POLY 1.5	P=0.123	P=0.101	P=0.094	P=0.130
POLY 6	P=0.144	P=0.098	P=0.095	P=0.162
RAO-SCOTT	P=0.171	P=0.137	P=0.129	P=0.181
LITTER C-A/FISHERS	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Heart: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	2/90 (2%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	0/74.05	2/78.74	0/66.24
POLY-3 PERCENT (g)	0%	0%	2.5%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	---	---	619	---
STATISTICAL TESTS				
POLY 3	P=0.568	(e)	P=0.281	(e)
POLY 1.5	P=0.573	(e)	P=0.261	(e)
POLY 6	P=0.580	(e)	P=0.316	(e)
RAO-SCOTT	P=0.660	(e)	P=0.537	(e)
LITTER C-A/FISHERS	P=0.695	(e)	P=0.500	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Artery Mineral				
LESION RATES				
OVERALL (a)	20/90 (22%)	7/90 (8%)	2/90 (2%)	1/90 (1%)
LITTERS (b)	16/35 (46%)	5/35 (14%)	2/35 (6%)	1/35 (3%)
POLY-3 RATE (c)	20/72.27	7/75.62	2/78.60	1/66.62
POLY-3 PERCENT (g)	27.7%	9.3%	2.5%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	552	582	677	621
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.003N**	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P=0.004N**	P<0.001N**	P<0.001N**
POLY 6	P<0.001N**	P=0.002N**	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.012N*	P<0.001N**	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P=0.004N**	P<0.001N**	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Atrium **Dilation**				
LESION RATES				
OVERALL (a)	3/90 (3%)	1/90 (1%)	0/90 (0%)	4/90 (4%)
LITTERS (b)	3/35 (9%)	1/35 (3%)	0/35 (0%)	4/35 (11%)
POLY-3 RATE (c)	3/65.61	1/74.13	0/78.35	4/67.78
POLY-3 PERCENT (g)	4.6%	1.4%	0%	5.9%
TERMINAL (d)	1/25 (4%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	704	711	---	440
STATISTICAL TESTS				
POLY 3	P=0.310	P=0.264N	P=0.093N	P=0.518
POLY 1.5	P=0.309	P=0.282N	P=0.105N	P=0.503
POLY 6	P=0.311	P=0.237N	P=0.076N	P=0.557
RAO-SCOTT	P=0.334	P=0.294N	P=0.128N	P=0.512
LITTER C-A/FISHERS	P=0.311	P=0.307N	P=0.120N	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Atrium Thrombus				
LESION RATES				
OVERALL (a)	1/90 (1%)	5/90 (6%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	1/35 (3%)	5/35 (14%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	1/65.53	5/75.40	0/78.35	1/66.24
POLY-3 PERCENT (g)	1.5%	6.6%	0%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	1/43 (2%)
FIRST INCIDENCE	715	552	---	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.248N	P=0.141	P=0.465N	P=0.759N
POLY 1.5	P=0.265N	P=0.125	P=0.481N	P=0.759
POLY 6	P=0.216N	P=0.170	P=0.439N	P=0.746N
RAO-SCOTT	P=0.303N	P=0.179	P=0.488N	P=0.725N
LITTER C-A/FISHERS	P=0.278N	P=0.099	P=0.500N	P=0.754

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Heart: Endocardium (All) **Hyperplasia Schwann Cell**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	3/90 (3%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	3/35 (9%)
POLY-3 RATE (c)	0/65.47	0/74.05	0/78.35	3/67.79
POLY-3 PERCENT (g)	0%	0%	0%	4.4%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	497
STATISTICAL TESTS				
POLY 3	P=0.011*	(e)	(e)	P=0.127
POLY 1.5	P=0.011*	(e)	(e)	P=0.122
POLY 6	P=0.012*	(e)	(e)	P=0.141
RAO-SCOTT	P=0.044*	(e)	(e)	P=0.221
LITTER C-A/FISHERS	P=0.012*	(e)	(e)	P=0.120

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Heart: Endocardium or Mycardium Hyperplasia Schwann Cell				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	3/90 (3%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	3/35 (9%)
POLY-3 RATE (c)	0/65.47	0/74.05	0/78.35	3/67.79
POLY-3 PERCENT (g)	0%	0%	0%	4.4%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	497
STATISTICAL TESTS				
POLY 3	P=0.011*	(e)	(e)	P=0.127
POLY 1.5	P=0.011*	(e)	(e)	P=0.122
POLY 6	P=0.012*	(e)	(e)	P=0.141
RAO-SCOTT	P=0.044*	(e)	(e)	P=0.221
LITTER C-A/FISHERS	P=0.012*	(e)	(e)	P=0.120

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Heart: Endocardium				
Hyperplasia Schwann Cell				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	3/90 (3%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	3/35 (9%)
POLY-3 RATE (c)	0/65.47	0/74.05	0/78.35	3/67.79
POLY-3 PERCENT (g)	0%	0%	0%	4.4%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	497
STATISTICAL TESTS				
POLY 3	P=0.011*	(e)	(e)	P=0.127
POLY 1.5	P=0.011*	(e)	(e)	P=0.122
POLY 6	P=0.012*	(e)	(e)	P=0.141
RAO-SCOTT	P=0.044*	(e)	(e)	P=0.221
LITTER C-A/FISHERS	P=0.012*	(e)	(e)	P=0.120

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Myocardium Mineral				
LESION RATES				
OVERALL (a)	9/90 (10%)	2/90 (2%)	1/90 (1%)	0/90 (0%)
LITTERS (b)	9/35 (26%)	1/35 (3%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	9/68.18	2/74.60	1/78.51	0/66.24
POLY-3 PERCENT (g)	13.2%	2.7%	1.3%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	577	615	688	---
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.019N*	P=0.005N**	P=0.003N**
POLY 1.5	P<0.001N**	P=0.023N*	P=0.007N**	P=0.003N**
POLY 6	P<0.001N**	P=0.015N*	P=0.003N**	P=0.002N**
RAO-SCOTT	P=0.004N**	P=0.049N*	P=0.020N*	P=0.013N*
LITTER C-A/FISHERS	P<0.001N**	P=0.007N**	P=0.007N**	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Ventricle Right Cardiomyopathy				
LESION RATES				
OVERALL (a)	54/90 (60%)	45/90 (50%)	62/90 (69%)	74/90 (82%)
LITTERS (b)	29/35 (83%)	27/35 (77%)	31/35 (89%)	35/35 (100%)
POLY-3 RATE (c)	54/80.08	45/82.04	62/84.61	74/87.68
POLY-3 PERCENT (g)	67.4%	54.9%	73.3%	84.4%
TERMINAL (d)	14/25 (56%)	20/43 (47%)	41/56 (73%)	32/43 (74%)
FIRST INCIDENCE	294	404	317	153
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.061N	P=0.247	P=0.005**
POLY 1.5	P<0.001**	P=0.076N	P=0.197	P=0.002**
POLY 6	P<0.001**	P=0.043N*	P=0.346	P=0.017*
RAO-SCOTT	P<0.001**	P=0.089N	P=0.280	P=0.015*
LITTER C-A/FISHERS	P=0.007**	P=0.383N	P=0.367	P=0.012*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Cecum **Edema**				
LESION RATES				
OVERALL (a)	11/75 (15%)	0/76 (0%)	0/74 (0%)	0/68 (0%)
LITTERS (b)	10/34 (29%)	0/34 (0%)	0/33 (0%)	0/35 (0%)
POLY-3 RATE (c)	11/59.62	0/65.29	0/67.32	0/56.89
POLY-3 PERCENT (g)	18.5%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/55 (0%)	0/43 (0%)
FIRST INCIDENCE	496	---	---	---
STATISTICAL TESTS				
POLY 3	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
POLY 6	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
RAO-SCOTT	P=0.002N**	P=0.006N**	P=0.005N**	P=0.010N**
LITTER C-A/FISHERS	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Cecum **Erosion**				
LESION RATES				
OVERALL (a)	10/75 (13%)	1/76 (1%)	1/74 (1%)	1/68 (1%)
LITTERS (b)	9/34 (26%)	1/34 (3%)	1/33 (3%)	1/35 (3%)
POLY-3 RATE (c)	10/59.11	1/65.69	1/67.61	1/57.27
POLY-3 PERCENT (g)	16.9%	1.5%	1.5%	1.8%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/55 (0%)	0/43 (0%)
FIRST INCIDENCE	510	615	652	621
STATISTICAL TESTS				
POLY 3	P=0.002N**	P=0.003N**	P=0.002N**	P=0.005N**
POLY 1.5	P=0.002N**	P=0.003N**	P=0.003N**	P=0.007N**
POLY 6	P=0.003N**	P=0.002N**	P<0.001N**	P=0.004N**
RAO-SCOTT	P=0.010N**	P=0.015N*	P=0.014N*	P=0.024N*
LITTER C-A/FISHERS	P=0.004N**	P=0.007N**	P=0.008N**	P=0.006N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Cecum Inflammation Acute				
LESION RATES				
OVERALL (a)	10/75 (13%)	1/76 (1%)	0/74 (0%)	1/68 (1%)
LITTERS (b)	10/34 (29%)	1/34 (3%)	0/33 (0%)	1/35 (3%)
POLY-3 RATE (c)	10/59.73	1/65.69	0/67.32	1/57.27
POLY-3 PERCENT (g)	16.7%	1.5%	0%	1.8%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/55 (0%)	0/43 (0%)
FIRST INCIDENCE	496	615	---	621
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.003N**	P<0.001N**	P=0.006N**
POLY 1.5	P<0.001N**	P=0.004N**	P<0.001N**	P=0.007N**
POLY 6	P<0.001N**	P=0.002N**	P<0.001N**	P=0.004N**
RAO-SCOTT	P=0.005N**	P=0.010N**	P=0.003N**	P=0.017N*
LITTER C-A/FISHERS	P<0.001N**	P=0.003N**	P<0.001N**	P=0.003N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Cecum **Ulcer**				
LESION RATES				
OVERALL (a)	6/75 (8%)	0/76 (0%)	0/74 (0%)	0/68 (0%)
LITTERS (b)	6/34 (18%)	0/34 (0%)	0/33 (0%)	0/35 (0%)
POLY-3 RATE (c)	6/58.92	0/65.29	0/67.32	0/56.89
POLY-3 PERCENT (g)	10.2%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/55 (0%)	0/43 (0%)
FIRST INCIDENCE	498	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.004N**	P=0.012N*	P=0.011N*	P=0.018N*
POLY 1.5	P=0.004N**	P=0.014N*	P=0.014N*	P=0.021N*
POLY 6	P=0.005N**	P=0.010N**	P=0.008N**	P=0.015N*
RAO-SCOTT	P=0.019N*	P=0.048N*	P=0.046N*	P=0.062N
LITTER C-A/FISHERS	P=0.004N**	P=0.012N*	P=0.013N*	P=0.011N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Cecum: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	20/75 (27%)	8/76 (11%)	7/74 (9%)	2/68 (3%)
LITTERS (b)	14/34 (41%)	8/34 (24%)	7/33 (21%)	2/35 (6%)
POLY-3 RATE (c)	20/64.16	8/66.35	7/67.94	2/57.27
POLY-3 PERCENT (g)	31.2%	12.1%	10.3%	3.5%
TERMINAL (d)	2/25 (8%)	5/43 (12%)	4/55 (7%)	1/43 (2%)
FIRST INCIDENCE	496	568	614	621
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.006N**	P=0.002N**	P<0.001N**
POLY 1.5	P<0.001N**	P=0.007N**	P=0.003N**	P<0.001N**
POLY 6	P<0.001N**	P=0.005N**	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.021N*	P=0.011N*	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P=0.097N	P=0.067N	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Cecum: Epithelium Regeneration				
LESION RATES				
OVERALL (a)	14/75 (19%)	1/76 (1%)	0/74 (0%)	1/68 (1%)
LITTERS (b)	11/34 (32%)	1/34 (3%)	0/33 (0%)	1/35 (3%)
POLY-3 RATE (c)	14/61.35	1/65.69	0/67.32	1/57.27
POLY-3 PERCENT (g)	22.8%	1.5%	0%	1.8%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/55 (0%)	0/43 (0%)
FIRST INCIDENCE	496	615	---	621
STATISTICAL TESTS				
POLY 3	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
POLY 6	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.004N**	P<0.001N**	P=0.007N**
LITTER C-A/FISHERS	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Colon: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	12/81 (15%)	4/83 (5%)	5/82 (6%)	1/76 (1%)
LITTERS (b)	11/35 (31%)	4/35 (11%)	5/34 (15%)	1/35 (3%)
POLY-3 RATE (c)	12/63.95	4/70.43	5/74.06	1/61.07
POLY-3 PERCENT (g)	18.8%	5.7%	6.8%	1.6%
TERMINAL (d)	2/25 (8%)	2/43 (5%)	3/56 (5%)	0/43 (0%)
FIRST INCIDENCE	580	568	614	621
STATISTICAL TESTS				
POLY 3	P=0.002N**	P=0.018N*	P=0.029N*	P=0.002N**
POLY 1.5	P=0.002N**	P=0.021N*	P=0.040N*	P=0.002N**
POLY 6	P=0.002N**	P=0.013N*	P=0.017N*	P<0.001N**
RAO-SCOTT	P=0.004N**	P=0.031N*	P=0.045N*	P=0.005N**
LITTER C-A/FISHERS	P=0.002N**	P=0.039N*	P=0.086N	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Colon: Artery Mineral				
LESION RATES				
OVERALL (a)	2/81 (2%)	0/83 (0%)	0/82 (0%)	0/76 (0%)
LITTERS (b)	2/35 (6%)	0/35 (0%)	0/34 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/61.05	0/69.41	0/73.45	0/60.68
POLY-3 PERCENT (g)	3.3%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	662	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.124N	P=0.211N	P=0.200N	P=0.239N
POLY 1.5	P=0.121N	P=0.220N	P=0.215N	P=0.247N
POLY 6	P=0.131N	P=0.196N	P=0.178N	P=0.223N
RAO-SCOTT	P=0.224N	P=0.355N	P=0.351N	P=0.376N
LITTER C-A/FISHERS	P=0.115N	P=0.246N	P=0.254N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Colon: Epithelium Regeneration				
LESION RATES				
OVERALL (a)	5/81 (6%)	0/83 (0%)	0/82 (0%)	0/76 (0%)
LITTERS (b)	5/35 (14%)	0/35 (0%)	0/34 (0%)	0/35 (0%)
POLY-3 RATE (c)	5/61.95	0/69.41	0/73.45	0/60.68
POLY-3 PERCENT (g)	8.1%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	510	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.009N**	P=0.024N*	P=0.021N*	P=0.034N*
POLY 1.5	P=0.009N**	P=0.027N*	P=0.025N*	P=0.037N*
POLY 6	P=0.010N**	P=0.020N*	P=0.015N*	P=0.028N*
RAO-SCOTT	P=0.033N*	P=0.076N	P=0.071N	P=0.093N
LITTER C-A/FISHERS	P=0.009N**	P=0.027N*	P=0.029N*	P=0.027N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Rectum **Hyperplasia Lymphocyte**				
LESION RATES				
OVERALL (a)	1/83 (1%)	0/81 (0%)	0/80 (0%)	0/76 (0%)
LITTERS (b)	1/35 (3%)	0/35 (0%)	0/34 (0%)	0/35 (0%)
POLY-3 RATE (c)	1/61.02	0/68.89	0/71.19	0/59.10
POLY-3 PERCENT (g)	1.6%	0%	0%	0%
TERMINAL (d)	1/25 (4%)	0/43 (0%)	0/55 (0%)	0/43 (0%)
FIRST INCIDENCE	730 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Rectum **Inflammation Acute**				
LESION RATES				
OVERALL (a)	2/83 (2%)	0/81 (0%)	0/80 (0%)	0/76 (0%)
LITTERS (b)	2/35 (6%)	0/35 (0%)	0/34 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/61.30	0/68.89	0/71.19	0/59.10
POLY-3 PERCENT (g)	3.3%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/55 (0%)	0/43 (0%)
FIRST INCIDENCE	685	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.129N	P=0.213N	P=0.207N	P=0.246N
POLY 1.5	P=0.125N	P=0.225N	P=0.224N	P=0.254N
POLY 6	P=0.137N	P=0.197N	P=0.183N	P=0.229N
RAO-SCOTT	P=0.224N	P=0.357N	P=0.356N	P=0.377N
LITTER C-A/FISHERS	P=0.115N	P=0.246N	P=0.254N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Rectum: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	4/83 (5%)	1/81 (1%)	1/80 (1%)	1/76 (1%)
LITTERS (b)	4/35 (11%)	1/35 (3%)	1/34 (3%)	1/35 (3%)
POLY-3 RATE (c)	4/61.99	1/68.89	1/71.19	1/59.10
POLY-3 PERCENT (g)	6.5%	1.5%	1.4%	1.7%
TERMINAL (d)	2/25 (8%)	1/43 (2%)	1/55 (2%)	1/43 (2%)
FIRST INCIDENCE	565	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.156N	P=0.151N	P=0.143N	P=0.195N
POLY 1.5	P=0.156N	P=0.166N	P=0.164N	P=0.204N
POLY 6	P=0.156N	P=0.131N	P=0.114N	P=0.173N
RAO-SCOTT	P=0.170N	P=0.183N	P=0.176N	P=0.222N
LITTER C-A/FISHERS	P=0.134N	P=0.178N	P=0.187N	P=0.178N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Rectum: Epithelium Regeneration				
LESION RATES				
OVERALL (a)	3/83 (4%)	0/81 (0%)	0/80 (0%)	0/76 (0%)
LITTERS (b)	3/35 (9%)	0/35 (0%)	0/34 (0%)	0/35 (0%)
POLY-3 RATE (c)	3/62.44	0/68.89	0/71.19	0/59.10
POLY-3 PERCENT (g)	4.8%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/55 (0%)	0/43 (0%)
FIRST INCIDENCE	498	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.054N	P=0.104N	P=0.099N	P=0.130N
POLY 1.5	P=0.053N	P=0.112N	P=0.111N	P=0.135N
POLY 6	P=0.058N	P=0.092N	P=0.083N	P=0.118N
RAO-SCOTT	P=0.116N	P=0.211N	P=0.208N	P=0.235N
LITTER C-A/FISHERS	P=0.048N*	P=0.120N	P=0.125N	P=0.120N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Small, Duodenum: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/81 (0%)	0/84 (0%)	3/83 (4%)	0/66 (0%)
LITTERS (b)	0/34 (0%)	0/35 (0%)	3/35 (9%)	0/34 (0%)
POLY-3 RATE (c)	0/61.22	0/70.31	3/74.45	0/55.45
POLY-3 PERCENT (g)	0%	0%	4%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	2/56 (4%)	0/43 (0%)
FIRST INCIDENCE	---	---	604	---
STATISTICAL TESTS				
POLY 3	P=0.523	(e)	P=0.160	(e)
POLY 1.5	P=0.498	(e)	P=0.143	(e)
POLY 6	P=0.574	(e)	P=0.189	(e)
RAO-SCOTT	P=0.549	(e)	P=0.253	(e)
LITTER C-A/FISHERS	P=0.538	(e)	P=0.125	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Small, Ileum: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	2/78 (3%)	0/76 (0%)	1/77 (1%)	0/63 (0%)
LITTERS (b)	2/34 (6%)	0/34 (0%)	1/34 (3%)	0/34 (0%)
POLY-3 RATE (c)	2/59.97	0/65.31	1/69.06	0/54.01
POLY-3 PERCENT (g)	3.3%	0%	1.5%	0%
TERMINAL (d)	1/25 (4%)	0/42 (0%)	1/55 (2%)	0/43 (0%)
FIRST INCIDENCE	604	---	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.219N	P=0.220N	P=0.451N	P=0.261N
POLY 1.5	P=0.219N	P=0.230N	P=0.476N	P=0.274N
POLY 6	P=0.220N	P=0.204N	P=0.411N	P=0.238N
RAO-SCOTT	P=0.267N	P=0.295N	P=0.497N	P=0.336N
LITTER C-A/FISHERS	P=0.187N	P=0.246N	P=0.500N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Islets, Pancreatic Hyperplasia				
LESION RATES				
OVERALL (a)	12/90 (13%)	15/88 (17%)	13/87 (15%)	12/79 (15%)
LITTERS (b)	11/35 (31%)	13/35 (37%)	12/35 (34%)	9/35 (26%)
POLY-3 RATE (c)	12/68.33	15/74.38	13/76.43	12/62.90
POLY-3 PERCENT (g)	17.6%	20.2%	17%	19.1%
TERMINAL (d)	4/25 (16%)	9/43 (21%)	11/56 (20%)	9/43 (21%)
FIRST INCIDENCE	510	447	652	590
STATISTICAL TESTS				
POLY 3	P=0.517	P=0.427	P=0.553N	P=0.501
POLY 1.5	P=0.490	P=0.379	P=0.550	P=0.471
POLY 6	P=0.511N	P=0.507	P=0.437N	P=0.567
RAO-SCOTT	P=0.507	P=0.424	P=0.543N	P=0.490
LITTER C-A/FISHERS	P=0.281N	P=0.401	P=0.500	P=0.396N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney **Mineral**				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	2/90 (2%)	0/87 (0%)
LITTERS (b)	1/35 (3%)	0/35 (0%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	1/65.91	0/74.05	2/78.65	0/65.00
POLY-3 PERCENT (g)	1.5%	0%	2.5%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	604	---	664	---
STATISTICAL TESTS				
POLY 3	P=0.484N	P=0.477N	P=0.561	P=0.503N
POLY 1.5	P=0.482N	P=0.487N	P=0.533	P=0.507N
POLY 6	P=0.482N	P=0.461N	P=0.604	P=0.490N
RAO-SCOTT	P=0.480N	P=0.518N	P=0.578	P=0.524N
LITTER C-A/FISHERS	P=0.461N	P=0.500N	P=0.500	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney **Nephropathy Chronic Progressive**				
LESION RATES				
OVERALL (a)	88/90 (98%)	90/90 (100%)	90/90 (100%)	86/87 (99%)
LITTERS (b)	35/35 (100%)	35/35 (100%)	35/35 (100%)	35/35 (100%)
POLY-3 RATE (c)	88/88.40	90/90.00	90/90.00	86/86.30
POLY-3 PERCENT (g)	99.6%	100%	100%	99.7%
TERMINAL (d)	25/25 (100%)	43/43 (100%)	56/56 (100%)	43/43 (100%)
FIRST INCIDENCE	248	388	317	153
STATISTICAL TESTS				
POLY 3	P=0.918	P=0.942	P=0.942	P=0.969
POLY 1.5	P=0.770	P=0.639	P=0.639	P=0.827
POLY 6	P=1.000	P=1.000	P=1.000	P=1.000
RAO-SCOTT	P=0.786	P=0.823	P=0.823	P=0.858
LITTER C-A/FISHERS	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney: Artery Mineral				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/90 (0%)	0/90 (0%)	0/87 (0%)
LITTERS (b)	2/35 (6%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/66.47	0/74.05	0/78.35	0/65.00
POLY-3 PERCENT (g)	3%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	565	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.120N	P=0.215N	P=0.204N	P=0.243N
POLY 1.5	P=0.118N	P=0.225N	P=0.219N	P=0.247N
POLY 6	P=0.126N	P=0.200N	P=0.182N	P=0.230N
RAO-SCOTT	P=0.216N	P=0.356N	P=0.351N	P=0.370N
LITTER C-A/FISHERS	P=0.114N	P=0.246N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Kidney: Pelvis **Dilation**				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	1/90 (1%)	1/87 (1%)
LITTERS (b)	1/35 (3%)	0/35 (0%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	1/65.51	0/74.05	1/78.36	1/65.07
POLY-3 PERCENT (g)	1.5%	0%	1.3%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	722	---	728	713
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Kidney: Pelvis Inflammation				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	1/90 (1%)	0/87 (0%)
LITTERS (b)	0/35 (0%)	1/35 (3%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	1/74.05	1/78.35	0/65.00
POLY-3 PERCENT (g)	0%	1.4%	1.3%	0%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	---	730 (T)	730 (T)	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney: Pelvis, Urothelium Hyperplasia				
LESION RATES				
OVERALL (a)	0/90 (0%)	3/90 (3%)	1/90 (1%)	0/87 (0%)
LITTERS (b)	0/35 (0%)	3/35 (9%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	3/74.05	1/78.35	0/65.00
POLY-3 PERCENT (g)	0%	4.1%	1.3%	0%
TERMINAL (d)	0/25 (0%)	3/43 (7%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	---	730 (T)	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.346N	P=0.144	P=0.536	(e)
POLY 1.5	P=0.363N	P=0.134	P=0.519	(e)
POLY 6	P=0.311N	P=0.162	P=0.561	(e)
RAO-SCOTT	P=0.398N	P=0.204	P=0.576	(e)
LITTER C-A/FISHERS	P=0.366N	P=0.120	P=0.500	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney: Renal Tubule Cyst				
LESION RATES				
OVERALL (a)	18/90 (20%)	17/90 (19%)	9/90 (10%)	6/87 (7%)
LITTERS (b)	15/35 (43%)	12/35 (34%)	7/35 (20%)	6/35 (17%)
POLY-3 RATE (c)	18/68.33	17/76.51	9/78.40	6/65.24
POLY-3 PERCENT (g)	26.3%	22.2%	11.5%	9.2%
TERMINAL (d)	6/25 (24%)	7/43 (16%)	8/56 (14%)	5/43 (12%)
FIRST INCIDENCE	527	568	717	665
STATISTICAL TESTS				
POLY 3	P=0.003N**	P=0.349N	P=0.016N*	P=0.008N**
POLY 1.5	P=0.003N**	P=0.411N	P=0.026N*	P=0.009N**
POLY 6	P=0.002N**	P=0.260N	P=0.007N**	P=0.005N**
RAO-SCOTT	P=0.006N**	P=0.367N	P=0.031N*	P=0.018N*
LITTER C-A/FISHERS	P=0.008N**	P=0.312N	P=0.035N*	P=0.018N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney: Renal Tubule Hyperplasia Atypical				
LESION RATES				
OVERALL (a)	2/90 (2%)	1/90 (1%)	3/90 (3%)	0/87 (0%)
LITTERS (b)	1/35 (3%)	1/35 (3%)	3/35 (9%)	0/35 (0%)
POLY-3 RATE (c)	2/66.69	1/74.31	3/78.78	0/65.00
POLY-3 PERCENT (g)	3%	1.4%	3.8%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	2/56 (4%)	0/43 (0%)
FIRST INCIDENCE	527	662	604	---
STATISTICAL TESTS				
POLY 3	P=0.263N	P=0.462N	P=0.575	P=0.243N
POLY 1.5	P=0.263N	P=0.478N	P=0.541	P=0.247N
POLY 6	P=0.255N	P=0.436N	P=0.627	P=0.231N
RAO-SCOTT	P=0.315N	P=0.524N	P=0.603	P=0.342N
LITTER C-A/FISHERS	P=0.409N	P=0.754	P=0.307	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney: Renal Tubule Hyperplasia Oncocytic				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/90 (0%)	0/90 (0%)	0/87 (0%)
LITTERS (b)	2/35 (6%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/65.97	0/74.05	0/78.35	0/65.00
POLY-3 PERCENT (g)	3%	0%	0%	0%
TERMINAL (d)	1/25 (4%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	580	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.121N	P=0.213N	P=0.202N	P=0.241N
POLY 1.5	P=0.119N	P=0.224N	P=0.218N	P=0.246N
POLY 6	P=0.128N	P=0.198N	P=0.180N	P=0.227N
RAO-SCOTT	P=0.213N	P=0.349N	P=0.344N	P=0.364N
LITTER C-A/FISHERS	P=0.114N	P=0.246N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lacrimal Gland				
Metaplasia Harderian Gland				
LESION RATES				
OVERALL (a)	2/2 (100%)	1/1 (100%)	1/1 (100%)	1/1 (100%)
LITTERS (b)	2/2 (100%)	1/1 (100%)	1/1 (100%)	1/1 (100%)
POLY-3 RATE (c)	2/2.00	1/1.00	1/1.00	1/1.00
POLY-3 PERCENT (g)	100%	100%	100%	100%
TERMINAL (d)	0/0 (0%)	1/1 (100%)	1/1 (100%)	0/0 (0%)
FIRST INCIDENCE	671	730 (T)	730 (T)	531
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
RAO-SCOTT	(e)	(e)	(e)	(e)
LITTER C-A/FISHERS	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Angiectasis**				
LESION RATES				
OVERALL (a)	1/90 (1%)	1/90 (1%)	0/89 (0%)	1/88 (1%)
LITTERS (b)	1/35 (3%)	1/35 (3%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	1/65.64	1/74.20	0/77.76	1/65.46
POLY-3 PERCENT (g)	1.5%	1.4%	0%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	1/43 (2%)
FIRST INCIDENCE	687	693	---	730 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Liver **Basophilic Focus**				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	2/89 (2%)	0/88 (0%)
LITTERS (b)	1/35 (3%)	0/35 (0%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	1/65.68	0/74.05	2/77.76	0/65.46
POLY-3 PERCENT (g)	1.5%	0%	2.6%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	2/56 (4%)	0/43 (0%)
FIRST INCIDENCE	677	---	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.483N	P=0.476N	P=0.558	P=0.501N
POLY 1.5	P=0.480N	P=0.486N	P=0.530	P=0.505N
POLY 6	P=0.480N	P=0.460N	P=0.602	P=0.488N
RAO-SCOTT	P=0.478N	P=0.517N	P=0.576	P=0.522N
LITTER C-A/FISHERS	P=0.461N	P=0.500N	P=0.500	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Clear Cell Focus**				
LESION RATES				
OVERALL (a)	8/90 (9%)	4/90 (4%)	5/89 (6%)	5/88 (6%)
LITTERS (b)	5/35 (14%)	4/35 (11%)	5/35 (14%)	5/35 (14%)
POLY-3 RATE (c)	8/67.12	4/74.05	5/77.76	5/65.46
POLY-3 PERCENT (g)	11.9%	5.4%	6.4%	7.6%
TERMINAL (d)	5/25 (20%)	4/43 (9%)	5/56 (9%)	5/43 (12%)
FIRST INCIDENCE	440	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.329N	P=0.138N	P=0.195N	P=0.295N
POLY 1.5	P=0.331N	P=0.157N	P=0.236N	P=0.304N
POLY 6	P=0.314N	P=0.110N	P=0.138N	P=0.260N
RAO-SCOTT	P=0.341N	P=0.176N	P=0.233N	P=0.320N
LITTER C-A/FISHERS	P=0.517	P=0.500N	P=0.633	P=0.633

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Eosinophilic Focus**				
LESION RATES				
OVERALL (a)	12/90 (13%)	5/90 (6%)	11/89 (12%)	4/88 (5%)
LITTERS (b)	11/35 (31%)	5/35 (14%)	9/35 (26%)	4/35 (11%)
POLY-3 RATE (c)	12/67.68	5/74.21	11/78.15	4/65.88
POLY-3 PERCENT (g)	17.7%	6.7%	14.1%	6.1%
TERMINAL (d)	4/25 (16%)	3/43 (7%)	10/56 (18%)	3/43 (7%)
FIRST INCIDENCE	552	705	619	608
STATISTICAL TESTS				
POLY 3	P=0.081N	P=0.038N*	P=0.353N	P=0.033N*
POLY 1.5	P=0.081N	P=0.047N*	P=0.424N	P=0.036N*
POLY 6	P=0.073N	P=0.026N*	P=0.252N	P=0.025N*
RAO-SCOTT	P=0.084N	P=0.051N	P=0.360N	P=0.045N*
LITTER C-A/FISHERS	P=0.065N	P=0.077N	P=0.396N	P=0.039N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Extramedullary Hematopoiesis**				
LESION RATES				
OVERALL (a)	5/90 (6%)	4/90 (4%)	3/89 (3%)	1/88 (1%)
LITTERS (b)	5/35 (14%)	3/35 (9%)	3/35 (9%)	1/35 (3%)
POLY-3 RATE (c)	5/68.09	4/76.17	3/78.65	1/66.08
POLY-3 PERCENT (g)	7.3%	5.3%	3.8%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	2/56 (4%)	0/43 (0%)
FIRST INCIDENCE	440	447	353	531
STATISTICAL TESTS				
POLY 3	P=0.076N	P=0.431N	P=0.284N	P=0.111N
POLY 1.5	P=0.078N	P=0.460N	P=0.319N	P=0.114N
POLY 6	P=0.071N	P=0.386N	P=0.233N	P=0.100N
RAO-SCOTT	P=0.098N	P=0.444N	P=0.314N	P=0.142N
LITTER C-A/FISHERS	P=0.077N	P=0.355N	P=0.355N	P=0.099N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Hepatodiaphragmatic Nodule**				
LESION RATES				
OVERALL (a)	1/90 (1%)	1/90 (1%)	0/89 (0%)	1/88 (1%)
LITTERS (b)	1/35 (3%)	1/35 (3%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	1/66.01	1/74.11	0/77.76	1/65.46
POLY-3 PERCENT (g)	1.5%	1.4%	0%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	1/43 (2%)
FIRST INCIDENCE	567	717	---	730 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Infiltration Cellular Mixed Cell**				
LESION RATES				
OVERALL (a)	3/90 (3%)	1/90 (1%)	3/89 (3%)	2/88 (2%)
LITTERS (b)	3/35 (9%)	1/35 (3%)	3/35 (9%)	2/35 (6%)
POLY-3 RATE (c)	3/66.00	1/74.31	3/79.08	2/66.86
POLY-3 PERCENT (g)	4.6%	1.4%	3.8%	3%
TERMINAL (d)	1/25 (4%)	0/43 (0%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	624	662	383	440
STATISTICAL TESTS				
POLY 3	P=0.539N	P=0.266N	P=0.575N	P=0.494N
POLY 1.5	P=0.541N	P=0.283N	P=0.616N	P=0.507N
POLY 6	P=0.530N	P=0.239N	P=0.511N	P=0.463N
RAO-SCOTT	P=0.512N	P=0.262N	P=0.558N	P=0.471N
LITTER C-A/FISHERS	P=0.523N	P=0.307N	P=0.663	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Mixed Cell Focus**				
LESION RATES				
OVERALL (a)	32/90 (36%)	51/90 (57%)	47/89 (53%)	37/88 (42%)
LITTERS (b)	23/35 (66%)	31/35 (89%)	28/35 (80%)	26/35 (74%)
POLY-3 RATE (c)	32/70.45	51/79.25	47/79.07	37/67.45
POLY-3 PERCENT (g)	45.4%	64.4%	59.4%	54.9%
TERMINAL (d)	17/25 (68%)	36/43 (84%)	43/56 (77%)	31/43 (72%)
FIRST INCIDENCE	552	517	577	469
STATISTICAL TESTS				
POLY 3	P=0.314	P=0.010**	P=0.051	P=0.159
POLY 1.5	P=0.342	P=0.006**	P=0.028*	P=0.177
POLY 6	P=0.327	P=0.023*	P=0.124	P=0.166
RAO-SCOTT	P=0.308	P=0.016*	P=0.062	P=0.172
LITTER C-A/FISHERS	P=0.446	P=0.022*	P=0.141	P=0.301

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	2/90 (2%)	1/90 (1%)	0/89 (0%)	0/88 (0%)
LITTERS (b)	2/35 (6%)	1/35 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/65.89	1/74.55	0/77.76	0/65.46
POLY-3 PERCENT (g)	3%	1.3%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	662	582	---	---
STATISTICAL TESTS				
POLY 3	P=0.101N	P=0.457N	P=0.204N	P=0.239N
POLY 1.5	P=0.103N	P=0.475N	P=0.220N	P=0.244N
POLY 6	P=0.101N	P=0.429N	P=0.181N	P=0.226N
RAO-SCOTT	P=0.154N	P=0.498N	P=0.288N	P=0.307N
LITTER C-A/FISHERS	P=0.100N	P=0.500N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Bile Duct Cyst				
LESION RATES				
OVERALL (a)	3/90 (3%)	5/90 (6%)	2/89 (2%)	1/88 (1%)
LITTERS (b)	2/35 (6%)	5/35 (14%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	3/66.01	5/74.66	2/77.76	1/65.46
POLY-3 PERCENT (g)	4.6%	6.7%	2.6%	1.5%
TERMINAL (d)	2/25 (8%)	3/43 (7%)	2/56 (4%)	1/43 (2%)
FIRST INCIDENCE	567	568	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.135N	P=0.427	P=0.427N	P=0.309N
POLY 1.5	P=0.143N	P=0.397	P=0.462N	P=0.316N
POLY 6	P=0.119N	P=0.476	P=0.372N	P=0.287N
RAO-SCOTT	P=0.188N	P=0.456	P=0.463N	P=0.353N
LITTER C-A/FISHERS	P=0.191N	P=0.214	P=0.500N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Bile Duct Fibrosis				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/89 (0%)	1/88 (1%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/65.47	0/74.05	0/77.76	1/65.93
POLY-3 PERCENT (g)	0%	0%	0%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	590
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Bile Duct Hyperplasia				
LESION RATES				
OVERALL (a)	41/90 (46%)	33/90 (37%)	26/89 (29%)	14/88 (16%)
LITTERS (b)	25/35 (71%)	25/35 (71%)	19/35 (54%)	10/35 (29%)
POLY-3 RATE (c)	41/76.21	33/78.30	26/81.03	14/68.84
POLY-3 PERCENT (g)	53.8%	42.2%	32.1%	20.3%
TERMINAL (d)	11/25 (44%)	19/43 (44%)	16/56 (29%)	7/43 (16%)
FIRST INCIDENCE	294	388	495	440
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.090N	P=0.004N**	P<0.001N**
POLY 1.5	P<0.001N**	P=0.106N	P=0.007N**	P<0.001N**
POLY 6	P<0.001N**	P=0.075N	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.111N	P=0.007N**	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P=0.604	P=0.108N	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Hepatocyte Hypertrophy				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/89 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	0/74.05	0/77.76	0/65.46
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Hepatocyte **Increased mitoses**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/89 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	0/74.05	0/77.76	0/65.46
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Hepatocyte Necrosis				
LESION RATES				
OVERALL (a)	5/90 (6%)	6/90 (7%)	6/89 (7%)	6/88 (7%)
LITTERS (b)	5/35 (14%)	4/35 (11%)	6/35 (17%)	6/35 (17%)
POLY-3 RATE (c)	5/66.43	6/76.88	6/78.91	6/67.06
POLY-3 PERCENT (g)	7.5%	7.8%	7.6%	9%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	3/56 (5%)	2/43 (5%)
FIRST INCIDENCE	654	404	393	590
STATISTICAL TESTS				
POLY 3	P=0.440	P=0.599	P=0.616	P=0.506
POLY 1.5	P=0.430	P=0.559	P=0.562	P=0.488
POLY 6	P=0.474	P=0.589N	P=0.547N	P=0.554
RAO-SCOTT	P=0.435	P=0.582	P=0.600	P=0.490
LITTER C-A/FISHERS	P=0.359	P=0.500N	P=0.500	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Hepatocyte Vacuolation, Cytoplasmic				
LESION RATES				
OVERALL (a)	6/90 (7%)	6/90 (7%)	7/89 (8%)	7/88 (8%)
LITTERS (b)	6/35 (17%)	5/35 (14%)	6/35 (17%)	7/35 (20%)
POLY-3 RATE (c)	6/66.43	6/74.58	7/78.96	7/68.27
POLY-3 PERCENT (g)	9%	8.1%	8.9%	10.3%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	2/56 (4%)	1/43 (2%)
FIRST INCIDENCE	642	663	471	469
STATISTICAL TESTS				
POLY 3	P=0.419	P=0.537N	P=0.600N	P=0.521
POLY 1.5	P=0.401	P=0.571N	P=0.567	P=0.495
POLY 6	P=0.461	P=0.482N	P=0.507N	P=0.578
RAO-SCOTT	P=0.413	P=0.516N	P=0.582N	P=0.498
LITTER C-A/FISHERS	P=0.381	P=0.500N	P=0.624	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Kupffer Cell Hyperplasia				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/89 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	0/74.05	0/77.76	0/65.46
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Kupffer Cell Hypertrophy				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/89 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	0/74.05	0/77.76	0/65.46
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Periductal Cholangiofibrosis				
LESION RATES				
OVERALL (a)	2/90 (2%)	2/90 (2%)	2/89 (2%)	0/88 (0%)
LITTERS (b)	2/35 (6%)	2/35 (6%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	2/65.61	2/74.17	2/78.01	0/65.46
POLY-3 PERCENT (g)	3.1%	2.7%	2.6%	0%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	704	701	664	---
STATISTICAL TESTS				
POLY 3	P=0.169N	P=0.648N	P=0.629N	P=0.238N
POLY 1.5	P=0.173N	P=0.668N	P=0.661N	P=0.243N
POLY 6	P=0.158N	P=0.616N	P=0.577N	P=0.224N
RAO-SCOTT	P=0.174N	P=0.624N	P=0.610N	P=0.234N
LITTER C-A/FISHERS	P=0.162N	P=0.693	P=0.693	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung **Congestion**				
LESION RATES				
OVERALL (a)	13/90 (14%)	13/90 (14%)	11/90 (12%)	33/90 (37%)
LITTERS (b)	10/35 (29%)	11/35 (31%)	10/35 (29%)	23/35 (66%)
POLY-3 RATE (c)	13/70.11	13/78.88	11/81.23	33/82.87
POLY-3 PERCENT (g)	18.5%	16.5%	13.5%	39.8%
TERMINAL (d)	1/25 (4%)	1/43 (2%)	2/56 (4%)	2/43 (5%)
FIRST INCIDENCE	294	388	317	201
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.454N	P=0.269N	P=0.003**
POLY 1.5	P<0.001**	P=0.509N	P=0.331N	P<0.001**
POLY 6	P<0.001**	P=0.374N	P=0.186N	P=0.011*
RAO-SCOTT	P<0.001**	P=0.455N	P=0.282N	P=0.006**
LITTER C-A/FISHERS	P<0.001**	P=0.500	P=0.604	P=0.002**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung **Foreign Body**				
LESION RATES				
OVERALL (a)	4/90 (4%)	2/90 (2%)	1/90 (1%)	1/90 (1%)
LITTERS (b)	4/35 (11%)	2/35 (6%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	4/67.95	2/74.05	1/78.67	1/66.60
POLY-3 PERCENT (g)	5.9%	2.7%	1.3%	1.5%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	248	730 (T)	642	630
STATISTICAL TESTS				
POLY 3	P=0.115N	P=0.300N	P=0.141N	P=0.187N
POLY 1.5	P=0.117N	P=0.317N	P=0.159N	P=0.189N
POLY 6	P=0.111N	P=0.272N	P=0.114N	P=0.172N
RAO-SCOTT	P=0.133N	P=0.316N	P=0.167N	P=0.205N
LITTER C-A/FISHERS	P=0.109N	P=0.337N	P=0.178N	P=0.178N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung **Hemorrhage**				
LESION RATES				
OVERALL (a)	3/90 (3%)	5/90 (6%)	2/90 (2%)	4/90 (4%)
LITTERS (b)	3/35 (9%)	5/35 (14%)	2/35 (6%)	4/35 (11%)
POLY-3 RATE (c)	3/66.59	5/76.47	2/79.23	4/67.56
POLY-3 PERCENT (g)	4.5%	6.5%	2.5%	5.9%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	552	388	393	500
STATISTICAL TESTS				
POLY 3	P=0.543	P=0.436	P=0.422N	P=0.508
POLY 1.5	P=0.533	P=0.404	P=0.457N	P=0.497
POLY 6	P=0.572	P=0.485	P=0.370N	P=0.541
RAO-SCOTT	P=0.515	P=0.420	P=0.405N	P=0.481
LITTER C-A/FISHERS	P=0.538	P=0.355	P=0.500N	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Lung Inflammation				
LESION RATES				
OVERALL (a)	3/90 (3%)	0/90 (0%)	1/90 (1%)	2/90 (2%)
LITTERS (b)	3/35 (9%)	0/35 (0%)	1/35 (3%)	2/35 (6%)
POLY-3 RATE (c)	3/67.40	0/74.05	1/78.67	2/67.59
POLY-3 PERCENT (g)	4.5%	0%	1.3%	3%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	248	---	642	153
STATISTICAL TESTS				
POLY 3	P=0.567N	P=0.105N	P=0.254N	P=0.499N
POLY 1.5	P=0.563N	P=0.112N	P=0.278N	P=0.505N
POLY 6	P=0.572N	P=0.094N	P=0.218N	P=0.475N
RAO-SCOTT	P=0.552N	P=0.148N	P=0.297N	P=0.502N
LITTER C-A/FISHERS	P=0.556N	P=0.120N	P=0.307N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung **Inflammation Acute**				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/65.70	0/74.05	0/78.35	0/66.24
POLY-3 PERCENT (g)	3%	0%	0%	0%
TERMINAL (d)	1/25 (4%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	671	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.119N	P=0.213N	P=0.202N	P=0.236N
POLY 1.5	P=0.117N	P=0.223N	P=0.218N	P=0.240N
POLY 6	P=0.125N	P=0.196N	P=0.179N	P=0.223N
RAO-SCOTT	P=0.205N	P=0.343N	P=0.338N	P=0.352N
LITTER C-A/FISHERS	P=0.114N	P=0.246N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	2/90 (2%)	2/90 (2%)	2/90 (2%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	1/35 (3%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	2/65.83	2/74.76	2/78.39	0/66.24
POLY-3 PERCENT (g)	3%	2.7%	2.6%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	663	552	720	---
STATISTICAL TESTS				
POLY 3	P=0.168N	P=0.647N	P=0.629N	P=0.236N
POLY 1.5	P=0.170N	P=0.667N	P=0.658N	P=0.240N
POLY 6	P=0.159N	P=0.614N	P=0.580N	P=0.224N
RAO-SCOTT	P=0.217N	P=0.649N	P=0.638N	P=0.304N
LITTER C-A/FISHERS	P=0.199N	P=0.500N	P=0.693	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung **Inflammation Granulomatous**				
LESION RATES				
OVERALL (a)	0/90 (0%)	6/90 (7%)	1/90 (1%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	5/35 (14%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	6/74.05	1/78.35	0/66.24
POLY-3 PERCENT (g)	0%	8.1%	1.3%	0%
TERMINAL (d)	0/25 (0%)	6/43 (14%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	---	730 (T)	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.168N	P=0.025*	P=0.536	(e)
POLY 1.5	P=0.185N	P=0.022*	P=0.519	(e)
POLY 6	P=0.135N	P=0.032*	P=0.561	(e)
RAO-SCOTT	P=0.273N	P=0.086	P=0.635	(e)
LITTER C-A/FISHERS	P=0.240N	P=0.027*	P=0.500	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung: Alveolar Epithelium Metaplasia				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	0/74.05	0/78.35	0/66.24
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung: Alveolus **Infiltration Cellular Histiocyte**				
LESION RATES				
OVERALL (a)	37/90 (41%)	38/90 (42%)	42/90 (47%)	47/90 (52%)
LITTERS (b)	25/35 (71%)	25/35 (71%)	26/35 (74%)	28/35 (80%)
POLY-3 RATE (c)	37/73.40	38/80.97	42/82.52	47/77.26
POLY-3 PERCENT (g)	50.4%	46.9%	50.9%	60.8%
TERMINAL (d)	13/25 (52%)	20/43 (47%)	25/56 (45%)	26/43 (61%)
FIRST INCIDENCE	440	404	353	201
STATISTICAL TESTS				
POLY 3	P=0.061	P=0.390N	P=0.541	P=0.118
POLY 1.5	P=0.054	P=0.481N	P=0.415	P=0.096
POLY 6	P=0.088	P=0.267N	P=0.392N	P=0.189
RAO-SCOTT	P=0.084	P=0.401N	P=0.537	P=0.149
LITTER C-A/FISHERS	P=0.216	P=0.604	P=0.500	P=0.289

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Lung: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	3/90 (3%)	3/90 (3%)	1/90 (1%)	0/90 (0%)
LITTERS (b)	3/35 (9%)	3/35 (9%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	3/65.83	3/74.53	1/78.78	0/66.24
POLY-3 PERCENT (g)	4.6%	4%	1.3%	0%
TERMINAL (d)	2/25 (8%)	1/43 (2%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	629	615	604	---
STATISTICAL TESTS				
POLY 3	P=0.051N	P=0.603N	P=0.246N	P=0.119N
POLY 1.5	P=0.053N	P=0.628N	P=0.273N	P=0.122N
POLY 6	P=0.047N*	P=0.561N	P=0.208N	P=0.109N
RAO-SCOTT	P=0.072N	P=0.593N	P=0.279N	P=0.149N
LITTER C-A/FISHERS	P=0.051N	P=0.663	P=0.307N	P=0.120N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung: Artery, Mediastinum **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/65.91	0/74.05	0/78.35	0/66.24
POLY-3 PERCENT (g)	3%	0%	0%	0%
TERMINAL (d)	1/25 (4%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	604	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.118N	P=0.213N	P=0.202N	P=0.237N
POLY 1.5	P=0.116N	P=0.224N	P=0.218N	P=0.240N
POLY 6	P=0.125N	P=0.197N	P=0.179N	P=0.224N
RAO-SCOTT	P=0.207N	P=0.346N	P=0.341N	P=0.355N
LITTER C-A/FISHERS	P=0.114N	P=0.246N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung: Epithelium Alveolus Hyperplasia				
LESION RATES				
OVERALL (a)	3/90 (3%)	2/90 (2%)	1/90 (1%)	1/90 (1%)
LITTERS (b)	3/35 (9%)	2/35 (6%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	3/66.23	2/74.05	1/78.35	1/66.24
POLY-3 PERCENT (g)	4.5%	2.7%	1.3%	1.5%
TERMINAL (d)	1/25 (4%)	2/43 (5%)	1/56 (2%)	1/43 (2%)
FIRST INCIDENCE	580	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.202N	P=0.450N	P=0.250N	P=0.306N
POLY 1.5	P=0.204N	P=0.471N	P=0.275N	P=0.311N
POLY 6	P=0.195N	P=0.416N	P=0.214N	P=0.288N
RAO-SCOTT	P=0.206N	P=0.439N	P=0.256N	P=0.298N
LITTER C-A/FISHERS	P=0.197N	P=0.500N	P=0.307N	P=0.307N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung: Interstitium **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	0/90 (0%)	6/90 (7%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	6/35 (17%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	6/74.81	0/78.35	0/66.24
POLY-3 PERCENT (g)	0%	8%	0%	0%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	615	---	---
STATISTICAL TESTS				
POLY 3	P=0.128N	P=0.026*	(e)	(e)
POLY 1.5	P=0.145N	P=0.022*	(e)	(e)
POLY 6	P=0.099N	P=0.035*	(e)	(e)
RAO-SCOTT	P=0.221N	P=0.071	(e)	(e)
LITTER C-A/FISHERS	P=0.162N	P=0.012*	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mandibular **Congestion**				
LESION RATES				
OVERALL (a)	0/89 (0%)	1/90 (1%)	2/90 (2%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	1/35 (3%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	0/64.73	1/74.62	2/78.76	0/65.38
POLY-3 PERCENT (g)	0%	1.3%	2.5%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	---	552	610	---
STATISTICAL TESTS				
POLY 3	P=0.618N	P=0.528	P=0.284	(e)
POLY 1.5	P=0.623N	P=0.517	P=0.264	(e)
POLY 6	P=0.599N	P=0.546	P=0.318	(e)
RAO-SCOTT	P=0.606N	P=0.547	P=0.332	(e)
LITTER C-A/FISHERS	P=0.616N	P=0.500	P=0.246	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mandibular **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	0/89 (0%)	3/90 (3%)	2/90 (2%)	1/88 (1%)
LITTERS (b)	0/35 (0%)	3/35 (9%)	2/35 (6%)	1/35 (3%)
POLY-3 RATE (c)	0/64.73	3/75.08	2/78.35	1/65.38
POLY-3 PERCENT (g)	0%	4%	2.6%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	2/56 (4%)	1/43 (2%)
FIRST INCIDENCE	---	568	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.564	P=0.149	P=0.283	P=0.502
POLY 1.5	P=0.552	P=0.138	P=0.263	P=0.498
POLY 6	P=0.599	P=0.170	P=0.316	P=0.514
RAO-SCOTT	P=0.534	P=0.166	P=0.292	P=0.466
LITTER C-A/FISHERS	P=0.556	P=0.120	P=0.246	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mandibular **Hyperplasia Lymphocyte**				
LESION RATES				
OVERALL (a)	41/89 (46%)	50/90 (56%)	52/90 (58%)	40/88 (45%)
LITTERS (b)	27/35 (77%)	32/35 (91%)	29/35 (83%)	28/35 (80%)
POLY-3 RATE (c)	41/70.78	50/78.58	52/80.32	40/68.75
POLY-3 PERCENT (g)	57.9%	63.6%	64.7%	58.2%
TERMINAL (d)	23/25 (92%)	35/43 (81%)	44/56 (79%)	29/43 (67%)
FIRST INCIDENCE	541	517	595	528
STATISTICAL TESTS				
POLY 3	P=0.489N	P=0.279	P=0.231	P=0.560
POLY 1.5	P=0.476N	P=0.208	P=0.143	P=0.552
POLY 6	P=0.430N	P=0.423	P=0.438	P=0.518N
RAO-SCOTT	P=0.481N	P=0.283	P=0.237	P=0.542
LITTER C-A/FISHERS	P=0.500N	P=0.094	P=0.383	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mandibular **Infiltration Cellular Histiocyte**				
LESION RATES				
OVERALL (a)	0/89 (0%)	2/90 (2%)	0/90 (0%)	1/88 (1%)
LITTERS (b)	0/35 (0%)	2/35 (6%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/64.73	2/74.57	0/78.35	1/65.38
POLY-3 PERCENT (g)	0%	2.7%	0%	1.5%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	0/56 (0%)	1/43 (2%)
FIRST INCIDENCE	---	573	---	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.557	P=0.271	(e)	P=0.502
POLY 1.5	P=0.544	P=0.258	(e)	P=0.498
POLY 6	P=0.586	P=0.293	(e)	P=0.514
RAO-SCOTT	P=0.538	P=0.333	(e)	P=0.526
LITTER C-A/FISHERS	P=0.539	P=0.246	(e)	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Lymph Node, Mandibular **Infiltration Cellular Polymorphonuclear**				
LESION RATES				
OVERALL (a)	2/89 (2%)	0/90 (0%)	0/90 (0%)	0/88 (0%)
LITTERS (b)	2/35 (6%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/65.75	0/74.05	0/78.35	0/65.38
POLY-3 PERCENT (g)	3%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	248	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.118N	P=0.213N	P=0.202N	P=0.239N
POLY 1.5	P=0.116N	P=0.223N	P=0.217N	P=0.243N
POLY 6	P=0.125N	P=0.197N	P=0.179N	P=0.226N
RAO-SCOTT	P=0.214N	P=0.354N	P=0.349N	P=0.366N
LITTER C-A/FISHERS	P=0.114N	P=0.246N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mandibular **Proliferation Plasma Cell**				
LESION RATES				
OVERALL (a)	49/89 (55%)	61/90 (68%)	62/90 (69%)	57/88 (65%)
LITTERS (b)	29/35 (83%)	34/35 (97%)	32/35 (91%)	33/35 (94%)
POLY-3 RATE (c)	49/73.96	61/83.26	62/83.04	57/76.08
POLY-3 PERCENT (g)	66.3%	73.3%	74.7%	74.9%
TERMINAL (d)	20/25 (80%)	34/43 (79%)	45/56 (80%)	31/43 (72%)
FIRST INCIDENCE	541	491	495	475
STATISTICAL TESTS				
POLY 3	P=0.159	P=0.201	P=0.148	P=0.142
POLY 1.5	P=0.138	P=0.122	P=0.082	P=0.114
POLY 6	P=0.236	P=0.363	P=0.312	P=0.241
RAO-SCOTT	P=0.165	P=0.214	P=0.161	P=0.159
LITTER C-A/FISHERS	P=0.154	P=0.053	P=0.239	P=0.130

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mandibular: Lymphatic Sinus Ectasia				
LESION RATES				
OVERALL (a)	16/89 (18%)	24/90 (27%)	29/90 (32%)	14/88 (16%)
LITTERS (b)	15/35 (43%)	20/35 (57%)	23/35 (66%)	13/35 (37%)
POLY-3 RATE (c)	16/68.47	24/75.56	29/78.84	14/65.43
POLY-3 PERCENT (g)	23.4%	31.8%	36.8%	21.4%
TERMINAL (d)	4/25 (16%)	16/43 (37%)	26/56 (46%)	13/43 (30%)
FIRST INCIDENCE	541	568	604	717
STATISTICAL TESTS				
POLY 3	P=0.390N	P=0.170	P=0.053	P=0.473N
POLY 1.5	P=0.374N	P=0.144	P=0.035*	P=0.466N
POLY 6	P=0.371N	P=0.217	P=0.098	P=0.454N
RAO-SCOTT	P=0.367N	P=0.167	P=0.054	P=0.455N
LITTER C-A/FISHERS	P=0.274N	P=0.170	P=0.046*	P=0.404N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mesenteric **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	17/90 (19%)	5/89 (6%)	5/88 (6%)	9/88 (10%)
LITTERS (b)	12/35 (34%)	5/35 (14%)	5/35 (14%)	8/35 (23%)
POLY-3 RATE (c)	17/70.61	5/73.54	5/76.92	9/67.85
POLY-3 PERCENT (g)	24.1%	6.8%	6.5%	13.3%
TERMINAL (d)	2/25 (8%)	2/43 (5%)	4/56 (7%)	3/43 (7%)
FIRST INCIDENCE	496	695	698	582
STATISTICAL TESTS				
POLY 3	P=0.104N	P=0.003N**	P=0.002N**	P=0.076N
POLY 1.5	P=0.106N	P=0.004N**	P=0.004N**	P=0.080N
POLY 6	P=0.095N	P=0.002N**	P<0.001N**	P=0.061N
RAO-SCOTT	P=0.140N	P=0.011N*	P=0.009N**	P=0.112N
LITTER C-A/FISHERS	P=0.265N	P=0.046N*	P=0.046N*	P=0.214N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mesenteric **Hyperplasia Lymphocyte**				
LESION RATES				
OVERALL (a)	2/90 (2%)	3/89 (3%)	3/88 (3%)	3/88 (3%)
LITTERS (b)	2/35 (6%)	3/35 (9%)	3/35 (9%)	3/35 (9%)
POLY-3 RATE (c)	2/65.70	3/73.22	3/76.79	3/65.59
POLY-3 PERCENT (g)	3%	4.1%	3.9%	4.6%
TERMINAL (d)	1/25 (4%)	3/43 (7%)	3/56 (5%)	3/43 (7%)
FIRST INCIDENCE	671	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.429	P=0.549	P=0.570	P=0.499
POLY 1.5	P=0.422	P=0.526	P=0.534	P=0.490
POLY 6	P=0.454	P=0.586	P=0.626	P=0.527
RAO-SCOTT	P=0.407	P=0.512	P=0.537	P=0.457
LITTER C-A/FISHERS	P=0.437	P=0.500	P=0.500	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mesenteric **Infiltration Cellular Histiocyte**				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/89 (0%)	0/88 (0%)	0/88 (0%)
LITTERS (b)	1/35 (3%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	1/65.53	0/73.22	0/76.79	0/65.59
POLY-3 PERCENT (g)	1.5%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	715	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Lymph Node, Mesenteric **Infiltration Cellular Polymorphonuclear**				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/89 (0%)	0/88 (0%)	1/88 (1%)
LITTERS (b)	2/35 (6%)	0/35 (0%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	2/66.65	0/73.22	0/76.79	1/65.98
POLY-3 PERCENT (g)	3%	0%	0%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	498	---	---	621
STATISTICAL TESTS				
POLY 3	P=0.471N	P=0.218N	P=0.209N	P=0.504N
POLY 1.5	P=0.469N	P=0.227N	P=0.224N	P=0.510N
POLY 6	P=0.480N	P=0.203N	P=0.186N	P=0.483N
RAO-SCOTT	P=0.492N	P=0.309N	P=0.305N	P=0.534N
LITTER C-A/FISHERS	P=0.461N	P=0.246N	P=0.246N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Lymph Node, Mesenteric: Lymphatic Sinus Ectasia				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/89 (2%)	3/88 (3%)	1/88 (1%)
LITTERS (b)	0/35 (0%)	2/35 (6%)	3/35 (9%)	1/35 (3%)
POLY-3 RATE (c)	0/65.47	2/73.22	3/76.79	1/65.59
POLY-3 PERCENT (g)	0%	2.7%	3.9%	1.5%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	3/56 (5%)	1/43 (2%)
FIRST INCIDENCE	---	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.439	P=0.264	P=0.152	P=0.500
POLY 1.5	P=0.431	P=0.252	P=0.135	P=0.496
POLY 6	P=0.471	P=0.285	P=0.183	P=0.513
RAO-SCOTT	P=0.433	P=0.275	P=0.174	P=0.469
LITTER C-A/FISHERS	P=0.444	P=0.246	P=0.120	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mesenteric: Lymphocyte Depletion				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/89 (0%)	0/88 (0%)	0/88 (0%)
LITTERS (b)	2/35 (6%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/65.65	0/73.22	0/76.79	0/65.59
POLY-3 PERCENT (g)	3.1%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	705	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.121N	P=0.215N	P=0.206N	P=0.238N
POLY 1.5	P=0.119N	P=0.226N	P=0.222N	P=0.243N
POLY 6	P=0.129N	P=0.198N	P=0.182N	P=0.224N
RAO-SCOTT	P=0.209N	P=0.346N	P=0.343N	P=0.356N
LITTER C-A/FISHERS	P=0.114N	P=0.246N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Bronchial **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	0/25 (0%)	2/23 (9%)	0/24 (0%)	0/16 (0%)
LITTERS (b)	0/19 (0%)	2/18 (11%)	0/22 (0%)	0/13 (0%)
POLY-3 RATE (c)	0/20.57	2/20.55	0/20.58	0/12.82
POLY-3 PERCENT (g)	0%	9.7%	0%	0%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	0/12 (0%)	0/9 (0%)
FIRST INCIDENCE	---	525	---	---
STATISTICAL TESTS				
POLY 3	P=0.473N	P=0.233	(e)	(e)
POLY 1.5	P=0.481N	P=0.226	(e)	(e)
POLY 6	P=0.459N	P=0.243	(e)	(e)
RAO-SCOTT	P=0.526N	P=0.336	(e)	(e)
LITTER C-A/FISHERS	P=0.465N	P=0.230	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Iliac **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	2/25 (8%)	2/23 (9%)	1/24 (4%)	0/16 (0%)
LITTERS (b)	2/19 (11%)	2/18 (11%)	1/22 (5%)	0/13 (0%)
POLY-3 RATE (c)	2/20.61	2/19.43	1/20.58	0/12.82
POLY-3 PERCENT (g)	9.7%	10.3%	4.9%	0%
TERMINAL (d)	1/9 (11%)	1/10 (10%)	1/12 (8%)	0/9 (0%)
FIRST INCIDENCE	719	711	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.189N	P=0.677	P=0.500N	P=0.346N
POLY 1.5	P=0.192N	P=0.672	P=0.508N	P=0.347N
POLY 6	P=0.181N	P=0.683	P=0.489N	P=0.337N
RAO-SCOTT	P=0.187N	P=0.656	P=0.484N	P=0.323N
LITTER C-A/FISHERS	P=0.160N	P=0.677	P=0.444N	P=0.345N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Iliac **Hyperplasia Lymphocyte**				
LESION RATES				
OVERALL (a)	2/25 (8%)	0/23 (0%)	2/24 (8%)	0/16 (0%)
LITTERS (b)	2/19 (11%)	0/18 (0%)	2/22 (9%)	0/13 (0%)
POLY-3 RATE (c)	2/20.57	0/19.36	2/20.58	0/12.82
POLY-3 PERCENT (g)	9.7%	0%	9.7%	0%
TERMINAL (d)	2/9 (22%)	0/10 (0%)	2/12 (17%)	0/9 (0%)
FIRST INCIDENCE	730 (T)	---	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.344N	P=0.247N	P=0.698N	P=0.345N
POLY 1.5	P=0.345N	P=0.250N	P=0.689	P=0.347N
POLY 6	P=0.337N	P=0.243N	P=0.686N	P=0.336N
RAO-SCOTT	P=0.371N	P=0.309N	P=0.697N	P=0.391N
LITTER C-A/FISHERS	P=0.307N	P=0.257N	P=0.639N	P=0.345N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Lymph Node: Iliac **Infiltration Cellular Histiocyte**				
LESION RATES				
OVERALL (a)	2/25 (8%)	1/23 (4%)	0/24 (0%)	0/16 (0%)
LITTERS (b)	2/19 (11%)	1/18 (6%)	0/22 (0%)	0/13 (0%)
POLY-3 RATE (c)	2/20.57	1/19.36	0/20.58	0/12.82
POLY-3 PERCENT (g)	9.7%	5.2%	0%	0%
TERMINAL (d)	2/9 (22%)	1/10 (10%)	0/12 (0%)	0/9 (0%)
FIRST INCIDENCE	730 (T)	730 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.131N	P=0.521N	P=0.233N	P=0.345N
POLY 1.5	P=0.133N	P=0.525N	P=0.239N	P=0.347N
POLY 6	P=0.128N	P=0.517N	P=0.225N	P=0.336N
RAO-SCOTT	P=0.174N	P=0.543N	P=0.293N	P=0.386N
LITTER C-A/FISHERS	P=0.117N	P=0.521N	P=0.209N	P=0.345N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Iliac **Pigment**				
LESION RATES				
OVERALL (a)	0/25 (0%)	0/23 (0%)	1/24 (4%)	0/16 (0%)
LITTERS (b)	0/19 (0%)	0/18 (0%)	1/22 (5%)	0/13 (0%)
POLY-3 RATE (c)	0/20.57	0/19.36	1/21.02	0/12.82
POLY-3 PERCENT (g)	0%	0%	4.8%	0%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	0/12 (0%)	0/9 (0%)
FIRST INCIDENCE	---	---	604	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Iliac **Proliferation Plasma Cell**				
LESION RATES				
OVERALL (a)	3/25 (12%)	0/23 (0%)	1/24 (4%)	0/16 (0%)
LITTERS (b)	3/19 (16%)	0/18 (0%)	1/22 (5%)	0/13 (0%)
POLY-3 RATE (c)	3/20.63	0/19.36	1/20.58	0/12.82
POLY-3 PERCENT (g)	14.6%	0%	4.9%	0%
TERMINAL (d)	2/9 (22%)	0/10 (0%)	1/12 (8%)	0/9 (0%)
FIRST INCIDENCE	715	---	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.120N	P=0.122N	P=0.301N	P=0.209N
POLY 1.5	P=0.121N	P=0.125N	P=0.309N	P=0.211N
POLY 6	P=0.117N	P=0.119N	P=0.288N	P=0.200N
RAO-SCOTT	P=0.164N	P=0.181N	P=0.350N	P=0.261N
LITTER C-A/FISHERS	P=0.104N	P=0.125N	P=0.249N	P=0.195N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Iliac, Lymphatic Sinus Ectasia				
LESION RATES				
OVERALL (a)	5/25 (20%)	3/23 (13%)	1/24 (4%)	0/16 (0%)
LITTERS (b)	4/19 (21%)	2/18 (11%)	1/22 (5%)	0/13 (0%)
POLY-3 RATE (c)	5/20.67	3/19.36	1/20.58	0/12.82
POLY-3 PERCENT (g)	24.2%	15.5%	4.9%	0%
TERMINAL (d)	3/9 (33%)	3/10 (30%)	1/12 (8%)	0/9 (0%)
FIRST INCIDENCE	715	730 (T)	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.021N*	P=0.385N	P=0.089N	P=0.074N
POLY 1.5	P=0.022N*	P=0.391N	P=0.095N	P=0.076N
POLY 6	P=0.018N*	P=0.379N	P=0.080N	P=0.066N
RAO-SCOTT	P=0.053N	P=0.435N	P=0.160N	P=0.140N
LITTER C-A/FISHERS	P=0.038N*	P=0.357N	P=0.129N	P=0.108N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Lumbar **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	2/25 (8%)	2/23 (9%)	1/24 (4%)	1/16 (6%)
LITTERS (b)	2/19 (11%)	2/18 (11%)	1/22 (5%)	1/13 (8%)
POLY-3 RATE (c)	2/20.60	2/19.36	1/20.58	1/12.82
POLY-3 PERCENT (g)	9.7%	10.3%	4.9%	7.8%
TERMINAL (d)	1/9 (11%)	2/10 (20%)	1/12 (8%)	1/9 (11%)
FIRST INCIDENCE	722	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.475N	P=0.675	P=0.500N	P=0.664N
POLY 1.5	P=0.479N	P=0.671	P=0.507N	P=0.665N
POLY 6	P=0.465N	P=0.681	P=0.488N	P=0.656N
RAO-SCOTT	P=0.466N	P=0.654	P=0.482N	P=0.636N
LITTER C-A/FISHERS	P=0.438N	P=0.677	P=0.444N	P=0.644N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Lumbar, Lymphatic Sinus Ectasia				
LESION RATES				
OVERALL (a)	0/25 (0%)	2/23 (9%)	1/24 (4%)	2/16 (13%)
LITTERS (b)	0/19 (0%)	2/18 (11%)	1/22 (5%)	2/13 (15%)
POLY-3 RATE (c)	0/20.57	2/19.40	1/20.58	2/12.82
POLY-3 PERCENT (g)	0%	10.3%	4.9%	15.6%
TERMINAL (d)	0/9 (0%)	1/10 (10%)	1/12 (8%)	2/9 (22%)
FIRST INCIDENCE	---	719	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.129	P=0.220	P=0.500	P=0.132
POLY 1.5	P=0.128	P=0.218	P=0.496	P=0.132
POLY 6	P=0.135	P=0.222	P=0.507	P=0.136
RAO-SCOTT	P=0.164	P=0.276	P=0.543	P=0.185
LITTER C-A/FISHERS	P=0.147	P=0.230	P=0.537	P=0.157

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Mediastinal **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	6/25 (24%)	7/23 (30%)	7/24 (29%)	3/16 (19%)
LITTERS (b)	5/19 (26%)	6/18 (33%)	7/22 (32%)	3/13 (23%)
POLY-3 RATE (c)	6/21.68	7/20.19	7/21.18	3/12.82
POLY-3 PERCENT (g)	27.7%	34.7%	33.1%	23.4%
TERMINAL (d)	3/9 (33%)	4/10 (40%)	3/12 (25%)	3/9 (33%)
FIRST INCIDENCE	552	552	614	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.467N	P=0.439	P=0.480	P=0.549N
POLY 1.5	P=0.455N	P=0.436	P=0.471	P=0.535N
POLY 6	P=0.464N	P=0.445	P=0.500	P=0.551N
RAO-SCOTT	P=0.447N	P=0.422	P=0.463	P=0.522N
LITTER C-A/FISHERS	P=0.481N	P=0.457	P=0.485	P=0.587N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Pancreatic **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	3/25 (12%)	1/23 (4%)	4/24 (17%)	3/16 (19%)
LITTERS (b)	3/19 (16%)	1/18 (6%)	4/22 (18%)	3/13 (23%)
POLY-3 RATE (c)	3/20.96	1/19.40	4/21.22	3/13.29
POLY-3 PERCENT (g)	14.3%	5.2%	18.9%	22.6%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	1/12 (8%)	1/9 (11%)
FIRST INCIDENCE	681	719	619	621
STATISTICAL TESTS				
POLY 3	P=0.229	P=0.329N	P=0.507	P=0.438
POLY 1.5	P=0.225	P=0.330N	P=0.492	P=0.432
POLY 6	P=0.247	P=0.329N	P=0.530	P=0.459
RAO-SCOTT	P=0.236	P=0.326N	P=0.501	P=0.429
LITTER C-A/FISHERS	P=0.267	P=0.323N	P=0.586	P=0.470

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Renal **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	8/25 (32%)	6/23 (26%)	4/24 (17%)	0/16 (0%)
LITTERS (b)	7/19 (37%)	6/18 (33%)	4/22 (18%)	0/13 (0%)
POLY-3 RATE (c)	8/22.92	6/19.94	4/20.61	0/12.82
POLY-3 PERCENT (g)	34.9%	30.1%	19.4%	0%
TERMINAL (d)	1/9 (11%)	4/10 (40%)	2/12 (17%)	0/9 (0%)
FIRST INCIDENCE	496	568	726	---
STATISTICAL TESTS				
POLY 3	P=0.010N**	P=0.496N	P=0.210N	P=0.019N*
POLY 1.5	P=0.009N**	P=0.475N	P=0.199N	P=0.017N*
POLY 6	P=0.011N*	P=0.526N	P=0.224N	P=0.021N*
RAO-SCOTT	P=0.012N*	P=0.489N	P=0.211N	P=0.024N*
LITTER C-A/FISHERS	P=0.008N**	P=0.548N	P=0.161N	P=0.015N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Renal **Proliferation Plasma Cell**				
LESION RATES				
OVERALL (a)	2/25 (8%)	0/23 (0%)	0/24 (0%)	0/16 (0%)
LITTERS (b)	2/19 (11%)	0/18 (0%)	0/22 (0%)	0/13 (0%)
POLY-3 RATE (c)	2/20.61	0/19.36	0/20.58	0/12.82
POLY-3 PERCENT (g)	9.7%	0%	0%	0%
TERMINAL (d)	1/9 (11%)	0/10 (0%)	0/12 (0%)	0/9 (0%)
FIRST INCIDENCE	719	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.135N	P=0.247N	P=0.234N	P=0.346N
POLY 1.5	P=0.137N	P=0.250N	P=0.239N	P=0.347N
POLY 6	P=0.135N	P=0.244N	P=0.226N	P=0.337N
RAO-SCOTT	P=0.190N	P=0.314N	P=0.303N	P=0.396N
LITTER C-A/FISHERS	P=0.127N	P=0.257N	P=0.209N	P=0.345N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Renal, Lymphatic Sinus Ectasia				
LESION RATES				
OVERALL (a)	0/25 (0%)	4/23 (17%)	3/24 (13%)	0/16 (0%)
LITTERS (b)	0/19 (0%)	4/18 (22%)	3/22 (14%)	0/13 (0%)
POLY-3 RATE (c)	0/20.57	4/19.89	3/20.60	0/12.82
POLY-3 PERCENT (g)	0%	20.1%	14.6%	0%
TERMINAL (d)	0/9 (0%)	3/10 (30%)	2/12 (17%)	0/9 (0%)
FIRST INCIDENCE	---	568	726	---
STATISTICAL TESTS				
POLY 3	P=0.542N	P=0.047*	P=0.111	(e)
POLY 1.5	P=0.547N	P=0.046*	P=0.109	(e)
POLY 6	P=0.520N	P=0.049*	P=0.117	(e)
RAO-SCOTT	P=0.542N	P=0.093	P=0.169	(e)
LITTER C-A/FISHERS	P=0.490N	P=0.046*	P=0.144	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mammary Gland **Atrophy**				
LESION RATES				
OVERALL (a)	1/82 (1%)	2/77 (3%)	3/80 (4%)	0/80 (0%)
LITTERS (b)	1/35 (3%)	2/34 (6%)	2/34 (6%)	0/35 (0%)
POLY-3 RATE (c)	1/59.80	2/64.63	3/72.29	0/61.05
POLY-3 PERCENT (g)	1.7%	3.1%	4.2%	0%
TERMINAL (d)	0/24 (0%)	0/41 (0%)	0/53 (0%)	0/42 (0%)
FIRST INCIDENCE	595	710	698	---
STATISTICAL TESTS				
POLY 3	P=0.328N	P=0.527	P=0.377	P=0.496N
POLY 1.5	P=0.338N	P=0.507	P=0.341	P=0.502N
POLY 6	P=0.303N	P=0.558	P=0.433	P=0.481N
RAO-SCOTT	P=0.376N	P=0.563	P=0.441	P=0.551N
LITTER C-A/FISHERS	P=0.294N	P=0.489	P=0.489	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mammary Gland **Galactocele**				
LESION RATES				
OVERALL (a)	1/82 (1%)	1/77 (1%)	2/80 (3%)	0/80 (0%)
LITTERS (b)	1/35 (3%)	1/34 (3%)	2/34 (6%)	0/35 (0%)
POLY-3 RATE (c)	1/59.59	1/64.48	2/72.10	0/61.05
POLY-3 PERCENT (g)	1.7%	1.6%	2.8%	0%
TERMINAL (d)	0/24 (0%)	1/41 (2%)	2/53 (4%)	0/42 (0%)
FIRST INCIDENCE	663	730 (T)	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.364N	P=0.743N	P=0.565	P=0.495N
POLY 1.5	P=0.370N	P=0.756N	P=0.533	P=0.501N
POLY 6	P=0.348N	P=0.722N	P=0.612	P=0.480N
RAO-SCOTT	P=0.357N	P=0.711N	P=0.551	P=0.457N
LITTER C-A/FISHERS	P=0.365N	P=0.746	P=0.489	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mammary Gland Hyperplasia				
LESION RATES				
OVERALL (a)	0/82 (0%)	0/77 (0%)	0/80 (0%)	0/80 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/34 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/59.34	0/64.48	0/72.10	0/61.05
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/24 (0%)	0/41 (0%)	0/53 (0%)	0/42 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mammary Gland **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	0/82 (0%)	0/77 (0%)	0/80 (0%)	0/80 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/34 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/59.34	0/64.48	0/72.10	0/61.05
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/24 (0%)	0/41 (0%)	0/53 (0%)	0/42 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Mammary Gland **Inflammation Granulomatous**				
LESION RATES				
OVERALL (a)	0/82 (0%)	0/77 (0%)	0/80 (0%)	0/80 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/34 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/59.34	0/64.48	0/72.10	0/61.05
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/24 (0%)	0/41 (0%)	0/53 (0%)	0/42 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mammary Gland: Duct Dilation				
LESION RATES				
OVERALL (a)	3/82 (4%)	8/77 (10%)	9/80 (11%)	3/80 (4%)
LITTERS (b)	3/35 (9%)	7/34 (21%)	8/34 (24%)	3/35 (9%)
POLY-3 RATE (c)	3/59.88	8/65.26	9/73.09	3/61.05
POLY-3 PERCENT (g)	5%	12.3%	12.3%	4.9%
TERMINAL (d)	1/24 (4%)	5/41 (12%)	6/53 (11%)	3/42 (7%)
FIRST INCIDENCE	624	610	604	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.401N	P=0.132	P=0.125	P=0.653N
POLY 1.5	P=0.423N	P=0.111	P=0.092	P=0.657
POLY 6	P=0.347N	P=0.169	P=0.189	P=0.621N
RAO-SCOTT	P=0.417N	P=0.153	P=0.145	P=0.626N
LITTER C-A/FISHERS	P=0.448N	P=0.141	P=0.085	P=0.663

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mesentery **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	2/39 (5%)	0/19 (0%)	0/17 (0%)	0/6 (0%)
LITTERS (b)	2/23 (9%)	0/13 (0%)	0/14 (0%)	0/6 (0%)
POLY-3 RATE (c)	2/28.07	0/15.81	0/14.43	0/4.33
POLY-3 PERCENT (g)	7.1%	0%	0%	0%
TERMINAL (d)	0/7 (0%)	0/8 (0%)	0/9 (0%)	0/2 (0%)
FIRST INCIDENCE	498	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.249N	P=0.367N	P=0.390N	P=0.689N
POLY 1.5	P=0.266N	P=0.386N	P=0.412N	P=0.691N
POLY 6	P=0.233N	P=0.336N	P=0.350N	P=0.678N
RAO-SCOTT	P=0.262N	P=0.384N	P=0.408N	P=0.642N
LITTER C-A/FISHERS	P=0.226N	P=0.402N	P=0.380N	P=0.623N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mesentery **Necrosis**				
LESION RATES				
OVERALL (a)	2/39 (5%)	1/19 (5%)	1/17 (6%)	1/6 (17%)
LITTERS (b)	2/23 (9%)	1/13 (8%)	1/14 (7%)	1/6 (17%)
POLY-3 RATE (c)	2/26.89	1/15.81	1/15.16	1/5.11
POLY-3 PERCENT (g)	7.4%	6.3%	6.6%	19.6%
TERMINAL (d)	1/7 (14%)	1/8 (13%)	0/9 (0%)	0/2 (0%)
FIRST INCIDENCE	688	730 (T)	471	440
STATISTICAL TESTS				
POLY 3	P=0.385	P=0.688N	P=0.704N	P=0.485
POLY 1.5	P=0.351	P=0.713N	P=0.738N	P=0.458
POLY 6	P=0.438	P=0.642N	P=0.641N	P=0.536
RAO-SCOTT	P=0.425	P=0.672N	P=0.693N	P=0.526
LITTER C-A/FISHERS	P=0.471	P=0.709N	P=0.684N	P=0.515

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mesentery Neovascularization				
LESION RATES				
OVERALL (a)	1/39 (3%)	2/19 (11%)	3/17 (18%)	0/6 (0%)
LITTERS (b)	1/23 (4%)	2/13 (15%)	3/14 (21%)	0/6 (0%)
POLY-3 RATE (c)	1/27.29	2/16.34	3/14.43	0/4.33
POLY-3 PERCENT (g)	3.7%	12.2%	20.8%	0%
TERMINAL (d)	0/7 (0%)	1/8 (13%)	3/9 (33%)	0/2 (0%)
FIRST INCIDENCE	555	568	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.320	P=0.316	P=0.096	P=0.857N
POLY 1.5	P=0.309	P=0.287	P=0.082	P=0.858N
POLY 6	P=0.366	P=0.368	P=0.130	P=0.851N
RAO-SCOTT	P=0.358	P=0.352	P=0.147	P=0.808N
LITTER C-A/FISHERS	P=0.495	P=0.291	P=0.142	P=0.793N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mesentery: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	32/39 (82%)	16/19 (84%)	13/17 (76%)	3/6 (50%)
LITTERS (b)	21/23 (91%)	12/13 (92%)	11/14 (79%)	3/6 (50%)
POLY-3 RATE (c)	32/37.06	16/18.63	13/16.27	3/4.72
POLY-3 PERCENT (g)	86.4%	85.9%	79.9%	63.6%
TERMINAL (d)	6/7 (86%)	6/8 (75%)	6/9 (67%)	2/2 (100%)
FIRST INCIDENCE	496	568	604	621
STATISTICAL TESTS				
POLY 3	P=0.162N	P=0.653N	P=0.422N	P=0.268N
POLY 1.5	P=0.135N	P=0.631	P=0.448N	P=0.190N
POLY 6	P=0.169N	P=0.599N	P=0.352N	P=0.373N
RAO-SCOTT	P=0.183N	P=0.655N	P=0.456N	P=0.288N
LITTER C-A/FISHERS	P=0.015N*	P=0.709	P=0.269N	P=0.046N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mesentery: Artery Mineral				
LESION RATES				
OVERALL (a)	21/39 (54%)	5/19 (26%)	2/17 (12%)	0/6 (0%)
LITTERS (b)	15/23 (65%)	3/13 (23%)	2/14 (14%)	0/6 (0%)
POLY-3 RATE (c)	21/35.01	5/17.39	2/14.68	0/4.33
POLY-3 PERCENT (g)	60%	28.8%	13.6%	0%
TERMINAL (d)	0/7 (0%)	0/8 (0%)	0/9 (0%)	0/2 (0%)
FIRST INCIDENCE	496	568	677	---
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.026N*	P=0.002N**	P=0.032N*
POLY 1.5	P<0.001N**	P=0.032N*	P=0.002N**	P=0.025N*
POLY 6	P<0.001N**	P=0.020N*	P<0.001N**	P=0.043N*
RAO-SCOTT	P<0.001N**	P=0.038N*	P=0.005N**	P=0.030N*
LITTER C-A/FISHERS	P<0.001N**	P=0.018N*	P=0.003N**	P=0.006N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mesentery: Vein **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	1/39 (3%)	2/19 (11%)	1/17 (6%)	0/6 (0%)
LITTERS (b)	1/23 (4%)	2/13 (15%)	1/14 (7%)	0/6 (0%)
POLY-3 RATE (c)	1/27.14	2/16.34	1/14.83	0/4.33
POLY-3 PERCENT (g)	3.7%	12.2%	6.7%	0%
TERMINAL (d)	0/7 (0%)	1/8 (13%)	0/9 (0%)	0/2 (0%)
FIRST INCIDENCE	610	568	614	---
STATISTICAL TESTS				
POLY 3	P=0.639N	P=0.318	P=0.626	P=0.857N
POLY 1.5	P=0.643	P=0.288	P=0.596	P=0.858N
POLY 6	P=0.577N	P=0.371	P=0.674	P=0.850N
RAO-SCOTT	P=0.621N	P=0.328	P=0.603	P=0.787N
LITTER C-A/FISHERS	P=0.558N	P=0.291	P=0.620	P=0.793N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nerve Trigeminal Degeneration				
LESION RATES				
OVERALL (a)	63/84 (75%)	66/90 (73%)	67/88 (76%)	49/90 (54%)
LITTERS (b)	34/35 (97%)	33/35 (94%)	33/35 (94%)	31/35 (89%)
POLY-3 RATE (c)	63/75.41	66/83.59	67/82.61	49/72.21
POLY-3 PERCENT (g)	83.5%	79%	81.1%	67.9%
TERMINAL (d)	20/25 (80%)	32/43 (74%)	45/56 (80%)	30/43 (70%)
FIRST INCIDENCE	496	388	471	552
STATISTICAL TESTS				
POLY 3	P=0.013N*	P=0.282N	P=0.420N	P=0.012N*
POLY 1.5	P=0.005N**	P=0.327N	P=0.504N	P=0.006N**
POLY 6	P=0.029N*	P=0.251N	P=0.317N	P=0.026N*
RAO-SCOTT	P=0.019N*	P=0.304N	P=0.427N	P=0.025N*
LITTER C-A/FISHERS	P=0.111N	P=0.500N	P=0.500N	P=0.178N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose				
Foreign Body				
LESION RATES				
OVERALL (a)	5/89 (6%)	2/90 (2%)	3/90 (3%)	8/87 (9%)
LITTERS (b)	5/35 (14%)	2/35 (6%)	3/35 (9%)	8/35 (23%)
POLY-3 RATE (c)	5/66.97	2/74.05	3/78.35	8/68.67
POLY-3 PERCENT (g)	7.5%	2.7%	3.8%	11.7%
TERMINAL (d)	1/25 (4%)	2/43 (5%)	3/56 (5%)	1/43 (2%)
FIRST INCIDENCE	248	730 (T)	730 (T)	289
STATISTICAL TESTS				
POLY 3	P=0.102	P=0.181N	P=0.278N	P=0.295
POLY 1.5	P=0.099	P=0.196N	P=0.312N	P=0.276
POLY 6	P=0.109	P=0.157N	P=0.226N	P=0.345
RAO-SCOTT	P=0.115	P=0.183N	P=0.276N	P=0.294
LITTER C-A/FISHERS	P=0.100	P=0.214N	P=0.355N	P=0.270

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose **Inflammation**				
LESION RATES				
OVERALL (a)	10/89 (11%)	6/90 (7%)	10/90 (11%)	17/87 (20%)
LITTERS (b)	8/35 (23%)	5/35 (14%)	10/35 (29%)	14/35 (40%)
POLY-3 RATE (c)	10/67.57	6/74.30	10/79.02	17/69.50
POLY-3 PERCENT (g)	14.8%	8.1%	12.7%	24.5%
TERMINAL (d)	4/25 (16%)	4/43 (9%)	6/56 (11%)	7/43 (16%)
FIRST INCIDENCE	248	694	642	289
STATISTICAL TESTS				
POLY 3	P=0.021*	P=0.158N	P=0.446N	P=0.110
POLY 1.5	P=0.020*	P=0.180N	P=0.511N	P=0.096
POLY 6	P=0.027*	P=0.125N	P=0.342N	P=0.155
RAO-SCOTT	P=0.032*	P=0.174N	P=0.446N	P=0.129
LITTER C-A/FISHERS	P=0.024*	P=0.270N	P=0.393	P=0.099

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose				
Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/89 (0%)	0/90 (0%)	0/90 (0%)	2/87 (2%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	2/35 (6%)
POLY-3 RATE (c)	0/64.98	0/74.05	0/78.35	2/66.00
POLY-3 PERCENT (g)	0%	0%	0%	3%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	425
STATISTICAL TESTS				
POLY 3	P=0.044*	(e)	(e)	P=0.241
POLY 1.5	P=0.043*	(e)	(e)	P=0.235
POLY 6	P=0.045*	(e)	(e)	P=0.258
RAO-SCOTT	P=0.116	(e)	(e)	P=0.358
LITTER C-A/FISHERS	P=0.046*	(e)	(e)	P=0.246

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose: Olfactory Epithelium Accumulation, Hyaline Droplet				
LESION RATES				
OVERALL (a)	79/89 (89%)	88/90 (98%)	90/90 (100%)	76/87 (87%)
LITTERS (b)	34/35 (97%)	35/35 (100%)	35/35 (100%)	33/35 (94%)
POLY-3 RATE (c)	79/86.13	88/90.00	90/90.00	76/82.90
POLY-3 PERCENT (g)	91.7%	97.8%	100%	91.7%
TERMINAL (d)	19/25 (76%)	41/43 (95%)	56/56 (100%)	39/43 (91%)
FIRST INCIDENCE	294	388	317	153
STATISTICAL TESTS				
POLY 3	P=0.433N	P=0.064	P=0.006**	P=0.612N
POLY 1.5	P=0.298N	P=0.044*	P=0.003**	P=0.523N
POLY 6	P=0.565	P=0.086	P=0.008**	P=0.536
RAO-SCOTT	P=0.471N	P=0.148	P=0.038*	P=0.627N
LITTER C-A/FISHERS	P=0.245N	P=0.500	P=0.500	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose: Olfactory Epithelium Metaplasia Respiratory				
LESION RATES				
OVERALL (a)	3/89 (3%)	2/90 (2%)	1/90 (1%)	4/87 (5%)
LITTERS (b)	3/35 (9%)	2/35 (6%)	1/35 (3%)	4/35 (11%)
POLY-3 RATE (c)	3/66.45	2/74.10	1/78.35	4/65.30
POLY-3 PERCENT (g)	4.5%	2.7%	1.3%	6.1%
TERMINAL (d)	1/25 (4%)	1/43 (2%)	1/56 (2%)	2/43 (5%)
FIRST INCIDENCE	294	719	730 (T)	531
STATISTICAL TESTS				
POLY 3	P=0.357	P=0.451N	P=0.251N	P=0.491
POLY 1.5	P=0.354	P=0.470N	P=0.274N	P=0.482
POLY 6	P=0.368	P=0.418N	P=0.215N	P=0.522
RAO-SCOTT	P=0.354	P=0.443N	P=0.261N	P=0.476
LITTER C-A/FISHERS	P=0.370	P=0.500N	P=0.307N	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose: Respiratory Epithelium Accumulation, Hyaline Droplet				
LESION RATES				
OVERALL (a)	3/89 (3%)	1/90 (1%)	2/90 (2%)	3/87 (3%)
LITTERS (b)	3/35 (9%)	1/35 (3%)	2/35 (6%)	3/35 (9%)
POLY-3 RATE (c)	3/65.77	1/74.90	2/79.06	3/66.16
POLY-3 PERCENT (g)	4.6%	1.3%	2.5%	4.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	604	388	606	500
STATISTICAL TESTS				
POLY 3	P=0.456	P=0.262N	P=0.418N	P=0.659N
POLY 1.5	P=0.455	P=0.278N	P=0.452N	P=0.653
POLY 6	P=0.466	P=0.238N	P=0.365N	P=0.629N
RAO-SCOTT	P=0.459	P=0.261N	P=0.410N	P=0.629N
LITTER C-A/FISHERS	P=0.477	P=0.307N	P=0.500N	P=0.663

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose: Respiratory Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	3/89 (3%)	4/90 (4%)	8/90 (9%)	7/87 (8%)
LITTERS (b)	3/35 (9%)	3/35 (9%)	7/35 (20%)	7/35 (20%)
POLY-3 RATE (c)	3/64.98	4/74.19	8/78.69	7/65.58
POLY-3 PERCENT (g)	4.6%	5.4%	10.2%	10.7%
TERMINAL (d)	3/25 (12%)	3/43 (7%)	6/56 (11%)	4/43 (9%)
FIRST INCIDENCE	730 (T)	695	677	425
STATISTICAL TESTS				
POLY 3	P=0.091	P=0.571	P=0.177	P=0.164
POLY 1.5	P=0.088	P=0.543	P=0.143	P=0.156
POLY 6	P=0.106	P=0.616	P=0.243	P=0.193
RAO-SCOTT	P=0.099	P=0.549	P=0.183	P=0.168
LITTER C-A/FISHERS	P=0.071	P=0.663	P=0.153	P=0.153

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pancreas **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/88 (1%)	0/87 (0%)	0/78 (0%)
LITTERS (b)	0/35 (0%)	1/35 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	1/72.74	0/76.07	0/61.86
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	615	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pancreas: Acinus Atrophy				
LESION RATES				
OVERALL (a)	13/90 (14%)	9/88 (10%)	10/87 (11%)	8/78 (10%)
LITTERS (b)	11/35 (31%)	8/35 (23%)	8/35 (23%)	8/35 (23%)
POLY-3 RATE (c)	13/68.98	9/74.07	10/76.75	8/62.82
POLY-3 PERCENT (g)	18.9%	12.2%	13%	12.7%
TERMINAL (d)	2/25 (8%)	2/43 (5%)	8/56 (14%)	3/43 (7%)
FIRST INCIDENCE	580	447	577	608
STATISTICAL TESTS				
POLY 3	P=0.256N	P=0.189N	P=0.231N	P=0.234N
POLY 1.5	P=0.273N	P=0.218N	P=0.285N	P=0.259N
POLY 6	P=0.223N	P=0.150N	P=0.160N	P=0.189N
RAO-SCOTT	P=0.258N	P=0.204N	P=0.244N	P=0.246N
LITTER C-A/FISHERS	P=0.287N	P=0.296N	P=0.296N	P=0.296N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pancreas: Acinus Hyperplasia				
LESION RATES				
OVERALL (a)	63/90 (70%)	55/88 (63%)	49/87 (56%)	28/78 (36%)
LITTERS (b)	31/35 (89%)	34/35 (97%)	29/35 (83%)	22/35 (63%)
POLY-3 RATE (c)	63/79.53	55/79.90	49/78.52	28/63.74
POLY-3 PERCENT (g)	79.2%	68.8%	62.4%	43.9%
TERMINAL (d)	21/25 (84%)	31/43 (72%)	37/56 (66%)	20/43 (47%)
FIRST INCIDENCE	498	517	606	529
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.078N	P=0.011N*	P<0.001N**
POLY 1.5	P<0.001N**	P=0.105N	P=0.018N*	P<0.001N**
POLY 6	P<0.001N**	P=0.055N	P=0.005N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.100N	P=0.018N*	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P=0.178	P=0.367N	P=0.012N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pancreas: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	48/90 (53%)	28/88 (32%)	23/87 (26%)	5/78 (6%)
LITTERS (b)	29/35 (83%)	20/35 (57%)	18/35 (51%)	4/35 (11%)
POLY-3 RATE (c)	48/76.62	28/76.23	23/78.30	5/62.34
POLY-3 PERCENT (g)	62.7%	36.7%	29.4%	8%
TERMINAL (d)	14/25 (56%)	11/43 (26%)	12/56 (21%)	3/43 (7%)
FIRST INCIDENCE	496	568	604	621
STATISTICAL TESTS				
POLY 3	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
POLY 6	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.002N**	P<0.001N**	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P=0.018N*	P=0.005N**	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pancreas: Artery Mineral				
LESION RATES				
OVERALL (a)	11/90 (12%)	2/88 (2%)	0/87 (0%)	0/78 (0%)
LITTERS (b)	10/35 (29%)	2/35 (6%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	11/69.38	2/72.49	0/76.07	0/61.86
POLY-3 PERCENT (g)	15.9%	2.8%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	563	705	---	---
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.007N**	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P=0.008N**	P<0.001N**	P<0.001N**
POLY 6	P<0.001N**	P=0.005N**	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.029N*	P=0.005N**	P=0.010N**
LITTER C-A/FISHERS	P<0.001N**	P=0.012N*	P<0.001N**	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pancreas: Periductal Cholangiofibrosis				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/88 (0%)	0/87 (0%)	0/78 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	0/72.34	0/76.07	0/61.86
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Parathyroid Gland **Cyst**				
LESION RATES				
OVERALL (a)	0/83 (0%)	0/83 (0%)	0/83 (0%)	0/82 (0%)
LITTERS (b)	0/34 (0%)	0/35 (0%)	0/34 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/61.26	0/68.35	0/72.36	0/60.97
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/40 (0%)	0/52 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Parathyroid Gland **Fibrosis**				
LESION RATES				
OVERALL (a)	0/83 (0%)	0/83 (0%)	3/83 (4%)	0/82 (0%)
LITTERS (b)	0/34 (0%)	0/35 (0%)	3/34 (9%)	0/35 (0%)
POLY-3 RATE (c)	0/61.26	0/68.35	3/72.36	0/60.97
POLY-3 PERCENT (g)	0%	0%	4.2%	0%
TERMINAL (d)	0/25 (0%)	0/40 (0%)	3/52 (6%)	0/40 (0%)
FIRST INCIDENCE	---	---	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.506	(e)	P=0.153	(e)
POLY 1.5	P=0.511	(e)	P=0.138	(e)
POLY 6	P=0.518	(e)	P=0.181	(e)
RAO-SCOTT	P=0.548	(e)	P=0.247	(e)
LITTER C-A/FISHERS	P=0.544	(e)	P=0.119	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Parathyroid Gland Hyperplasia				
LESION RATES				
OVERALL (a)	51/83 (61%)	35/83 (42%)	32/83 (39%)	17/82 (21%)
LITTERS (b)	29/34 (85%)	25/35 (71%)	24/34 (71%)	13/35 (37%)
POLY-3 RATE (c)	51/75.36	35/72.56	32/75.68	17/62.95
POLY-3 PERCENT (g)	67.7%	48.2%	42.3%	27%
TERMINAL (d)	9/25 (36%)	15/40 (38%)	15/52 (29%)	8/40 (20%)
FIRST INCIDENCE	496	591	606	552
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.010N**	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P=0.008N**	P<0.001N**	P<0.001N**
POLY 6	P<0.001N**	P=0.014N*	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.014N*	P=0.002N**	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P=0.135N	P=0.121N	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Parathyroid Gland **Hyperplasia Focal**				
LESION RATES				
OVERALL (a)	0/83 (0%)	1/83 (1%)	0/83 (0%)	0/82 (0%)
LITTERS (b)	0/34 (0%)	1/35 (3%)	0/34 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/61.26	1/68.45	0/72.36	0/60.97
POLY-3 PERCENT (g)	0%	1.5%	0%	0%
TERMINAL (d)	0/25 (0%)	0/40 (0%)	0/52 (0%)	0/40 (0%)
FIRST INCIDENCE	---	704	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Penis **Concretion**				
LESION RATES				
OVERALL (a)	0/0 (0%)	3/4 (75%)	2/2 (100%)	1/1 (100%)
LITTERS (b)	0/0 (0%)	3/4 (75%)	2/2 (100%)	1/1 (100%)
POLY-3 RATE (c)	0/0.00	3/3.92	2/2.00	1/1.00
POLY-3 PERCENT (g)	0%	76.5%	100%	100%
TERMINAL (d)	0/0 (0%)	3/3 (100%)	2/2 (100%)	1/1 (100%)
FIRST INCIDENCE	---	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
RAO-SCOTT	(e)	(e)	(e)	(e)
LITTER C-A/FISHERS	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Peripheral Nerve, Sciatic Degeneration				
LESION RATES				
OVERALL (a)	86/90 (96%)	90/90 (100%)	88/90 (98%)	84/90 (93%)
LITTERS (b)	35/35 (100%)	35/35 (100%)	35/35 (100%)	35/35 (100%)
POLY-3 RATE (c)	86/86.63	90/90.00	88/88.24	84/84.92
POLY-3 PERCENT (g)	99.3%	100%	99.7%	98.9%
TERMINAL (d)	25/25 (100%)	43/43 (100%)	56/56 (100%)	43/43 (100%)
FIRST INCIDENCE	440	388	353	201
STATISTICAL TESTS				
POLY 3	P=0.474N	P=0.759	P=0.866	P=0.847N
POLY 1.5	P=0.181N	P=0.335	P=0.645	P=0.541N
POLY 6	P=0.991N	P=0.998	P=0.999	P=1.000
RAO-SCOTT	P=0.477N	P=0.665	P=0.730	P=0.700N
LITTER C-A/FISHERS	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Peripheral Nerve, Tibial **Degeneration**				
LESION RATES				
OVERALL (a)	84/88 (95%)	90/90 (100%)	89/90 (99%)	81/89 (91%)
LITTERS (b)	35/35 (100%)	35/35 (100%)	35/35 (100%)	35/35 (100%)
POLY-3 RATE (c)	84/84.82	90/90.00	89/89.08	81/82.37
POLY-3 PERCENT (g)	99%	100%	99.9%	98.3%
TERMINAL (d)	25/25 (100%)	43/43 (100%)	56/56 (100%)	43/43 (100%)
FIRST INCIDENCE	440	388	353	201
STATISTICAL TESTS				
POLY 3	P=0.261N	P=0.618	P=0.676	P=0.709N
POLY 1.5	P=0.071N	P=0.222	P=0.335	P=0.369N
POLY 6	P=0.984N	P=1.000	P=1.000	P=1.000N
RAO-SCOTT	P=0.357N	P=0.559	P=0.589	P=0.598N
LITTER C-A/FISHERS	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pituitary Gland **Pigment**				
LESION RATES				
OVERALL (a)	0/89 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/64.89	0/74.05	0/78.35	0/66.24
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pituitary Gland: Pars Distalis **Angiectasis**				
LESION RATES				
OVERALL (a)	0/89 (0%)	0/90 (0%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/64.89	0/74.05	0/78.35	1/66.31
POLY-3 PERCENT (g)	0%	0%	0%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	713
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pituitary Gland: Pars Distalis **Cyst**				
LESION RATES				
OVERALL (a)	5/89 (6%)	15/90 (17%)	7/90 (8%)	6/90 (7%)
LITTERS (b)	5/35 (14%)	13/35 (37%)	5/35 (14%)	6/35 (17%)
POLY-3 RATE (c)	5/65.47	15/75.78	7/78.40	6/66.87
POLY-3 PERCENT (g)	7.6%	19.8%	8.9%	9%
TERMINAL (d)	3/25 (12%)	9/43 (21%)	6/56 (11%)	4/43 (9%)
FIRST INCIDENCE	567	404	717	547
STATISTICAL TESTS				
POLY 3	P=0.291N	P=0.032*	P=0.509	P=0.515
POLY 1.5	P=0.312N	P=0.024*	P=0.455	P=0.503
POLY 6	P=0.240N	P=0.049*	P=0.596	P=0.555
RAO-SCOTT	P=0.332N	P=0.048*	P=0.505	P=0.502
LITTER C-A/FISHERS	P=0.349N	P=0.027*	P=0.633	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pituitary Gland: Pars Distalis Hyperplasia				
LESION RATES				
OVERALL (a)	32/89 (36%)	32/90 (36%)	34/90 (38%)	27/90 (30%)
LITTERS (b)	23/35 (66%)	23/35 (66%)	23/35 (66%)	21/35 (60%)
POLY-3 RATE (c)	32/70.46	32/78.13	34/79.40	27/67.45
POLY-3 PERCENT (g)	45.4%	41%	42.8%	40%
TERMINAL (d)	14/25 (56%)	18/43 (42%)	30/56 (54%)	23/43 (54%)
FIRST INCIDENCE	510	525	606	582
STATISTICAL TESTS				
POLY 3	P=0.331N	P=0.347N	P=0.437N	P=0.313N
POLY 1.5	P=0.297N	P=0.424N	P=0.538N	P=0.295N
POLY 6	P=0.339N	P=0.241N	P=0.288N	P=0.303N
RAO-SCOTT	P=0.321N	P=0.341N	P=0.428N	P=0.307N
LITTER C-A/FISHERS	P=0.338N	P=0.599	P=0.599	P=0.402N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pituitary Gland: Pars Intermedia Cyst				
LESION RATES				
OVERALL (a)	6/89 (7%)	1/90 (1%)	5/90 (6%)	7/90 (8%)
LITTERS (b)	6/35 (17%)	1/35 (3%)	4/35 (11%)	7/35 (20%)
POLY-3 RATE (c)	6/66.38	1/74.05	5/78.68	7/67.32
POLY-3 PERCENT (g)	9%	1.4%	6.4%	10.4%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	2/56 (4%)	5/43 (12%)
FIRST INCIDENCE	552	730 (T)	647	531
STATISTICAL TESTS				
POLY 3	P=0.207	P=0.043N*	P=0.385N	P=0.511
POLY 1.5	P=0.210	P=0.049N*	P=0.433N	P=0.501
POLY 6	P=0.210	P=0.035N*	P=0.315N	P=0.547
RAO-SCOTT	P=0.233	P=0.061N	P=0.394N	P=0.501
LITTER C-A/FISHERS	P=0.221	P=0.053N	P=0.367N	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pituitary Gland: Pars Intermedia Hyperplasia				
LESION RATES				
OVERALL (a)	1/89 (1%)	3/90 (3%)	0/90 (0%)	2/90 (2%)
LITTERS (b)	1/35 (3%)	2/35 (6%)	0/35 (0%)	2/35 (6%)
POLY-3 RATE (c)	1/65.08	3/74.05	0/78.35	2/66.24
POLY-3 PERCENT (g)	1.5%	4.1%	0%	3%
TERMINAL (d)	0/25 (0%)	3/43 (7%)	0/56 (0%)	2/43 (5%)
FIRST INCIDENCE	681	730 (T)	---	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.573	P=0.354	P=0.463N	P=0.506
POLY 1.5	P=0.563	P=0.335	P=0.479N	P=0.501
POLY 6	P=0.598	P=0.384	P=0.439N	P=0.525
RAO-SCOTT	P=0.560	P=0.426	P=0.565N	P=0.543
LITTER C-A/FISHERS	P=0.469	P=0.500	P=0.500N	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Preputial Gland **Fibrosis**				
LESION RATES				
OVERALL (a)	0/88 (0%)	0/88 (0%)	2/89 (2%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	0/64.45	0/73.14	2/78.24	0/65.48
POLY-3 PERCENT (g)	0%	0%	2.6%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	---	---	720	---
STATISTICAL TESTS				
POLY 3	P=0.566	(e)	P=0.284	(e)
POLY 1.5	P=0.573	(e)	P=0.264	(e)
POLY 6	P=0.575	(e)	P=0.316	(e)
RAO-SCOTT	P=0.602	(e)	P=0.387	(e)
LITTER C-A/FISHERS	P=0.595	(e)	P=0.246	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Preputial Gland Inflammation Chronic				
LESION RATES				
OVERALL (a)	46/88 (52%)	53/88 (60%)	46/89 (52%)	49/89 (55%)
LITTERS (b)	30/35 (86%)	29/35 (83%)	32/35 (91%)	32/35 (91%)
POLY-3 RATE (c)	46/76.06	53/82.87	46/82.69	49/80.15
POLY-3 PERCENT (g)	60.5%	64%	55.6%	61.1%
TERMINAL (d)	15/25 (60%)	27/43 (63%)	31/56 (55%)	21/43 (49%)
FIRST INCIDENCE	212	388	471	348
STATISTICAL TESTS				
POLY 3	P=0.465N	P=0.382	P=0.319N	P=0.533
POLY 1.5	P=0.519N	P=0.294	P=0.410N	P=0.458
POLY 6	P=0.366N	P=0.513	P=0.199N	P=0.476N
RAO-SCOTT	P=0.469N	P=0.387	P=0.326N	P=0.527
LITTER C-A/FISHERS	P=0.203	P=0.500N	P=0.355	P=0.355

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Preputial Gland: Duct Dilation				
LESION RATES				
OVERALL (a)	51/88 (58%)	54/88 (61%)	50/89 (56%)	48/89 (54%)
LITTERS (b)	32/35 (91%)	31/35 (89%)	30/35 (86%)	28/35 (80%)
POLY-3 RATE (c)	51/74.80	54/78.92	50/81.65	48/70.30
POLY-3 PERCENT (g)	68.2%	68.4%	61.2%	68.3%
TERMINAL (d)	17/25 (68%)	33/43 (77%)	39/56 (70%)	37/43 (86%)
FIRST INCIDENCE	541	404	317	440
STATISTICAL TESTS				
POLY 3	P=0.461N	P=0.560	P=0.219N	P=0.572
POLY 1.5	P=0.379N	P=0.499	P=0.303N	P=0.487N
POLY 6	P=0.534	P=0.528N	P=0.134N	P=0.486
RAO-SCOTT	P=0.472N	P=0.548	P=0.224N	P=0.553
LITTER C-A/FISHERS	P=0.098N	P=0.500N	P=0.355N	P=0.153N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Prostate **Decreased Secretory Fluid**				
LESION RATES				
OVERALL (a)	4/90 (4%)	5/90 (6%)	7/90 (8%)	3/85 (4%)
LITTERS (b)	4/35 (11%)	5/35 (14%)	6/35 (17%)	3/35 (9%)
POLY-3 RATE (c)	4/66.15	5/75.50	7/79.10	3/65.43
POLY-3 PERCENT (g)	6.1%	6.6%	8.9%	4.6%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	666	525	619	594
STATISTICAL TESTS				
POLY 3	P=0.443N	P=0.581	P=0.375	P=0.506N
POLY 1.5	P=0.460N	P=0.547	P=0.324	P=0.524N
POLY 6	P=0.402N	P=0.633	P=0.460	P=0.463N
RAO-SCOTT	P=0.438N	P=0.564	P=0.375	P=0.488N
LITTER C-A/FISHERS	P=0.399N	P=0.500	P=0.367	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Prostate **Inflammation Acute**				
LESION RATES				
OVERALL (a)	7/90 (8%)	9/90 (10%)	4/90 (4%)	2/85 (2%)
LITTERS (b)	7/35 (20%)	7/35 (20%)	4/35 (11%)	2/35 (6%)
POLY-3 RATE (c)	7/67.02	9/75.91	4/78.96	2/64.73
POLY-3 PERCENT (g)	10.4%	11.9%	5.1%	3.1%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	1/56 (2%)	1/43 (2%)
FIRST INCIDENCE	567	610	642	592
STATISTICAL TESTS				
POLY 3	P=0.033N*	P=0.499	P=0.182N	P=0.090N
POLY 1.5	P=0.036N*	P=0.455	P=0.218N	P=0.098N
POLY 6	P=0.026N*	P=0.571	P=0.134N	P=0.075N
RAO-SCOTT	P=0.049N*	P=0.499	P=0.209N	P=0.115N
LITTER C-A/FISHERS	P=0.036N*	P=0.617	P=0.256N	P=0.075N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Prostate **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	6/90 (7%)	10/90 (11%)	10/90 (11%)	5/85 (6%)
LITTERS (b)	6/35 (17%)	10/35 (29%)	10/35 (29%)	4/35 (11%)
POLY-3 RATE (c)	6/66.91	10/74.39	10/78.42	5/64.73
POLY-3 PERCENT (g)	9%	13.4%	12.8%	7.7%
TERMINAL (d)	4/25 (16%)	7/43 (16%)	9/56 (16%)	4/43 (9%)
FIRST INCIDENCE	294	686	713	594
STATISTICAL TESTS				
POLY 3	P=0.370N	P=0.283	P=0.323	P=0.523N
POLY 1.5	P=0.391N	P=0.252	P=0.270	P=0.541N
POLY 6	P=0.314N	P=0.342	P=0.420	P=0.473N
RAO-SCOTT	P=0.361N	P=0.264	P=0.304	P=0.492N
LITTER C-A/FISHERS	P=0.222N	P=0.197	P=0.197	P=0.367N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Prostate: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	3/90 (3%)	0/85 (0%)
LITTERS (b)	1/35 (3%)	0/35 (0%)	3/35 (9%)	0/35 (0%)
POLY-3 RATE (c)	1/65.47	0/74.05	3/78.92	0/64.26
POLY-3 PERCENT (g)	1.5%	0%	3.8%	0%
TERMINAL (d)	1/25 (4%)	0/43 (0%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	730 (T)	---	604	---
STATISTICAL TESTS				
POLY 3	P=0.529N	P=0.475N	P=0.376	P=0.504N
POLY 1.5	P=0.530N	P=0.486N	P=0.344	P=0.510N
POLY 6	P=0.518N	P=0.459N	P=0.429	P=0.488N
RAO-SCOTT	P=0.517N	P=0.516N	P=0.417	P=0.526N
LITTER C-A/FISHERS	P=0.500N	P=0.500N	P=0.307	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Prostate: Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	5/90 (6%)	11/90 (12%)	9/90 (10%)	15/85 (18%)
LITTERS (b)	5/35 (14%)	10/35 (29%)	9/35 (26%)	11/35 (31%)
POLY-3 RATE (c)	5/66.33	11/75.54	9/79.10	15/66.32
POLY-3 PERCENT (g)	7.5%	14.6%	11.4%	22.6%
TERMINAL (d)	2/25 (8%)	7/43 (16%)	7/56 (13%)	10/43 (23%)
FIRST INCIDENCE	562	404	606	531
STATISTICAL TESTS				
POLY 3	P=0.016*	P=0.145	P=0.310	P=0.013*
POLY 1.5	P=0.013*	P=0.122	P=0.257	P=0.011*
POLY 6	P=0.023*	P=0.189	P=0.401	P=0.020*
RAO-SCOTT	P=0.025*	P=0.174	P=0.330	P=0.026*
LITTER C-A/FISHERS	P=0.099	P=0.122	P=0.185	P=0.077

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	11/90 (12%)	6/90 (7%)	2/90 (2%)	1/86 (1%)
LITTERS (b)	11/35 (31%)	5/35 (14%)	2/35 (6%)	1/35 (3%)
POLY-3 RATE (c)	11/67.40	6/74.65	2/78.39	1/64.89
POLY-3 PERCENT (g)	16.3%	8%	2.6%	1.5%
TERMINAL (d)	4/25 (16%)	4/43 (9%)	1/56 (2%)	1/43 (2%)
FIRST INCIDENCE	595	597	720	730 (T)
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.102N	P=0.004N**	P=0.003N**
POLY 1.5	P<0.001N**	P=0.122N	P=0.006N**	P=0.004N**
POLY 6	P<0.001N**	P=0.077N	P=0.002N**	P=0.002N**
RAO-SCOTT	P=0.002N**	P=0.121N	P=0.008N**	P=0.007N**
LITTER C-A/FISHERS	P<0.001N**	P=0.077N	P=0.006N**	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Artery Mineral				
LESION RATES				
OVERALL (a)	2/90 (2%)	1/90 (1%)	1/90 (1%)	0/86 (0%)
LITTERS (b)	2/35 (6%)	1/35 (3%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	2/66.19	1/74.11	1/78.40	0/64.89
POLY-3 PERCENT (g)	3%	1.4%	1.3%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	595	717	717	---
STATISTICAL TESTS				
POLY 3	P=0.161N	P=0.461N	P=0.442N	P=0.242N
POLY 1.5	P=0.162N	P=0.477N	P=0.468N	P=0.247N
POLY 6	P=0.157N	P=0.435N	P=0.401N	P=0.229N
RAO-SCOTT	P=0.173N	P=0.459N	P=0.446N	P=0.254N
LITTER C-A/FISHERS	P=0.152N	P=0.500N	P=0.500N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Duct, Parotid Gland Dilation				
LESION RATES				
OVERALL (a)	5/90 (6%)	1/90 (1%)	1/90 (1%)	0/86 (0%)
LITTERS (b)	5/35 (14%)	1/35 (3%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	5/66.73	1/74.10	1/78.55	0/64.89
POLY-3 PERCENT (g)	7.5%	1.4%	1.3%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	580	719	677	---
STATISTICAL TESTS				
POLY 3	P=0.018N*	P=0.082N	P=0.072N	P=0.035N*
POLY 1.5	P=0.018N*	P=0.091N	P=0.086N	P=0.037N*
POLY 6	P=0.018N*	P=0.070N	P=0.055N	P=0.030N*
RAO-SCOTT	P=0.033N*	P=0.124N	P=0.113N	P=0.065N
LITTER C-A/FISHERS	P=0.015N*	P=0.099N	P=0.099N	P=0.027N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Parotid Gland Atrophy				
LESION RATES				
OVERALL (a)	18/90 (20%)	15/90 (17%)	8/90 (9%)	3/86 (3%)
LITTERS (b)	13/35 (37%)	13/35 (37%)	7/35 (20%)	3/35 (9%)
POLY-3 RATE (c)	18/71.39	15/76.81	8/79.86	3/65.97
POLY-3 PERCENT (g)	25.2%	19.5%	10%	4.6%
TERMINAL (d)	3/25 (12%)	2/43 (5%)	1/56 (2%)	1/43 (2%)
FIRST INCIDENCE	496	568	471	531
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.261N	P=0.011N*	P<0.001N**
POLY 1.5	P<0.001N**	P=0.296N	P=0.016N*	P<0.001N**
POLY 6	P<0.001N**	P=0.208N	P=0.005N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.291N	P=0.024N*	P=0.003N**
LITTER C-A/FISHERS	P<0.001N**	P=0.598	P=0.093N	P=0.005N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Parotid Gland Fibrosis				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/86 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	0/74.05	0/78.35	0/64.89
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Parotid Gland Inflammation Acute				
LESION RATES				
OVERALL (a)	2/90 (2%)	4/90 (4%)	2/90 (2%)	0/86 (0%)
LITTERS (b)	2/35 (6%)	3/35 (9%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	2/66.24	4/74.60	2/78.88	0/64.89
POLY-3 PERCENT (g)	3%	5.4%	2.5%	0%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	580	597	652	---
STATISTICAL TESTS				
POLY 3	P=0.111N	P=0.394	P=0.628N	P=0.242N
POLY 1.5	P=0.118N	P=0.371	P=0.658N	P=0.247N
POLY 6	P=0.097N	P=0.434	P=0.579N	P=0.229N
RAO-SCOTT	P=0.162N	P=0.431	P=0.634N	P=0.301N
LITTER C-A/FISHERS	P=0.133N	P=0.500	P=0.693	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Parotid Gland **Vacuolation, Cytoplasmic**				
LESION RATES				
OVERALL (a)	1/90 (1%)	2/90 (2%)	0/90 (0%)	0/86 (0%)
LITTERS (b)	1/35 (3%)	2/35 (6%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	1/65.51	2/74.05	0/78.35	0/64.89
POLY-3 PERCENT (g)	1.5%	2.7%	0%	0%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	722	730 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.179N	P=0.542	P=0.465N	P=0.502N
POLY 1.5	P=0.187N	P=0.524	P=0.481N	P=0.507N
POLY 6	P=0.166N	P=0.572	P=0.439N	P=0.488N
RAO-SCOTT	P=0.239N	P=0.560	P=0.522N	P=0.531N
LITTER C-A/FISHERS	P=0.187N	P=0.500	P=0.500N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Sublingual Gland Atrophy				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	1/90 (1%)	1/86 (1%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	0/65.47	0/74.05	1/78.35	1/65.14
POLY-3 PERCENT (g)	0%	0%	1.3%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	---	---	730 (T)	665
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Submandibular Gland Atrophy				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/90 (2%)	0/90 (0%)	0/86 (0%)
LITTERS (b)	0/35 (0%)	2/35 (6%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	2/74.47	0/78.35	0/64.89
POLY-3 PERCENT (g)	0%	2.7%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	637	---	---
STATISTICAL TESTS				
POLY 3	P=0.377N	P=0.268	(e)	(e)
POLY 1.5	P=0.395N	P=0.255	(e)	(e)
POLY 6	P=0.347N	P=0.290	(e)	(e)
RAO-SCOTT	P=0.464N	P=0.373	(e)	(e)
LITTER C-A/FISHERS	P=0.405N	P=0.246	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Seminal Vesicle **Decreased Secretory Fluid**				
LESION RATES				
OVERALL (a)	35/90 (39%)	34/90 (38%)	18/90 (20%)	7/90 (8%)
LITTERS (b)	21/35 (60%)	22/35 (63%)	14/35 (40%)	7/35 (20%)
POLY-3 RATE (c)	35/75.39	34/80.72	18/81.23	7/68.07
POLY-3 PERCENT (g)	46.4%	42.1%	22.2%	10.3%
TERMINAL (d)	5/25 (20%)	9/43 (21%)	3/56 (5%)	2/43 (5%)
FIRST INCIDENCE	541	525	592	531
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.349N	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P=0.404N	P=0.002N**	P<0.001N**
POLY 6	P<0.001N**	P=0.277N	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.381N	P=0.005N**	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P=0.500	P=0.076N	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Seminal Vesicle Inflammation Acute				
LESION RATES				
OVERALL (a)	4/90 (4%)	1/90 (1%)	3/90 (3%)	1/90 (1%)
LITTERS (b)	4/35 (11%)	1/35 (3%)	3/35 (9%)	1/35 (3%)
POLY-3 RATE (c)	4/66.08	1/74.39	3/79.32	1/66.24
POLY-3 PERCENT (g)	6.1%	1.3%	3.8%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	1/56 (2%)	1/43 (2%)
FIRST INCIDENCE	630	637	393	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.211N	P=0.148N	P=0.403N	P=0.180N
POLY 1.5	P=0.208N	P=0.162N	P=0.446N	P=0.184N
POLY 6	P=0.209N	P=0.127N	P=0.340N	P=0.164N
RAO-SCOTT	P=0.209N	P=0.168N	P=0.408N	P=0.194N
LITTER C-A/FISHERS	P=0.191N	P=0.178N	P=0.500N	P=0.178N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Seminal Vesicle Inflammation Chronic				
LESION RATES				
OVERALL (a)	1/90 (1%)	4/90 (4%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	1/35 (3%)	4/35 (11%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	1/66.16	4/74.48	0/78.35	0/66.24
POLY-3 PERCENT (g)	1.5%	5.4%	0%	0%
TERMINAL (d)	0/25 (0%)	3/43 (7%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	496	608	---	---
STATISTICAL TESTS				
POLY 3	P=0.110N	P=0.219	P=0.466N	P=0.500N
POLY 1.5	P=0.118N	P=0.203	P=0.482N	P=0.502N
POLY 6	P=0.094N	P=0.248	P=0.442N	P=0.489N
RAO-SCOTT	P=0.169N	P=0.275	P=0.521N	P=0.522N
LITTER C-A/FISHERS	P=0.124N	P=0.178	P=0.500N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skeletal Muscle Degeneration				
LESION RATES				
OVERALL (a)	34/90 (38%)	35/90 (39%)	30/90 (33%)	26/90 (29%)
LITTERS (b)	24/35 (69%)	26/35 (74%)	20/35 (57%)	19/35 (54%)
POLY-3 RATE (c)	34/71.92	35/79.05	30/82.07	26/68.29
POLY-3 PERCENT (g)	47.3%	44.3%	36.6%	38.1%
TERMINAL (d)	5/25 (20%)	13/43 (30%)	13/56 (23%)	18/43 (42%)
FIRST INCIDENCE	541	568	353	528
STATISTICAL TESTS				
POLY 3	P=0.117N	P=0.416N	P=0.114N	P=0.167N
POLY 1.5	P=0.107N	P=0.499N	P=0.185N	P=0.158N
POLY 6	P=0.118N	P=0.308N	P=0.052N	P=0.165N
RAO-SCOTT	P=0.130N	P=0.417N	P=0.126N	P=0.180N
LITTER C-A/FISHERS	P=0.065N	P=0.396	P=0.229N	P=0.163N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skeletal Muscle **Mineral**				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/90 (0%)	1/90 (1%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	0/35 (0%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	2/65.90	0/74.05	1/78.51	0/66.24
POLY-3 PERCENT (g)	3%	0%	1.3%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	641	---	688	---
STATISTICAL TESTS				
POLY 3	P=0.200N	P=0.213N	P=0.440N	P=0.237N
POLY 1.5	P=0.196N	P=0.224N	P=0.467N	P=0.240N
POLY 6	P=0.204N	P=0.198N	P=0.397N	P=0.225N
RAO-SCOTT	P=0.237N	P=0.287N	P=0.484N	P=0.298N
LITTER C-A/FISHERS	P=0.187N	P=0.246N	P=0.500N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin **Cyst Epithelial Inclusion**				
LESION RATES				
OVERALL (a)	3/90 (3%)	12/90 (13%)	3/90 (3%)	2/90 (2%)
LITTERS (b)	3/35 (9%)	12/35 (34%)	3/35 (9%)	2/35 (6%)
POLY-3 RATE (c)	3/66.33	12/75.53	3/78.42	2/66.24
POLY-3 PERCENT (g)	4.5%	15.9%	3.8%	3%
TERMINAL (d)	1/25 (4%)	7/43 (16%)	2/56 (4%)	2/43 (5%)
FIRST INCIDENCE	580	525	711	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.089N	P=0.026*	P=0.582N	P=0.501N
POLY 1.5	P=0.099N	P=0.020*	P=0.618N	P=0.506N
POLY 6	P=0.068N	P=0.038*	P=0.523N	P=0.478N
RAO-SCOTT	P=0.114N	P=0.033*	P=0.562N	P=0.472N
LITTER C-A/FISHERS	P=0.096N	P=0.009**	P=0.663	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin **Inflammation**				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/90 (2%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	2/35 (6%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	2/74.48	0/78.35	0/66.24
POLY-3 PERCENT (g)	0%	2.7%	0%	0%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	608	---	---
STATISTICAL TESTS				
POLY 3	P=0.372N	P=0.268	(e)	(e)
POLY 1.5	P=0.389N	P=0.255	(e)	(e)
POLY 6	P=0.343N	P=0.290	(e)	(e)
RAO-SCOTT	P=0.459N	P=0.379	(e)	(e)
LITTER C-A/FISHERS	P=0.405N	P=0.246	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	1/90 (1%)	2/90 (2%)	2/90 (2%)	1/90 (1%)
LITTERS (b)	1/35 (3%)	2/35 (6%)	2/35 (6%)	1/35 (3%)
POLY-3 RATE (c)	1/65.47	2/74.05	2/78.35	1/66.24
POLY-3 PERCENT (g)	1.5%	2.7%	2.6%	1.5%
TERMINAL (d)	1/25 (4%)	2/43 (5%)	2/56 (4%)	1/43 (2%)
FIRST INCIDENCE	730 (T)	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.553N	P=0.543	P=0.562	P=0.758N
POLY 1.5	P=0.559N	P=0.524	P=0.534	P=0.759
POLY 6	P=0.533N	P=0.572	P=0.605	P=0.745N
RAO-SCOTT	P=0.536N	P=0.510	P=0.533	P=0.707N
LITTER C-A/FISHERS	P=0.556N	P=0.500	P=0.500	P=0.754

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin **Ulcer**				
LESION RATES				
OVERALL (a)	2/90 (2%)	2/90 (2%)	4/90 (4%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	2/35 (6%)	4/35 (11%)	0/35 (0%)
POLY-3 RATE (c)	2/66.03	2/74.05	4/79.23	0/66.24
POLY-3 PERCENT (g)	3%	2.7%	5.1%	0%
TERMINAL (d)	1/25 (4%)	2/43 (5%)	3/56 (5%)	0/43 (0%)
FIRST INCIDENCE	555	730 (T)	353	---
STATISTICAL TESTS				
POLY 3	P=0.245N	P=0.651N	P=0.425	P=0.237N
POLY 1.5	P=0.246N	P=0.669N	P=0.386	P=0.240N
POLY 6	P=0.232N	P=0.621N	P=0.488	P=0.225N
RAO-SCOTT	P=0.237N	P=0.625N	P=0.420	P=0.227N
LITTER C-A/FISHERS	P=0.230N	P=0.693	P=0.337	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin: Epidermis **Hyperplasia**				
LESION RATES				
OVERALL (a)	1/90 (1%)	1/90 (1%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	1/35 (3%)	1/35 (3%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	1/65.47	1/74.05	0/78.35	1/66.24
POLY-3 PERCENT (g)	1.5%	1.4%	0%	1.5%
TERMINAL (d)	1/25 (4%)	1/43 (2%)	0/56 (0%)	1/43 (2%)
FIRST INCIDENCE	730 (T)	730 (T)	---	730 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin: Prepuce **Hyperplasia**				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/90 (2%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	2/35 (6%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/65.47	2/74.05	0/78.35	1/66.24
POLY-3 PERCENT (g)	0%	2.7%	0%	1.5%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	0/56 (0%)	1/43 (2%)
FIRST INCIDENCE	---	730 (T)	---	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.557	P=0.266	(e)	P=0.502
POLY 1.5	P=0.545	P=0.254	(e)	P=0.499
POLY 6	P=0.586	P=0.287	(e)	P=0.514
RAO-SCOTT	P=0.539	P=0.330	(e)	P=0.526
LITTER C-A/FISHERS	P=0.539	P=0.246	(e)	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin: Prepuce **Ulcer**				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/90 (2%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	2/35 (6%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/65.47	2/74.05	0/78.35	1/66.24
POLY-3 PERCENT (g)	0%	2.7%	0%	1.5%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	0/56 (0%)	1/43 (2%)
FIRST INCIDENCE	---	730 (T)	---	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.557	P=0.266	(e)	P=0.502
POLY 1.5	P=0.545	P=0.254	(e)	P=0.499
POLY 6	P=0.586	P=0.287	(e)	P=0.514
RAO-SCOTT	P=0.539	P=0.330	(e)	P=0.526
LITTER C-A/FISHERS	P=0.539	P=0.246	(e)	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin: Subcutaneous Tissue Inflammation				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	1/90 (1%)	2/90 (2%)
LITTERS (b)	1/35 (3%)	0/35 (0%)	1/35 (3%)	2/35 (6%)
POLY-3 RATE (c)	1/66.01	0/74.05	1/78.35	2/66.84
POLY-3 PERCENT (g)	1.5%	0%	1.3%	3%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	567	---	730 (T)	630
STATISTICAL TESTS				
POLY 3	P=0.237	P=0.477N	P=0.721N	P=0.504
POLY 1.5	P=0.239	P=0.487N	P=0.739N	P=0.498
POLY 6	P=0.239	P=0.461N	P=0.690N	P=0.526
RAO-SCOTT	P=0.257	P=0.473N	P=0.701N	P=0.491
LITTER C-A/FISHERS	P=0.246	P=0.500N	P=0.754	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin: Subcutaneous Tissue **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	3/90 (3%)	0/90 (0%)
LITTERS (b)	1/35 (3%)	0/35 (0%)	3/35 (9%)	0/35 (0%)
POLY-3 RATE (c)	1/65.47	0/74.05	3/79.23	0/66.24
POLY-3 PERCENT (g)	1.5%	0%	3.8%	0%
TERMINAL (d)	1/25 (4%)	0/43 (0%)	2/56 (4%)	0/43 (0%)
FIRST INCIDENCE	730 (T)	---	353	---
STATISTICAL TESTS				
POLY 3	P=0.524N	P=0.475N	P=0.377	P=0.498N
POLY 1.5	P=0.520N	P=0.486N	P=0.345	P=0.501N
POLY 6	P=0.520N	P=0.459N	P=0.430	P=0.486N
RAO-SCOTT	P=0.503N	P=0.506N	P=0.413	P=0.507N
LITTER C-A/FISHERS	P=0.500N	P=0.500N	P=0.307	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spinal Cord, Cervical Degeneration				
LESION RATES				
OVERALL (a)	30/90 (33%)	36/90 (40%)	42/90 (47%)	35/90 (39%)
LITTERS (b)	21/35 (60%)	25/35 (71%)	29/35 (83%)	22/35 (63%)
POLY-3 RATE (c)	30/71.34	36/76.32	42/79.96	35/70.74
POLY-3 PERCENT (g)	42.1%	47.2%	52.5%	49.5%
TERMINAL (d)	12/25 (48%)	26/43 (61%)	33/56 (59%)	20/43 (47%)
FIRST INCIDENCE	552	614	632	497
STATISTICAL TESTS				
POLY 3	P=0.201	P=0.317	P=0.122	P=0.226
POLY 1.5	P=0.203	P=0.277	P=0.079	P=0.226
POLY 6	P=0.247	P=0.387	P=0.225	P=0.275
RAO-SCOTT	P=0.213	P=0.322	P=0.136	P=0.236
LITTER C-A/FISHERS	P=0.488	P=0.225	P=0.031*	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spinal Cord, Lumbar Degeneration				
LESION RATES				
OVERALL (a)	21/90 (23%)	15/90 (17%)	21/90 (23%)	24/90 (27%)
LITTERS (b)	15/35 (43%)	13/35 (37%)	16/35 (46%)	18/35 (51%)
POLY-3 RATE (c)	21/68.62	15/77.20	21/81.38	24/71.43
POLY-3 PERCENT (g)	30.6%	19.4%	25.8%	33.6%
TERMINAL (d)	8/25 (32%)	4/43 (9%)	10/56 (18%)	8/43 (19%)
FIRST INCIDENCE	604	550	383	510
STATISTICAL TESTS				
POLY 3	P=0.185	P=0.082N	P=0.318N	P=0.420
POLY 1.5	P=0.175	P=0.115N	P=0.426N	P=0.376
POLY 6	P=0.224	P=0.047N*	P=0.185N	P=0.533
RAO-SCOTT	P=0.210	P=0.097N	P=0.326N	P=0.419
LITTER C-A/FISHERS	P=0.194	P=0.404N	P=0.500	P=0.316

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spinal Cord, Lumbar: Nerve Degeneration				
LESION RATES				
OVERALL (a)	79/90 (88%)	85/90 (94%)	83/90 (92%)	76/90 (84%)
LITTERS (b)	35/35 (100%)	35/35 (100%)	34/35 (97%)	34/35 (97%)
POLY-3 RATE (c)	79/83.64	85/86.83	83/85.19	76/79.49
POLY-3 PERCENT (g)	94.5%	97.9%	97.4%	95.6%
TERMINAL (d)	25/25 (100%)	43/43 (100%)	56/56 (100%)	43/43 (100%)
FIRST INCIDENCE	248	388	471	433
STATISTICAL TESTS				
POLY 3	P=0.525	P=0.151	P=0.215	P=0.511
POLY 1.5	P=0.424N	P=0.126	P=0.209	P=0.636N
POLY 6	P=0.305	P=0.231	P=0.287	P=0.397
RAO-SCOTT	P=0.515	P=0.213	P=0.269	P=0.494
LITTER C-A/FISHERS	P=0.235N	(e)	P=0.500N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spinal Cord, Thoracic **Degeneration**				
LESION RATES				
OVERALL (a)	58/90 (64%)	69/90 (77%)	74/90 (82%)	62/90 (69%)
LITTERS (b)	31/35 (89%)	33/35 (94%)	35/35 (100%)	34/35 (97%)
POLY-3 RATE (c)	58/74.55	69/80.15	74/81.71	62/72.13
POLY-3 PERCENT (g)	77.8%	86.1%	90.6%	86%
TERMINAL (d)	25/25 (100%)	43/43 (100%)	56/56 (100%)	42/43 (98%)
FIRST INCIDENCE	555	550	595	469
STATISTICAL TESTS				
POLY 3	P=0.074	P=0.087	P=0.007**	P=0.092
POLY 1.5	P=0.155	P=0.069	P=0.005**	P=0.162
POLY 6	P=0.034*	P=0.149	P=0.019*	P=0.051
RAO-SCOTT	P=0.125	P=0.131	P=0.026*	P=0.143
LITTER C-A/FISHERS	P=0.084	P=0.337	P=0.057	P=0.178

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spleen **Extramedullary Hematopoiesis**				
LESION RATES				
OVERALL (a)	45/90 (50%)	60/90 (67%)	56/90 (62%)	48/85 (56%)
LITTERS (b)	27/35 (77%)	31/35 (89%)	26/35 (74%)	28/35 (80%)
POLY-3 RATE (c)	45/72.79	60/82.54	56/82.11	48/69.02
POLY-3 PERCENT (g)	61.8%	72.7%	68.2%	69.5%
TERMINAL (d)	23/25 (92%)	39/43 (91%)	47/56 (84%)	36/43 (84%)
FIRST INCIDENCE	294	404	353	289
STATISTICAL TESTS				
POLY 3	P=0.292	P=0.082	P=0.238	P=0.191
POLY 1.5	P=0.297	P=0.042*	P=0.137	P=0.188
POLY 6	P=0.361	P=0.213	P=0.483	P=0.270
RAO-SCOTT	P=0.301	P=0.117	P=0.267	P=0.227
LITTER C-A/FISHERS	P=0.500N	P=0.171	P=0.500N	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spleen **Hyperplasia Lymphocyte**				
LESION RATES				
OVERALL (a)	5/90 (6%)	0/90 (0%)	0/90 (0%)	0/85 (0%)
LITTERS (b)	5/35 (14%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	5/65.47	0/74.05	0/78.35	0/64.12
POLY-3 PERCENT (g)	7.6%	0%	0%	0%
TERMINAL (d)	5/25 (20%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	730 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.010N**	P=0.024N*	P=0.020N*	P=0.034N*
POLY 1.5	P=0.009N**	P=0.027N*	P=0.026N*	P=0.037N*
POLY 6	P=0.011N*	P=0.018N*	P=0.014N*	P=0.028N*
RAO-SCOTT	P=0.035N*	P=0.079N	P=0.073N	P=0.097N
LITTER C-A/FISHERS	P=0.009N**	P=0.027N*	P=0.027N*	P=0.027N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spleen **Necrosis**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	2/90 (2%)	0/85 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	0/74.05	2/78.70	0/64.12
POLY-3 PERCENT (g)	0%	0%	2.5%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	1/56 (2%)	0/43 (0%)
FIRST INCIDENCE	---	---	632	---
STATISTICAL TESTS				
POLY 3	P=0.571	(e)	P=0.281	(e)
POLY 1.5	P=0.569	(e)	P=0.261	(e)
POLY 6	P=0.591	(e)	P=0.316	(e)
RAO-SCOTT	P=0.603	(e)	P=0.386	(e)
LITTER C-A/FISHERS	P=0.595	(e)	P=0.246	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spleen **Pigment**				
LESION RATES				
OVERALL (a)	57/90 (63%)	54/90 (60%)	64/90 (71%)	63/85 (74%)
LITTERS (b)	32/35 (91%)	29/35 (83%)	35/35 (100%)	33/35 (94%)
POLY-3 RATE (c)	57/79.60	54/78.69	64/82.71	63/75.07
POLY-3 PERCENT (g)	71.6%	68.6%	77.4%	83.9%
TERMINAL (d)	19/25 (76%)	34/43 (79%)	43/56 (77%)	38/43 (88%)
FIRST INCIDENCE	294	573	577	153
STATISTICAL TESTS				
POLY 3	P=0.013*	P=0.399N	P=0.240	P=0.035*
POLY 1.5	P=0.016*	P=0.379N	P=0.197	P=0.046*
POLY 6	P=0.017*	P=0.417N	P=0.353	P=0.036*
RAO-SCOTT	P=0.020*	P=0.401N	P=0.252	P=0.050*
LITTER C-A/FISHERS	P=0.183	P=0.239N	P=0.120	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spleen: Red Pulp Atrophy				
LESION RATES				
OVERALL (a)	26/90 (29%)	14/90 (16%)	12/90 (13%)	13/85 (15%)
LITTERS (b)	20/35 (57%)	11/35 (31%)	9/35 (26%)	12/35 (34%)
POLY-3 RATE (c)	26/72.87	14/76.86	12/80.34	13/68.80
POLY-3 PERCENT (g)	35.7%	18.2%	14.9%	18.9%
TERMINAL (d)	1/25 (4%)	1/43 (2%)	1/56 (2%)	3/43 (7%)
FIRST INCIDENCE	555	568	577	153
STATISTICAL TESTS				
POLY 3	P=0.022N*	P=0.011N*	P=0.002N**	P=0.018N*
POLY 1.5	P=0.024N*	P=0.015N*	P=0.004N**	P=0.020N*
POLY 6	P=0.019N*	P=0.008N**	P<0.001N**	P=0.014N*
RAO-SCOTT	P=0.031N*	P=0.018N*	P=0.005N**	P=0.027N*
LITTER C-A/FISHERS	P=0.062N	P=0.027N*	P=0.007N**	P=0.046N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spleen: White Pulp Atrophy				
LESION RATES				
OVERALL (a)	30/90 (33%)	11/90 (12%)	10/90 (11%)	24/85 (28%)
LITTERS (b)	19/35 (54%)	11/35 (31%)	8/35 (23%)	16/35 (46%)
POLY-3 RATE (c)	30/74.18	11/76.02	10/80.26	24/75.78
POLY-3 PERCENT (g)	40.5%	14.5%	12.5%	31.7%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	498	610	577	348
STATISTICAL TESTS				
POLY 3	P=0.390N	P<0.001N**	P<0.001N**	P=0.167N
POLY 1.5	P=0.431N	P<0.001N**	P<0.001N**	P=0.220N
POLY 6	P=0.329N	P<0.001N**	P<0.001N**	P=0.105N
RAO-SCOTT	P=0.376N	P=0.002N**	P<0.001N**	P=0.210N
LITTER C-A/FISHERS	P=0.385N	P=0.045N*	P=0.007N**	P=0.316N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Forestomach **Edema**				
LESION RATES				
OVERALL (a)	5/90 (6%)	5/90 (6%)	1/89 (1%)	1/90 (1%)
LITTERS (b)	5/35 (14%)	5/35 (14%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	5/66.73	5/74.52	1/77.87	1/67.23
POLY-3 PERCENT (g)	7.5%	6.7%	1.3%	1.5%
TERMINAL (d)	0/25 (0%)	1/43 (2%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	541	662	713	153
STATISTICAL TESTS				
POLY 3	P=0.034N*	P=0.558N	P=0.074N	P=0.102N
POLY 1.5	P=0.036N*	P=0.588N	P=0.088N	P=0.106N
POLY 6	P=0.030N*	P=0.510N	P=0.056N	P=0.091N
RAO-SCOTT	P=0.051N	P=0.551N	P=0.100N	P=0.127N
LITTER C-A/FISHERS	P=0.033N*	P=0.633	P=0.099N	P=0.099N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Forestomach **Erosion**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/89 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/35 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	1/74.10	0/77.81	0/66.24
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	719	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Forestomach **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	7/90 (8%)	4/90 (4%)	10/89 (11%)	2/90 (2%)
LITTERS (b)	7/35 (20%)	4/35 (11%)	8/35 (23%)	2/35 (6%)
POLY-3 RATE (c)	7/67.57	4/74.27	10/79.41	2/66.29
POLY-3 PERCENT (g)	10.4%	5.4%	12.6%	3%
TERMINAL (d)	1/25 (4%)	2/43 (5%)	3/56 (5%)	1/43 (2%)
FIRST INCIDENCE	541	701	471	717
STATISTICAL TESTS				
POLY 3	P=0.170N	P=0.214N	P=0.436	P=0.087N
POLY 1.5	P=0.166N	P=0.235N	P=0.371	P=0.089N
POLY 6	P=0.162N	P=0.183N	P=0.538	P=0.077N
RAO-SCOTT	P=0.176N	P=0.243N	P=0.446	P=0.114N
LITTER C-A/FISHERS	P=0.107N	P=0.256N	P=0.500	P=0.075N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Forestomach **Ulcer**				
LESION RATES				
OVERALL (a)	6/90 (7%)	8/90 (9%)	4/89 (4%)	1/90 (1%)
LITTERS (b)	6/35 (17%)	8/35 (23%)	4/35 (11%)	1/35 (3%)
POLY-3 RATE (c)	6/67.48	8/75.63	4/78.19	1/67.23
POLY-3 PERCENT (g)	8.9%	10.6%	5.1%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	2/56 (4%)	0/43 (0%)
FIRST INCIDENCE	510	573	642	153
STATISTICAL TESTS				
POLY 3	P=0.024N*	P=0.477	P=0.285N	P=0.059N
POLY 1.5	P=0.026N*	P=0.440	P=0.326N	P=0.061N
POLY 6	P=0.021N*	P=0.537	P=0.227N	P=0.053N
RAO-SCOTT	P=0.029N*	P=0.467	P=0.286N	P=0.065N
LITTER C-A/FISHERS	P=0.020N*	P=0.383	P=0.367N	P=0.053N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Forestomach: Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	11/90 (12%)	17/90 (19%)	11/89 (12%)	6/90 (7%)
LITTERS (b)	10/35 (29%)	15/35 (43%)	10/35 (29%)	6/35 (17%)
POLY-3 RATE (c)	11/68.12	17/77.03	11/79.66	6/67.04
POLY-3 PERCENT (g)	16.2%	22.1%	13.8%	9%
TERMINAL (d)	1/25 (4%)	4/43 (9%)	3/56 (5%)	2/43 (5%)
FIRST INCIDENCE	541	552	471	531
STATISTICAL TESTS				
POLY 3	P=0.058N	P=0.243	P=0.434N	P=0.156N
POLY 1.5	P=0.061N	P=0.201	P=0.509N	P=0.160N
POLY 6	P=0.048N*	P=0.319	P=0.326N	P=0.137N
RAO-SCOTT	P=0.071N	P=0.256	P=0.434N	P=0.168N
LITTER C-A/FISHERS	P=0.070N	P=0.159	P=0.604	P=0.197N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Forestomach: Epithelium Hyperplasia Basal Cell				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	1/89 (1%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	0/65.47	0/74.05	1/77.81	1/66.24
POLY-3 PERCENT (g)	0%	0%	1.3%	1.5%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	1/56 (2%)	1/43 (2%)
FIRST INCIDENCE	---	---	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Glandular Erosion				
LESION RATES				
OVERALL (a)	3/86 (3%)	2/86 (2%)	3/85 (4%)	0/78 (0%)
LITTERS (b)	3/35 (9%)	2/35 (6%)	3/35 (9%)	0/35 (0%)
POLY-3 RATE (c)	3/65.34	2/71.78	3/76.35	0/60.80
POLY-3 PERCENT (g)	4.6%	2.8%	3.9%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	541	447	471	---
STATISTICAL TESTS				
POLY 3	P=0.129N	P=0.458N	P=0.588N	P=0.133N
POLY 1.5	P=0.133N	P=0.476N	P=0.624N	P=0.138N
POLY 6	P=0.120N	P=0.427N	P=0.529N	P=0.122N
RAO-SCOTT	P=0.138N	P=0.453N	P=0.578N	P=0.147N
LITTER C-A/FISHERS	P=0.109N	P=0.500N	P=0.663	P=0.120N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Glandular Mineral				
LESION RATES				
OVERALL (a)	31/86 (36%)	9/86 (10%)	6/85 (7%)	1/78 (1%)
LITTERS (b)	21/35 (60%)	7/35 (20%)	6/35 (17%)	1/35 (3%)
POLY-3 RATE (c)	31/74.81	9/73.09	6/76.71	1/61.19
POLY-3 PERCENT (g)	41.4%	12.3%	7.8%	1.6%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	496	568	614	621
STATISTICAL TESTS				
POLY 3	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
POLY 6	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P<0.001N**	P<0.001N**	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Glandular **Necrosis**				
LESION RATES				
OVERALL (a)	0/86 (0%)	0/86 (0%)	3/85 (4%)	0/78 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	3/35 (9%)	0/35 (0%)
POLY-3 RATE (c)	0/63.98	0/70.64	3/76.06	0/60.80
POLY-3 PERCENT (g)	0%	0%	3.9%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	664	---
STATISTICAL TESTS				
POLY 3	P=0.511	(e)	P=0.155	(e)
POLY 1.5	P=0.505	(e)	P=0.137	(e)
POLY 6	P=0.541	(e)	P=0.187	(e)
RAO-SCOTT	P=0.545	(e)	P=0.245	(e)
LITTER C-A/FISHERS	P=0.539	(e)	P=0.120	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Glandular: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	3/86 (3%)	0/86 (0%)	0/85 (0%)	0/78 (0%)
LITTERS (b)	3/35 (9%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	3/64.41	0/70.64	0/75.45	0/60.80
POLY-3 PERCENT (g)	4.7%	0%	0%	0%
TERMINAL (d)	2/25 (8%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	604	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.052N	P=0.105N	P=0.095N	P=0.130N
POLY 1.5	P=0.051N	P=0.112N	P=0.107N	P=0.136N
POLY 6	P=0.056N	P=0.094N	P=0.079N	P=0.117N
RAO-SCOTT	P=0.117N	P=0.212N	P=0.204N	P=0.238N
LITTER C-A/FISHERS	P=0.047N*	P=0.120N	P=0.120N	P=0.120N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Testis				
Edema				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/89 (2%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	2/35 (6%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.47	2/73.43	0/78.35	0/66.24
POLY-3 PERCENT (g)	0%	2.7%	0%	0%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	730 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.372N	P=0.264	(e)	(e)
POLY 1.5	P=0.388N	P=0.252	(e)	(e)
POLY 6	P=0.343N	P=0.286	(e)	(e)
RAO-SCOTT	P=0.456N	P=0.372	(e)	(e)
LITTER C-A/FISHERS	P=0.405N	P=0.246	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Testis **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/89 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/65.64	0/73.43	0/78.35	0/66.24
POLY-3 PERCENT (g)	3.1%	0%	0%	0%
TERMINAL (d)	1/25 (4%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	687	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.119N	P=0.214N	P=0.202N	P=0.236N
POLY 1.5	P=0.117N	P=0.225N	P=0.218N	P=0.240N
POLY 6	P=0.126N	P=0.197N	P=0.178N	P=0.223N
RAO-SCOTT	P=0.214N	P=0.357N	P=0.350N	P=0.364N
LITTER C-A/FISHERS	P=0.114N	P=0.246N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Testis: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	52/90 (58%)	37/89 (42%)	30/90 (33%)	12/90 (13%)
LITTERS (b)	30/35 (86%)	24/35 (69%)	24/35 (69%)	11/35 (31%)
POLY-3 RATE (c)	52/76.11	37/77.37	30/80.67	12/66.62
POLY-3 PERCENT (g)	68.3%	47.8%	37.2%	18%
TERMINAL (d)	15/25 (60%)	21/43 (49%)	17/56 (30%)	9/43 (21%)
FIRST INCIDENCE	496	568	604	665
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.005N**	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P=0.008N**	P<0.001N**	P<0.001N**
POLY 6	P<0.001N**	P=0.003N**	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.009N**	P<0.001N**	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P=0.077N	P=0.077N	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Testis: Germ Cell Degeneration				
LESION RATES				
OVERALL (a)	51/90 (57%)	37/89 (42%)	31/90 (34%)	24/90 (27%)
LITTERS (b)	30/35 (86%)	25/35 (71%)	22/35 (63%)	17/35 (49%)
POLY-3 RATE (c)	51/80.13	37/78.92	31/82.41	24/69.61
POLY-3 PERCENT (g)	63.6%	46.9%	37.6%	34.5%
TERMINAL (d)	8/25 (32%)	16/43 (37%)	16/56 (29%)	15/43 (35%)
FIRST INCIDENCE	496	550	495	433
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.020N*	P<0.001N**	P<0.001N**
POLY 1.5	P<0.001N**	P=0.021N*	P<0.001N**	P<0.001N**
POLY 6	P<0.001N**	P=0.021N*	P<0.001N**	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.028N*	P<0.001N**	P<0.001N**
LITTER C-A/FISHERS	P<0.001N**	P=0.122N	P=0.027N*	P<0.001N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Testis: Interstitial Cell Hyperplasia				
LESION RATES				
OVERALL (a)	1/90 (1%)	2/89 (2%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	1/35 (3%)	2/35 (6%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	1/65.79	2/73.43	0/78.35	1/66.24
POLY-3 PERCENT (g)	1.5%	2.7%	0%	1.5%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	0/56 (0%)	1/43 (2%)
FIRST INCIDENCE	642	730 (T)	---	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.481N	P=0.538	P=0.465N	P=0.759N
POLY 1.5	P=0.491N	P=0.520	P=0.481N	P=0.759
POLY 6	P=0.464N	P=0.567	P=0.441N	P=0.747N
RAO-SCOTT	P=0.490N	P=0.527	P=0.464N	P=0.719N
LITTER C-A/FISHERS	P=0.500N	P=0.500	P=0.500N	P=0.754

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thymus **Atrophy**				
LESION RATES				
OVERALL (a)	79/88 (90%)	76/85 (89%)	80/87 (92%)	65/82 (79%)
LITTERS (b)	35/35 (100%)	33/35 (94%)	35/35 (100%)	32/34 (94%)
POLY-3 RATE (c)	79/85.04	76/83.22	80/84.34	65/75.15
POLY-3 PERCENT (g)	92.9%	91.3%	94.9%	86.5%
TERMINAL (d)	19/24 (79%)	35/40 (88%)	52/55 (95%)	36/42 (86%)
FIRST INCIDENCE	248	388	383	153
STATISTICAL TESTS				
POLY 3	P=0.106N	P=0.461N	P=0.413	P=0.122N
POLY 1.5	P=0.054N	P=0.459N	P=0.429	P=0.071N
POLY 6	P=0.215N	P=0.507N	P=0.382	P=0.229N
RAO-SCOTT	P=0.123N	P=0.468N	P=0.423	P=0.147N
LITTER C-A/FISHERS	P=0.238N	P=0.246N	(e)	P=0.239N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thymus **Cyst**				
LESION RATES				
OVERALL (a)	10/88 (11%)	10/85 (12%)	10/87 (11%)	17/82 (21%)
LITTERS (b)	9/35 (26%)	10/35 (29%)	9/35 (26%)	13/34 (38%)
POLY-3 RATE (c)	10/65.49	10/69.73	10/75.65	17/60.97
POLY-3 PERCENT (g)	15.3%	14.3%	13.2%	27.9%
TERMINAL (d)	5/24 (21%)	6/40 (15%)	10/55 (18%)	16/42 (38%)
FIRST INCIDENCE	565	663	730 (T)	708
STATISTICAL TESTS				
POLY 3	P=0.034*	P=0.536N	P=0.458N	P=0.061
POLY 1.5	P=0.033*	P=0.574N	P=0.524N	P=0.060
POLY 6	P=0.039*	P=0.474N	P=0.355N	P=0.075
RAO-SCOTT	P=0.042*	P=0.527N	P=0.457N	P=0.080
LITTER C-A/FISHERS	P=0.159	P=0.500	P=0.607	P=0.196

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thymus **Ectopic Parathyroid Gland**				
LESION RATES				
OVERALL (a)	6/88 (7%)	6/85 (7%)	7/87 (8%)	5/82 (6%)
LITTERS (b)	6/35 (17%)	5/35 (14%)	7/35 (20%)	5/34 (15%)
POLY-3 RATE (c)	6/64.67	6/70.33	7/75.77	5/60.88
POLY-3 PERCENT (g)	9.3%	8.5%	9.2%	8.2%
TERMINAL (d)	2/24 (8%)	3/40 (8%)	6/55 (11%)	5/42 (12%)
FIRST INCIDENCE	629	582	698	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.494N	P=0.560N	P=0.611N	P=0.542N
POLY 1.5	P=0.502N	P=0.595N	P=0.561	P=0.554N
POLY 6	P=0.463N	P=0.503N	P=0.522N	P=0.501N
RAO-SCOTT	P=0.479N	P=0.537N	P=0.591N	P=0.513N
LITTER C-A/FISHERS	P=0.508N	P=0.500N	P=0.500	P=0.521N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thymus **Hemorrhage**				
LESION RATES				
OVERALL (a)	2/88 (2%)	2/85 (2%)	2/87 (2%)	20/82 (24%)
LITTERS (b)	2/35 (6%)	2/35 (6%)	2/35 (6%)	15/34 (44%)
POLY-3 RATE (c)	2/65.27	2/70.35	2/75.73	20/70.91
POLY-3 PERCENT (g)	3.1%	2.8%	2.6%	28.2%
TERMINAL (d)	0/24 (0%)	0/40 (0%)	0/55 (0%)	0/42 (0%)
FIRST INCIDENCE	294	388	713	201
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.666N	P=0.638N	P<0.001**
POLY 1.5	P<0.001**	P=0.683N	P=0.666N	P<0.001**
POLY 6	P<0.001**	P=0.637N	P=0.590N	P<0.001**
RAO-SCOTT	P<0.001**	P=0.659N	P=0.639N	P<0.001**
LITTER C-A/FISHERS	P<0.001**	P=0.693	P=0.693	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thymus **Hyperplasia Epithelial**				
LESION RATES				
OVERALL (a)	2/88 (2%)	2/85 (2%)	4/87 (5%)	4/82 (5%)
LITTERS (b)	2/35 (6%)	2/35 (6%)	3/35 (9%)	4/34 (12%)
POLY-3 RATE (c)	2/63.81	2/69.28	4/75.95	4/61.27
POLY-3 PERCENT (g)	3.1%	2.9%	5.3%	6.5%
TERMINAL (d)	0/24 (0%)	2/40 (5%)	3/55 (6%)	3/42 (7%)
FIRST INCIDENCE	715	730 (T)	647	621
STATISTICAL TESTS				
POLY 3	P=0.189	P=0.664N	P=0.421	P=0.319
POLY 1.5	P=0.183	P=0.681N	P=0.381	P=0.307
POLY 6	P=0.209	P=0.633N	P=0.488	P=0.354
RAO-SCOTT	P=0.213	P=0.644N	P=0.432	P=0.333
LITTER C-A/FISHERS	P=0.201	P=0.693	P=0.500	P=0.323

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thymus: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	6/88 (7%)	3/85 (4%)	2/87 (2%)	1/82 (1%)
LITTERS (b)	4/35 (11%)	3/35 (9%)	2/35 (6%)	1/34 (3%)
POLY-3 RATE (c)	6/65.19	3/69.74	2/75.65	1/60.88
POLY-3 PERCENT (g)	9.2%	4.3%	2.6%	1.6%
TERMINAL (d)	1/24 (4%)	2/40 (5%)	2/55 (4%)	1/42 (2%)
FIRST INCIDENCE	584	597	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.042N*	P=0.213N	P=0.095N	P=0.070N
POLY 1.5	P=0.044N*	P=0.234N	P=0.114N	P=0.074N
POLY 6	P=0.039N*	P=0.183N	P=0.070N	P=0.060N
RAO-SCOTT	P=0.079N	P=0.277N	P=0.159N	P=0.126N
LITTER C-A/FISHERS	P=0.117N	P=0.500N	P=0.337N	P=0.187N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thyroid Gland: C-Cell Hyperplasia				
LESION RATES				
OVERALL (a)	16/89 (18%)	17/87 (20%)	17/86 (20%)	22/85 (26%)
LITTERS (b)	12/35 (34%)	14/35 (40%)	14/34 (41%)	17/35 (49%)
POLY-3 RATE (c)	16/68.70	17/72.12	17/76.36	22/67.57
POLY-3 PERCENT (g)	23.3%	23.6%	22.3%	32.6%
TERMINAL (d)	7/25 (28%)	16/43 (37%)	14/56 (25%)	14/43 (33%)
FIRST INCIDENCE	440	711	652	580
STATISTICAL TESTS				
POLY 3	P=0.115	P=0.564	P=0.520N	P=0.149
POLY 1.5	P=0.104	P=0.521	P=0.550	P=0.135
POLY 6	P=0.154	P=0.525N	P=0.376N	P=0.208
RAO-SCOTT	P=0.125	P=0.552	P=0.513N	P=0.163
LITTER C-A/FISHERS	P=0.139	P=0.402	P=0.366	P=0.166

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thyroid Gland: Follicle Cyst				
LESION RATES				
OVERALL (a)	0/89 (0%)	2/87 (2%)	0/86 (0%)	1/85 (1%)
LITTERS (b)	0/35 (0%)	2/35 (6%)	0/34 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/65.45	2/72.04	0/75.66	1/64.54
POLY-3 PERCENT (g)	0%	2.8%	0%	1.6%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	0/56 (0%)	1/43 (2%)
FIRST INCIDENCE	---	730 (T)	---	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.553	P=0.260	(e)	P=0.497
POLY 1.5	P=0.538	P=0.248	(e)	P=0.492
POLY 6	P=0.585	P=0.282	(e)	P=0.511
RAO-SCOTT	P=0.542	P=0.333	(e)	P=0.536
LITTER C-A/FISHERS	P=0.538	P=0.246	(e)	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Tissue NOS: Abdominal, Fat Necrosis				
LESION RATES				
OVERALL (a)	0/3 (0%)	0/1 (0%)	0/3 (0%)	0/3 (0%)
LITTERS (b)	0/3 (0%)	0/1 (0%)	0/3 (0%)	0/2 (0%)
POLY-3 RATE (c)	0/2.27	0/0.96	0/2.74	0/2.01
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/2 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Tissue NOS: Fat Necrosis				
LESION RATES				
OVERALL (a)	2/3 (67%)	0/1 (0%)	1/3 (33%)	1/3 (33%)
LITTERS (b)	2/3 (67%)	0/1 (0%)	1/3 (33%)	1/2 (50%)
POLY-3 RATE (c)	2/2.76	0/0.96	1/2.75	1/2.01
POLY-3 PERCENT (g)	72.5%	0%	36.3%	49.8%
TERMINAL (d)	1/1 (100%)	0/0 (0%)	0/1 (0%)	1/2 (50%)
FIRST INCIDENCE	582	---	726	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.464N	P=0.487N	P=0.501N	P=0.649N
POLY 1.5	P=0.463N	P=0.493N	P=0.501N	P=0.643N
POLY 6	P=0.458N	P=0.476N	P=0.502N	P=0.629N
RAO-SCOTT	P=0.497N	P=0.597N	P=0.568N	P=0.656N
LITTER C-A/FISHERS	P=0.560N	P=0.500N	P=0.500N	P=0.700N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Trachea: Glands **Cyst**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/88 (0%)	0/88 (0%)	0/72 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	0/34 (0%)
POLY-3 RATE (c)	0/65.47	0/73.00	0/76.88	0/56.58
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Trigeminal Ganglion Degeneration				
LESION RATES				
OVERALL (a)	23/75 (31%)	22/77 (29%)	21/79 (27%)	16/83 (19%)
LITTERS (b)	19/34 (56%)	20/35 (57%)	17/35 (49%)	15/35 (43%)
POLY-3 RATE (c)	23/58.42	22/65.54	21/69.90	16/62.56
POLY-3 PERCENT (g)	39.4%	33.6%	30%	25.6%
TERMINAL (d)	11/21 (52%)	12/37 (32%)	16/49 (33%)	11/40 (28%)
FIRST INCIDENCE	541	582	677	545
STATISTICAL TESTS				
POLY 3	P=0.062N	P=0.310N	P=0.174N	P=0.070N
POLY 1.5	P=0.063N	P=0.370N	P=0.243N	P=0.076N
POLY 6	P=0.050N*	P=0.222N	P=0.094N	P=0.050N*
RAO-SCOTT	P=0.058N	P=0.302N	P=0.170N	P=0.070N
LITTER C-A/FISHERS	P=0.122N	P=0.554	P=0.357N	P=0.200N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Urinary Bladder				
Edema				
LESION RATES				
OVERALL (a)	0/89 (0%)	0/83 (0%)	0/83 (0%)	0/78 (0%)
LITTERS (b)	0/35 (0%)	0/35 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.00	0/68.82	0/73.91	0/60.42
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Urinary Bladder Hemorrhage				
LESION RATES				
OVERALL (a)	2/89 (2%)	1/83 (1%)	2/83 (2%)	1/78 (1%)
LITTERS (b)	2/35 (6%)	1/35 (3%)	2/35 (6%)	1/35 (3%)
POLY-3 RATE (c)	2/65.18	1/69.66	2/75.01	1/60.42
POLY-3 PERCENT (g)	3.1%	1.4%	2.7%	1.7%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	1/43 (2%)
FIRST INCIDENCE	691	388	393	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.481N	P=0.477N	P=0.641N	P=0.526N
POLY 1.5	P=0.488N	P=0.497N	P=0.676N	P=0.539N
POLY 6	P=0.468N	P=0.445N	P=0.586N	P=0.497N
RAO-SCOTT	P=0.458N	P=0.453N	P=0.618N	P=0.493N
LITTER C-A/FISHERS	P=0.444N	P=0.500N	P=0.693	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Urinary Bladder **Inflammation Acute**				
LESION RATES				
OVERALL (a)	2/89 (2%)	1/83 (1%)	1/83 (1%)	0/78 (0%)
LITTERS (b)	2/35 (6%)	1/35 (3%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	2/65.18	1/69.66	1/74.16	0/60.42
POLY-3 PERCENT (g)	3.1%	1.4%	1.4%	0%
TERMINAL (d)	0/25 (0%)	0/43 (0%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	691	388	664	---
STATISTICAL TESTS				
POLY 3	P=0.170N	P=0.477N	P=0.455N	P=0.254N
POLY 1.5	P=0.173N	P=0.497N	P=0.486N	P=0.263N
POLY 6	P=0.165N	P=0.445N	P=0.408N	P=0.236N
RAO-SCOTT	P=0.183N	P=0.475N	P=0.461N	P=0.267N
LITTER C-A/FISHERS	P=0.152N	P=0.500N	P=0.500N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Urinary Bladder **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	0/89 (0%)	2/83 (2%)	0/83 (0%)	0/78 (0%)
LITTERS (b)	0/35 (0%)	2/35 (6%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/65.00	2/68.82	0/73.91	0/60.42
POLY-3 PERCENT (g)	0%	2.9%	0%	0%
TERMINAL (d)	0/25 (0%)	2/43 (5%)	0/56 (0%)	0/43 (0%)
FIRST INCIDENCE	---	730 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.387N	P=0.251	(e)	(e)
POLY 1.5	P=0.407N	P=0.239	(e)	(e)
POLY 6	P=0.354N	P=0.273	(e)	(e)
RAO-SCOTT	P=0.478N	P=0.362	(e)	(e)
LITTER C-A/FISHERS	P=0.405N	P=0.246	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 105 WEEKS

	Males			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Urinary Bladder: Urothelium Hyperplasia				
LESION RATES				
OVERALL (a)	1/89 (1%)	4/83 (5%)	2/83 (2%)	1/78 (1%)
LITTERS (b)	1/35 (3%)	4/35 (11%)	2/35 (6%)	1/35 (3%)
POLY-3 RATE (c)	1/65.53	4/68.82	2/73.91	1/60.42
POLY-3 PERCENT (g)	1.5%	5.8%	2.7%	1.7%
TERMINAL (d)	0/25 (0%)	4/43 (9%)	2/56 (4%)	1/43 (2%)
FIRST INCIDENCE	567	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.416N	P=0.196	P=0.542	P=0.743
POLY 1.5	P=0.438N	P=0.180	P=0.512	P=0.735
POLY 6	P=0.374N	P=0.224	P=0.587	P=0.761
RAO-SCOTT	P=0.433N	P=0.209	P=0.530	P=0.705
LITTER C-A/FISHERS	P=0.403N	P=0.178	P=0.500	P=0.754

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

Females

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Adrenal Cortex				
Accessory Adrenal Cortical Nodule				
LESION RATES				
OVERALL (a)	5/90 (6%)	7/90 (8%)	6/90 (7%)	12/90 (13%)
LITTERS (b)	5/35 (14%)	7/34 (21%)	6/35 (17%)	10/35 (29%)
POLY-3 RATE (c)	5/69.46	7/73.83	6/72.00	12/79.63
POLY-3 PERCENT (g)	7.2%	9.5%	8.3%	15.1%
TERMINAL (d)	5/48 (10%)	6/45 (13%)	5/50 (10%)	12/61 (20%)
FIRST INCIDENCE	737 (T)	579	707	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.066	P=0.424	P=0.525	P=0.105
POLY 1.5	P=0.055	P=0.406	P=0.512	P=0.087
POLY 6	P=0.080	P=0.444	P=0.541	P=0.128
RAO-SCOTT	P=0.087	P=0.422	P=0.513	P=0.121
LITTER C-A/FISHERS	P=0.103	P=0.355	P=0.500	P=0.122

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex **Atrophy**				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	2/90 (2%)	0/90 (0%)
LITTERS (b)	1/35 (3%)	0/34 (0%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	1/69.46	0/73.31	2/72.26	0/79.63
POLY-3 PERCENT (g)	1.4%	0%	2.8%	0%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	1/50 (2%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	---	627	---
STATISTICAL TESTS				
POLY 3	P=0.426N	P=0.489N	P=0.514	P=0.473N
POLY 1.5	P=0.438N	P=0.494N	P=0.507	P=0.483N
POLY 6	P=0.412N	P=0.485N	P=0.523	P=0.462N
RAO-SCOTT	P=0.488N	P=0.561N	P=0.550	P=0.562N
LITTER C-A/FISHERS	P=0.458N	P=0.507N	P=0.500	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex Degeneration				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex **Degeneration Cystic**				
LESION RATES				
OVERALL (a)	22/90 (24%)	19/90 (21%)	18/90 (20%)	19/90 (21%)
LITTERS (b)	15/35 (43%)	15/34 (44%)	14/35 (40%)	16/35 (46%)
POLY-3 RATE (c)	22/70.42	19/74.98	18/73.27	19/80.05
POLY-3 PERCENT (g)	31.2%	25.3%	24.6%	23.7%
TERMINAL (d)	18/48 (38%)	12/45 (27%)	12/50 (24%)	17/61 (28%)
FIRST INCIDENCE	622	612	550	669
STATISTICAL TESTS				
POLY 3	P=0.207N	P=0.270N	P=0.237N	P=0.196N
POLY 1.5	P=0.255N	P=0.309N	P=0.264N	P=0.252N
POLY 6	P=0.163N	P=0.229N	P=0.205N	P=0.146N
RAO-SCOTT	P=0.224N	P=0.288N	P=0.256N	P=0.218N
LITTER C-A/FISHERS	P=0.469	P=0.554	P=0.500N	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex Hyperplasia				
LESION RATES				
OVERALL (a)	14/90 (16%)	31/90 (34%)	26/90 (29%)	19/90 (21%)
LITTERS (b)	12/35 (34%)	21/34 (62%)	19/35 (54%)	15/35 (43%)
POLY-3 RATE (c)	14/70.96	31/77.38	26/74.97	19/81.96
POLY-3 PERCENT (g)	19.7%	40.1%	34.7%	23.2%
TERMINAL (d)	11/48 (23%)	18/45 (40%)	18/50 (36%)	12/61 (20%)
FIRST INCIDENCE	531	300	450	536
STATISTICAL TESTS				
POLY 3	P=0.321N	P=0.005**	P=0.030*	P=0.374
POLY 1.5	P=0.418N	P=0.003**	P=0.026*	P=0.311
POLY 6	P=0.227N	P=0.007**	P=0.037*	P=0.449
RAO-SCOTT	P=0.389N	P=0.010**	P=0.043*	P=0.381
LITTER C-A/FISHERS	P=0.482	P=0.020*	P=0.074	P=0.312

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex Hypertrophy				
LESION RATES				
OVERALL (a)	52/90 (58%)	55/90 (61%)	56/90 (62%)	50/90 (56%)
LITTERS (b)	31/35 (89%)	31/34 (91%)	30/35 (86%)	30/35 (86%)
POLY-3 RATE (c)	52/76.48	55/78.42	56/77.46	50/83.11
POLY-3 PERCENT (g)	68%	70.1%	72.3%	60.2%
TERMINAL (d)	37/48 (77%)	37/45 (82%)	42/50 (84%)	42/61 (69%)
FIRST INCIDENCE	492	550	450	522
STATISTICAL TESTS				
POLY 3	P=0.108N	P=0.452	P=0.331	P=0.183N
POLY 1.5	P=0.180N	P=0.409	P=0.318	P=0.265N
POLY 6	P=0.059N	P=0.520	P=0.351	P=0.117N
RAO-SCOTT	P=0.131N	P=0.447	P=0.336	P=0.192N
LITTER C-A/FISHERS	P=0.353N	P=0.517	P=0.500N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex **Necrosis**				
LESION RATES				
OVERALL (a)	2/90 (2%)	2/90 (2%)	2/90 (2%)	4/90 (4%)
LITTERS (b)	2/35 (6%)	2/34 (6%)	2/35 (6%)	4/35 (11%)
POLY-3 RATE (c)	2/69.57	2/73.41	2/72.97	4/80.08
POLY-3 PERCENT (g)	2.9%	2.7%	2.7%	5%
TERMINAL (d)	1/48 (2%)	1/45 (2%)	0/50 (0%)	2/61 (3%)
FIRST INCIDENCE	709	711	417	633
STATISTICAL TESTS				
POLY 3	P=0.272	P=0.674N	P=0.676N	P=0.405
POLY 1.5	P=0.253	P=0.682N	P=0.684N	P=0.380
POLY 6	P=0.294	P=0.666N	P=0.666N	P=0.433
RAO-SCOTT	P=0.282	P=0.643N	P=0.645N	P=0.392
LITTER C-A/FISHERS	P=0.223	P=0.682	P=0.693	P=0.337

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex **Thrombus**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Cortex **Vacuolation, Cytoplasmic**				
LESION RATES				
OVERALL (a)	18/90 (20%)	17/90 (19%)	11/90 (12%)	14/90 (16%)
LITTERS (b)	14/35 (40%)	15/34 (44%)	9/35 (26%)	11/35 (31%)
POLY-3 RATE (c)	18/71.37	17/73.71	11/72.80	14/80.64
POLY-3 PERCENT (g)	25.2%	23.1%	15.1%	17.4%
TERMINAL (d)	12/48 (25%)	15/45 (33%)	6/50 (12%)	10/61 (16%)
FIRST INCIDENCE	578	656	631	492
STATISTICAL TESTS				
POLY 3	P=0.109N	P=0.456N	P=0.093N	P=0.161N
POLY 1.5	P=0.137N	P=0.474N	P=0.101N	P=0.199N
POLY 6	P=0.084N	P=0.447N	P=0.085N	P=0.129N
RAO-SCOTT	P=0.115N	P=0.448N	P=0.099N	P=0.166N
LITTER C-A/FISHERS	P=0.169N	P=0.459	P=0.154N	P=0.309N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Adrenal Medulla **Hyperplasia**				
LESION RATES				
OVERALL (a)	13/86 (15%)	20/89 (22%)	20/87 (23%)	18/88 (20%)
LITTERS (b)	11/35 (31%)	16/34 (47%)	16/35 (46%)	15/35 (43%)
POLY-3 RATE (c)	13/66.92	20/74.41	20/71.46	18/78.71
POLY-3 PERCENT (g)	19.4%	26.9%	28%	22.9%
TERMINAL (d)	10/45 (22%)	15/44 (34%)	13/48 (27%)	15/60 (25%)
FIRST INCIDENCE	524	570	531	522
STATISTICAL TESTS				
POLY 3	P=0.474	P=0.196	P=0.160	P=0.381
POLY 1.5	P=0.402	P=0.172	P=0.143	P=0.322
POLY 6	P=0.528N	P=0.226	P=0.187	P=0.447
RAO-SCOTT	P=0.452	P=0.204	P=0.170	P=0.380
LITTER C-A/FISHERS	P=0.274	P=0.139	P=0.163	P=0.229

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Aorta **Dilation**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

Females

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Aorta Mineral				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Bone Marrow **Fibrosis**				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/90 (2%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	2/34 (6%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	2/73.47	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	2.7%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	696	---	---
STATISTICAL TESTS				
POLY 3	P=0.373N	P=0.251	(e)	(e)
POLY 1.5	P=0.386N	P=0.245	(e)	(e)
POLY 6	P=0.359N	P=0.256	(e)	(e)
RAO-SCOTT	P=0.482N	P=0.373	(e)	(e)
LITTER C-A/FISHERS	P=0.403N	P=0.239	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Bone Marrow Hemorrhage				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Bone Marrow Hypercellularity				
LESION RATES				
OVERALL (a)	56/90 (62%)	52/90 (58%)	43/90 (48%)	43/90 (48%)
LITTERS (b)	31/35 (89%)	31/34 (91%)	28/35 (80%)	29/35 (83%)
POLY-3 RATE (c)	56/85.79	52/87.76	43/84.90	43/87.87
POLY-3 PERCENT (g)	65.3%	59.3%	50.7%	48.9%
TERMINAL (d)	24/48 (50%)	17/45 (38%)	16/50 (32%)	21/61 (34%)
FIRST INCIDENCE	268	300	268	305
STATISTICAL TESTS				
POLY 3	P=0.013N*	P=0.251N	P=0.035N*	P=0.020N*
POLY 1.5	P=0.015N*	P=0.271N	P=0.036N*	P=0.024N*
POLY 6	P=0.011N*	P=0.238N	P=0.033N*	P=0.016N*
RAO-SCOTT	P=0.018N*	P=0.266N	P=0.045N*	P=0.027N*
LITTER C-A/FISHERS	P=0.213N	P=0.517	P=0.256N	P=0.367N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Bone **Fibrous Osteodystrophy**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain **Compression**				
LESION RATES				
OVERALL (a)	26/90 (29%)	31/90 (34%)	16/90 (18%)	20/90 (22%)
LITTERS (b)	19/35 (54%)	24/34 (71%)	15/35 (43%)	15/35 (43%)
POLY-3 RATE (c)	26/73.88	31/77.00	16/74.03	20/81.60
POLY-3 PERCENT (g)	35.2%	40.3%	21.6%	24.5%
TERMINAL (d)	15/48 (31%)	13/45 (29%)	8/50 (16%)	13/61 (21%)
FIRST INCIDENCE	464	578	516	557
STATISTICAL TESTS				
POLY 3	P=0.024N*	P=0.315	P=0.046N*	P=0.097N
POLY 1.5	P=0.034N*	P=0.287	P=0.050N*	P=0.128N
POLY 6	P=0.017N*	P=0.353	P=0.043N*	P=0.074N
RAO-SCOTT	P=0.034N*	P=0.324	P=0.058N	P=0.112N
LITTER C-A/FISHERS	P=0.066N	P=0.125	P=0.237N	P=0.237N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain				
Edema				
LESION RATES				
OVERALL (a)	2/90 (2%)	1/90 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/69.55	1/73.60	0/71.88	0/79.63
POLY-3 PERCENT (g)	2.9%	1.4%	0%	0%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	712	657	---	---
STATISTICAL TESTS				
POLY 3	P=0.098N	P=0.480N	P=0.231N	P=0.210N
POLY 1.5	P=0.100N	P=0.489N	P=0.235N	P=0.220N
POLY 6	P=0.097N	P=0.472N	P=0.226N	P=0.199N
RAO-SCOTT	P=0.162N	P=0.520N	P=0.310N	P=0.300N
LITTER C-A/FISHERS	P=0.099N	P=0.511N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain **Hemorrhage**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.63	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	649	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain **Mineral**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	1/90 (1%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.31	1/72.19	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	1.4%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	652	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain **Necrosis**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain: Choroid Plexus Mineral				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain: Glial Cell Hyperplasia				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	1/90 (1%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	0/73.31	1/71.88	1/79.63
POLY-3 PERCENT (g)	0%	0%	1.4%	1.3%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	1/50 (2%)	1/61 (2%)
FIRST INCIDENCE	---	---	737 (T)	737 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain: Hypothalamus **Cyst**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain: Pineal Gland Mineral				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	1/35 (3%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	1/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	1.4%	0%	0%	0%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Brain: Pineal Gland **Vacuolation, Cytoplasmic**				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	2/90 (2%)	0/90 (0%)
LITTERS (b)	1/35 (3%)	0/34 (0%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	1/69.46	0/73.31	2/71.88	0/79.63
POLY-3 PERCENT (g)	1.4%	0%	2.8%	0%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	2/50 (4%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	---	737 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.426N	P=0.489N	P=0.512	P=0.473N
POLY 1.5	P=0.438N	P=0.494N	P=0.506	P=0.483N
POLY 6	P=0.412N	P=0.485N	P=0.520	P=0.462N
RAO-SCOTT	P=0.485N	P=0.555N	P=0.545	P=0.556N
LITTER C-A/FISHERS	P=0.458N	P=0.507N	P=0.500	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Clitoral Gland **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	28/87 (32%)	43/88 (49%)	36/89 (40%)	43/86 (50%)
LITTERS (b)	18/35 (51%)	28/34 (82%)	25/35 (71%)	29/35 (83%)
POLY-3 RATE (c)	28/71.43	43/80.00	36/76.31	43/81.69
POLY-3 PERCENT (g)	39.2%	53.8%	47.2%	52.6%
TERMINAL (d)	18/47 (38%)	26/45 (58%)	27/50 (54%)	30/59 (51%)
FIRST INCIDENCE	489	300	268	522
STATISTICAL TESTS				
POLY 3	P=0.132	P=0.047*	P=0.202	P=0.063
POLY 1.5	P=0.083	P=0.033*	P=0.193	P=0.035*
POLY 6	P=0.206	P=0.064	P=0.206	P=0.108
RAO-SCOTT	P=0.139	P=0.058	P=0.215	P=0.074
LITTER C-A/FISHERS	P=0.013*	P=0.006**	P=0.070	P=0.005**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Clitoral Gland: Duct Dilation				
LESION RATES				
OVERALL (a)	47/87 (54%)	64/88 (73%)	65/89 (73%)	60/86 (70%)
LITTERS (b)	29/35 (83%)	34/34 (100%)	35/35 (100%)	34/35 (97%)
POLY-3 RATE (c)	47/75.37	64/81.80	65/85.02	60/83.39
POLY-3 PERCENT (g)	62.4%	78.2%	76.5%	72%
TERMINAL (d)	29/47 (62%)	37/45 (82%)	37/50 (74%)	41/59 (70%)
FIRST INCIDENCE	353	300	268	305
STATISTICAL TESTS				
POLY 3	P=0.250	P=0.016*	P=0.031*	P=0.123
POLY 1.5	P=0.147	P=0.010**	P=0.017*	P=0.069
POLY 6	P=0.396	P=0.031*	P=0.057	P=0.217
RAO-SCOTT	P=0.231	P=0.021*	P=0.037*	P=0.129
LITTER C-A/FISHERS	P=0.028*	P=0.014*	P=0.012*	P=0.053

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Clitoral Gland: Duct Hyperplasia				
LESION RATES				
OVERALL (a)	0/87 (0%)	3/88 (3%)	4/89 (4%)	1/86 (1%)
LITTERS (b)	0/35 (0%)	3/34 (9%)	4/35 (11%)	1/35 (3%)
POLY-3 RATE (c)	0/66.99	3/72.22	4/72.48	1/76.49
POLY-3 PERCENT (g)	0%	4.2%	5.5%	1.3%
TERMINAL (d)	0/47 (0%)	1/45 (2%)	3/50 (6%)	1/59 (2%)
FIRST INCIDENCE	---	699	545	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.597	P=0.135	P=0.073	P=0.526
POLY 1.5	P=0.560	P=0.130	P=0.071	P=0.516
POLY 6	P=0.574N	P=0.140	P=0.077	P=0.537
RAO-SCOTT	P=0.558	P=0.174	P=0.107	P=0.551
LITTER C-A/FISHERS	P=0.504	P=0.114	P=0.057	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Coagulating Gland Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
LITTERS (b)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (c)	0/0.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Esophagus **Dilation**				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/90 (2%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	2/34 (6%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	2/73.34	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	2.7%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	729	---	---
STATISTICAL TESTS				
POLY 3	P=0.373N	P=0.250	(e)	(e)
POLY 1.5	P=0.386N	P=0.245	(e)	(e)
POLY 6	P=0.359N	P=0.256	(e)	(e)
RAO-SCOTT	P=0.491N	P=0.386	(e)	(e)
LITTER C-A/FISHERS	P=0.403N	P=0.239	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Anterior Chamber Inflammation Acute				
LESION RATES				
OVERALL (a)	0/88 (0%)	0/86 (0%)	1/88 (1%)	2/86 (2%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	1/35 (3%)	2/35 (6%)
POLY-3 RATE (c)	0/68.01	0/70.94	1/71.50	2/77.49
POLY-3 PERCENT (g)	0%	0%	1.4%	2.6%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	559	668
STATISTICAL TESTS				
POLY 3	P=0.085	(e)	P=0.510	P=0.268
POLY 1.5	P=0.079	(e)	P=0.505	P=0.255
POLY 6	P=0.093	(e)	P=0.515	P=0.285
RAO-SCOTT	P=0.146	(e)	P=0.552	P=0.341
LITTER C-A/FISHERS	P=0.071	(e)	P=0.500	P=0.246

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Cornea				
Fibrosis				
LESION RATES				
OVERALL (a)	0/88 (0%)	1/86 (1%)	0/88 (0%)	0/86 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/68.01	1/71.24	0/70.93	0/77.07
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	656	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Cornea **Inflammation Acute**				
LESION RATES				
OVERALL (a)	1/88 (1%)	2/86 (2%)	1/88 (1%)	2/86 (2%)
LITTERS (b)	1/35 (3%)	2/34 (6%)	1/35 (3%)	2/35 (6%)
POLY-3 RATE (c)	1/68.01	2/70.94	1/71.50	2/77.49
POLY-3 PERCENT (g)	1.5%	2.8%	1.4%	2.6%
TERMINAL (d)	1/48 (2%)	2/45 (4%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	737 (T)	559	668
STATISTICAL TESTS				
POLY 3	P=0.499	P=0.515	P=0.750N	P=0.545
POLY 1.5	P=0.476	P=0.505	P=0.755N	P=0.525
POLY 6	P=0.525	P=0.524	P=0.744N	P=0.567
RAO-SCOTT	P=0.494	P=0.493	P=0.715N	P=0.530
LITTER C-A/FISHERS	P=0.448	P=0.489	P=0.754	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Cornea **Neovascularization**				
LESION RATES				
OVERALL (a)	0/88 (0%)	1/86 (1%)	0/88 (0%)	0/86 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/68.01	1/71.24	0/70.93	0/77.07
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	656	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Cornea **Ulcer**				
LESION RATES				
OVERALL (a)	0/88 (0%)	0/86 (0%)	0/88 (0%)	1/86 (1%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/68.01	0/70.94	0/70.93	1/77.23
POLY-3 PERCENT (g)	0%	0%	0%	1.3%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	694
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Cornea, Epithelium Degeneration				
LESION RATES				
OVERALL (a)	0/88 (0%)	0/86 (0%)	0/88 (0%)	0/86 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/68.01	0/70.94	0/70.93	0/77.07
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Cornea, Epithelium **Hyperplasia**				
LESION RATES				
OVERALL (a)	1/88 (1%)	2/86 (2%)	0/88 (0%)	1/86 (1%)
LITTERS (b)	1/35 (3%)	2/34 (6%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	1/68.01	2/71.24	0/70.93	1/77.32
POLY-3 PERCENT (g)	1.5%	2.8%	0%	1.3%
TERMINAL (d)	1/48 (2%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	656	---	668
STATISTICAL TESTS				
POLY 3	P=0.476N	P=0.516	P=0.492N	P=0.731N
POLY 1.5	P=0.488N	P=0.506	P=0.495N	P=0.745N
POLY 6	P=0.463N	P=0.527	P=0.487N	P=0.716N
RAO-SCOTT	P=0.483N	P=0.514	P=0.487N	P=0.718N
LITTER C-A/FISHERS	P=0.497N	P=0.489	P=0.500N	P=0.754

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Lens **Cataract**				
LESION RATES				
OVERALL (a)	1/88 (1%)	3/86 (3%)	0/88 (0%)	0/86 (0%)
LITTERS (b)	1/35 (3%)	3/34 (9%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	1/68.01	3/71.34	0/70.93	0/77.07
POLY-3 PERCENT (g)	1.5%	4.2%	0%	0%
TERMINAL (d)	1/48 (2%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	656	---	---
STATISTICAL TESTS				
POLY 3	P=0.131N	P=0.324	P=0.492N	P=0.475N
POLY 1.5	P=0.140N	P=0.313	P=0.495N	P=0.486N
POLY 6	P=0.121N	P=0.335	P=0.487N	P=0.463N
RAO-SCOTT	P=0.203N	P=0.375	P=0.538N	P=0.543N
LITTER C-A/FISHERS	P=0.151N	P=0.296	P=0.500N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Retina				
Atrophy				
LESION RATES				
OVERALL (a)	18/88 (20%)	17/86 (20%)	18/88 (20%)	18/86 (21%)
LITTERS (b)	16/35 (46%)	15/34 (44%)	12/35 (34%)	13/35 (37%)
POLY-3 RATE (c)	18/68.09	17/71.23	18/70.93	18/77.52
POLY-3 PERCENT (g)	26.4%	23.9%	25.4%	23.2%
TERMINAL (d)	17/48 (35%)	16/45 (36%)	18/50 (36%)	16/61 (26%)
FIRST INCIDENCE	719	657	737 (T)	651
STATISTICAL TESTS				
POLY 3	P=0.391N	P=0.438N	P=0.520N	P=0.399N
POLY 1.5	P=0.466N	P=0.478N	P=0.546N	P=0.479N
POLY 6	P=0.308N	P=0.396N	P=0.491N	P=0.313N
RAO-SCOTT	P=0.403N	P=0.443N	P=0.516N	P=0.409N
LITTER C-A/FISHERS	P=0.231N	P=0.543N	P=0.232N	P=0.314N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Eye: Retina **Dysplasia**				
LESION RATES				
OVERALL (a)	1/88 (1%)	1/86 (1%)	1/88 (1%)	3/86 (3%)
LITTERS (b)	1/35 (3%)	1/34 (3%)	1/35 (3%)	3/35 (9%)
POLY-3 RATE (c)	1/68.99	1/71.24	1/70.93	3/77.97
POLY-3 PERCENT (g)	1.5%	1.4%	1.4%	3.9%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	1/50 (2%)	1/61 (2%)
FIRST INCIDENCE	202	656	737 (T)	522
STATISTICAL TESTS				
POLY 3	P=0.191	P=0.754N	P=0.755N	P=0.352
POLY 1.5	P=0.179	P=0.759N	P=0.758N	P=0.330
POLY 6	P=0.206	P=0.747N	P=0.750N	P=0.376
RAO-SCOTT	P=0.223	P=0.727N	P=0.726N	P=0.362
LITTER C-A/FISHERS	P=0.165	P=0.746	P=0.754	P=0.307

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Harderian Gland **Atrophy**				
LESION RATES				
OVERALL (a)	13/90 (14%)	15/90 (17%)	16/90 (18%)	17/90 (19%)
LITTERS (b)	12/35 (34%)	14/34 (41%)	13/35 (37%)	15/35 (43%)
POLY-3 RATE (c)	13/70.67	15/73.72	16/72.25	17/80.54
POLY-3 PERCENT (g)	18.4%	20.4%	22.2%	21.1%
TERMINAL (d)	11/48 (23%)	12/45 (27%)	14/50 (28%)	14/61 (23%)
FIRST INCIDENCE	531	696	678	579
STATISTICAL TESTS				
POLY 3	P=0.391	P=0.466	P=0.362	P=0.416
POLY 1.5	P=0.332	P=0.444	P=0.351	P=0.359
POLY 6	P=0.461	P=0.488	P=0.380	P=0.481
RAO-SCOTT	P=0.385	P=0.453	P=0.353	P=0.408
LITTER C-A/FISHERS	P=0.311	P=0.366	P=0.500	P=0.312

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Harderian Gland **Degeneration Cystic**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Harderian Gland Hyperplasia				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	1/79.63
POLY-3 PERCENT (g)	0%	0%	0%	1.3%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	1/61 (2%)
FIRST INCIDENCE	---	---	---	737 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Harderian Gland				
Infiltration Cellular Lymphocyte				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/90 (0%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	2/35 (6%)	0/34 (0%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	2/70.05	0/73.31	0/71.88	1/79.63
POLY-3 PERCENT (g)	2.9%	0%	0%	1.3%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	0/50 (0%)	1/61 (2%)
FIRST INCIDENCE	547	---	---	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.468N	P=0.228N	P=0.232N	P=0.456N
POLY 1.5	P=0.465N	P=0.233N	P=0.235N	P=0.472N
POLY 6	P=0.469N	P=0.224N	P=0.229N	P=0.438N
RAO-SCOTT	P=0.485N	P=0.309N	P=0.310N	P=0.508N
LITTER C-A/FISHERS	P=0.458N	P=0.254N	P=0.246N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Harderian Gland **Inflammation Acute**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Harderian Gland **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	8/90 (9%)	5/90 (6%)	3/90 (3%)	2/90 (2%)
LITTERS (b)	7/35 (20%)	5/34 (15%)	3/35 (9%)	2/35 (6%)
POLY-3 RATE (c)	8/69.46	5/74.28	3/72.03	2/79.63
POLY-3 PERCENT (g)	11.5%	6.7%	4.2%	2.5%
TERMINAL (d)	8/48 (17%)	2/45 (4%)	2/50 (4%)	2/61 (3%)
FIRST INCIDENCE	737 (T)	493	699	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.020N*	P=0.239N	P=0.092N	P=0.030N*
POLY 1.5	P=0.023N*	P=0.258N	P=0.099N	P=0.037N*
POLY 6	P=0.017N*	P=0.220N	P=0.084N	P=0.024N*
RAO-SCOTT	P=0.033N*	P=0.262N	P=0.117N	P=0.048N*
LITTER C-A/FISHERS	P=0.043N*	P=0.397N	P=0.153N	P=0.075N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Harderian Gland				
Inflammation Granulomatous				
LESION RATES				
OVERALL (a)	7/90 (8%)	6/90 (7%)	4/90 (4%)	9/90 (10%)
LITTERS (b)	6/35 (17%)	6/34 (18%)	4/35 (11%)	8/35 (23%)
POLY-3 RATE (c)	7/70.42	6/73.79	4/71.88	9/79.87
POLY-3 PERCENT (g)	9.9%	8.1%	5.6%	11.3%
TERMINAL (d)	4/48 (8%)	3/45 (7%)	4/50 (8%)	8/61 (13%)
FIRST INCIDENCE	550	695	737 (T)	674
STATISTICAL TESTS				
POLY 3	P=0.385	P=0.465N	P=0.253N	P=0.501
POLY 1.5	P=0.359	P=0.480N	P=0.260N	P=0.462
POLY 6	P=0.415	P=0.450N	P=0.246N	P=0.541
RAO-SCOTT	P=0.412	P=0.462N	P=0.265N	P=0.499
LITTER C-A/FISHERS	P=0.332	P=0.603	P=0.367N	P=0.383

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart **Cardiomyopathy**				
LESION RATES				
OVERALL (a)	40/90 (44%)	43/90 (48%)	33/90 (37%)	45/90 (50%)
LITTERS (b)	25/35 (71%)	24/34 (71%)	24/35 (69%)	28/35 (80%)
POLY-3 RATE (c)	40/75.73	43/79.94	33/76.05	45/83.49
POLY-3 PERCENT (g)	52.8%	53.8%	43.4%	53.9%
TERMINAL (d)	25/48 (52%)	21/45 (47%)	23/50 (46%)	33/61 (54%)
FIRST INCIDENCE	268	300	417	536
STATISTICAL TESTS				
POLY 3	P=0.523	P=0.516	P=0.151N	P=0.509
POLY 1.5	P=0.445	P=0.453	P=0.168N	P=0.413
POLY 6	P=0.464N	P=0.545N	P=0.135N	P=0.522N
RAO-SCOTT	P=0.527N	P=0.515	P=0.176N	P=0.510
LITTER C-A/FISHERS	P=0.232	P=0.574N	P=0.500N	P=0.289

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart **Thrombus**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: All Sites **Cardiomyopathy**				
LESION RATES				
OVERALL (a)	40/90 (44%)	45/90 (50%)	35/90 (39%)	46/90 (51%)
LITTERS (b)	25/35 (71%)	25/34 (74%)	24/35 (69%)	28/35 (80%)
POLY-3 RATE (c)	40/75.73	45/79.96	35/76.05	46/83.49
POLY-3 PERCENT (g)	52.8%	56.3%	46%	55.1%
TERMINAL (d)	25/48 (52%)	22/45 (49%)	25/50 (50%)	34/61 (56%)
FIRST INCIDENCE	268	300	417	536
STATISTICAL TESTS				
POLY 3	P=0.496	P=0.390	P=0.243N	P=0.448
POLY 1.5	P=0.415	P=0.333	P=0.262N	P=0.355
POLY 6	P=0.488N	P=0.462	P=0.224N	P=0.550
RAO-SCOTT	P=0.504	P=0.401	P=0.265N	P=0.454
LITTER C-A/FISHERS	P=0.261	P=0.530	P=0.500N	P=0.289

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Artery **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Artery Mineral				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.47	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	696	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Atrium **Dilation**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Atrium **Thrombus**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Endocardium (All) **Hyperplasia Schwann Cell**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	1/90 (1%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	1/73.31	1/72.63	1/79.63
POLY-3 PERCENT (g)	0%	1.4%	1.4%	1.3%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	1/61 (2%)
FIRST INCIDENCE	---	737 (T)	464	737 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Endocardium or Mycardium **Hyperplasia Schwann Cell**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	1/90 (1%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	1/73.31	1/72.63	1/79.63
POLY-3 PERCENT (g)	0%	1.4%	1.4%	1.3%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	1/61 (2%)
FIRST INCIDENCE	---	737 (T)	464	737 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Endocardium **Hyperplasia Schwann Cell**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	1/73.31	0/71.88	1/79.63
POLY-3 PERCENT (g)	0%	1.4%	0%	1.3%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	1/61 (2%)
FIRST INCIDENCE	---	737 (T)	---	737 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Myocardium Mineral				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Heart: Ventricle Right Cardiomyopathy				
LESION RATES				
OVERALL (a)	4/90 (4%)	7/90 (8%)	9/90 (10%)	9/90 (10%)
LITTERS (b)	4/35 (11%)	7/34 (21%)	9/35 (26%)	8/35 (23%)
POLY-3 RATE (c)	4/69.73	7/75.15	9/72.62	9/80.00
POLY-3 PERCENT (g)	5.7%	9.3%	12.4%	11.3%
TERMINAL (d)	3/48 (6%)	3/45 (7%)	7/50 (14%)	8/61 (13%)
FIRST INCIDENCE	662	407	598	633
STATISTICAL TESTS				
POLY 3	P=0.178	P=0.309	P=0.137	P=0.183
POLY 1.5	P=0.152	P=0.291	P=0.130	P=0.159
POLY 6	P=0.211	P=0.328	P=0.147	P=0.212
RAO-SCOTT	P=0.176	P=0.300	P=0.137	P=0.182
LITTER C-A/FISHERS	P=0.164	P=0.239	P=0.109	P=0.171

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Cecum **Edema**				
LESION RATES				
OVERALL (a)	0/84 (0%)	0/82 (0%)	0/86 (0%)	0/80 (0%)
LITTERS (b)	0/35 (0%)	0/33 (0%)	0/34 (0%)	0/33 (0%)
POLY-3 RATE (c)	0/65.56	0/67.76	0/69.71	0/72.60
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Cecum **Erosion**				
LESION RATES				
OVERALL (a)	0/84 (0%)	0/82 (0%)	0/86 (0%)	0/80 (0%)
LITTERS (b)	0/35 (0%)	0/33 (0%)	0/34 (0%)	0/33 (0%)
POLY-3 RATE (c)	0/65.56	0/67.76	0/69.71	0/72.60
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Cecum **Inflammation Acute**				
LESION RATES				
OVERALL (a)	0/84 (0%)	0/82 (0%)	0/86 (0%)	0/80 (0%)
LITTERS (b)	0/35 (0%)	0/33 (0%)	0/34 (0%)	0/33 (0%)
POLY-3 RATE (c)	0/65.56	0/67.76	0/69.71	0/72.60
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Cecum **Ulcer**				
LESION RATES				
OVERALL (a)	0/84 (0%)	0/82 (0%)	1/86 (1%)	0/80 (0%)
LITTERS (b)	0/35 (0%)	0/33 (0%)	1/34 (3%)	0/33 (0%)
POLY-3 RATE (c)	0/65.56	0/67.76	1/69.95	0/72.60
POLY-3 PERCENT (g)	0%	0%	1.4%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	674	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Cecum: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/84 (0%)	2/82 (2%)	0/86 (0%)	0/80 (0%)
LITTERS (b)	0/35 (0%)	2/33 (6%)	0/34 (0%)	0/33 (0%)
POLY-3 RATE (c)	0/65.56	2/68.05	0/69.71	0/72.60
POLY-3 PERCENT (g)	0%	2.9%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	657	---	---
STATISTICAL TESTS				
POLY 3	P=0.377N	P=0.246	(e)	(e)
POLY 1.5	P=0.391N	P=0.240	(e)	(e)
POLY 6	P=0.361N	P=0.253	(e)	(e)
RAO-SCOTT	P=0.493N	P=0.375	(e)	(e)
LITTER C-A/FISHERS	P=0.414N	P=0.232	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Cecum: Epithelium Regeneration				
LESION RATES				
OVERALL (a)	0/84 (0%)	0/82 (0%)	0/86 (0%)	0/80 (0%)
LITTERS (b)	0/35 (0%)	0/33 (0%)	0/34 (0%)	0/33 (0%)
POLY-3 RATE (c)	0/65.56	0/67.76	0/69.71	0/72.60
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Colon: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/89 (0%)	1/89 (1%)	0/88 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/68.71	1/72.43	0/71.52	0/78.81
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Colon: Artery Mineral				
LESION RATES				
OVERALL (a)	0/89 (0%)	0/89 (0%)	0/88 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/68.71	0/72.43	0/71.52	0/78.81
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Colon: Epithelium Regeneration				
LESION RATES				
OVERALL (a)	0/89 (0%)	0/89 (0%)	0/88 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/68.71	0/72.43	0/71.52	0/78.81
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Rectum **Hyperplasia Lymphocyte**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/88 (0%)	3/87 (3%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	2/35 (6%)	0/34 (0%)
POLY-3 RATE (c)	0/69.46	0/71.76	3/69.80	0/78.50
POLY-3 PERCENT (g)	0%	0%	4.3%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	3/50 (6%)	0/61 (0%)
FIRST INCIDENCE	---	---	737 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.617	(e)	P=0.121	(e)
POLY 1.5	P=0.588	(e)	P=0.118	(e)
POLY 6	P=0.649	(e)	P=0.126	(e)
RAO-SCOTT	P=0.654	(e)	P=0.338	(e)
LITTER C-A/FISHERS	P=0.591	(e)	P=0.246	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Rectum **Inflammation Acute**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/88 (0%)	0/87 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/34 (0%)
POLY-3 RATE (c)	0/69.46	0/71.76	0/69.80	0/78.50
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Rectum: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/88 (1%)	0/87 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/34 (0%)
POLY-3 RATE (c)	0/69.46	1/71.76	0/69.80	0/78.50
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Large, Rectum: Epithelium Regeneration				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/88 (0%)	0/87 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/34 (0%)
POLY-3 RATE (c)	0/69.46	0/71.76	0/69.80	0/78.50
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Small, Duodenum: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/88 (0%)	0/86 (0%)	0/87 (0%)	0/85 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/67.81	0/70.28	0/70.73	0/76.15
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Intestine Small, Ileum: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/86 (0%)	0/83 (0%)	0/84 (0%)	0/83 (0%)
LITTERS (b)	0/35 (0%)	0/33 (0%)	0/34 (0%)	0/34 (0%)
POLY-3 RATE (c)	0/66.72	0/68.37	0/68.93	0/75.77
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Islets, Pancreatic Hyperplasia				
LESION RATES				
OVERALL (a)	15/90 (17%)	12/89 (13%)	14/90 (16%)	13/88 (15%)
LITTERS (b)	13/35 (37%)	11/34 (32%)	10/35 (29%)	10/35 (29%)
POLY-3 RATE (c)	15/70.91	12/72.62	14/72.71	13/79.13
POLY-3 PERCENT (g)	21.2%	16.5%	19.3%	16.4%
TERMINAL (d)	12/48 (25%)	9/45 (20%)	10/50 (20%)	10/61 (16%)
FIRST INCIDENCE	464	711	550	626
STATISTICAL TESTS				
POLY 3	P=0.318N	P=0.309N	P=0.470N	P=0.297N
POLY 1.5	P=0.373N	P=0.327N	P=0.486N	P=0.351N
POLY 6	P=0.259N	P=0.290N	P=0.446N	P=0.241N
RAO-SCOTT	P=0.333N	P=0.321N	P=0.468N	P=0.312N
LITTER C-A/FISHERS	P=0.260N	P=0.435N	P=0.306N	P=0.306N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney **Mineral**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.19
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney **Nephropathy Chronic Progressive**				
LESION RATES				
OVERALL (a)	74/90 (82%)	76/90 (84%)	76/90 (84%)	65/89 (73%)
LITTERS (b)	35/35 (100%)	33/34 (97%)	34/35 (97%)	31/35 (89%)
POLY-3 RATE (c)	74/85.18	76/86.70	76/83.51	65/85.08
POLY-3 PERCENT (g)	86.9%	87.7%	91%	76.4%
TERMINAL (d)	42/48 (88%)	40/45 (89%)	48/50 (96%)	48/61 (79%)
FIRST INCIDENCE	202	300	416	492
STATISTICAL TESTS				
POLY 3	P=0.018N*	P=0.531	P=0.251	P=0.048N*
POLY 1.5	P=0.025N*	P=0.474	P=0.279	P=0.064N
POLY 6	P=0.014N*	P=0.593N	P=0.238	P=0.037N*
RAO-SCOTT	P=0.038N*	P=0.538	P=0.296	P=0.078N
LITTER C-A/FISHERS	P=0.018N*	P=0.493N	P=0.500N	P=0.057N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney: Artery Mineral				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.19
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney: Pelvis **Dilation**				
LESION RATES				
OVERALL (a)	3/90 (3%)	0/90 (0%)	2/90 (2%)	0/89 (0%)
LITTERS (b)	3/35 (9%)	0/34 (0%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	3/69.82	0/73.31	2/72.85	0/79.19
POLY-3 PERCENT (g)	4.3%	0%	2.8%	0%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	668	---	545	---
STATISTICAL TESTS				
POLY 3	P=0.113N	P=0.112N	P=0.481N	P=0.100N
POLY 1.5	P=0.118N	P=0.116N	P=0.490N	P=0.108N
POLY 6	P=0.108N	P=0.109N	P=0.469N	P=0.092N
RAO-SCOTT	P=0.175N	P=0.180N	P=0.509N	P=0.171N
LITTER C-A/FISHERS	P=0.123N	P=0.125N	P=0.500N	P=0.120N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney: Pelvis **Inflammation**				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/90 (2%)	0/90 (0%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	2/34 (6%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	2/73.83	0/71.88	0/79.19
POLY-3 PERCENT (g)	0%	2.7%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	579	---	---
STATISTICAL TESTS				
POLY 3	P=0.373N	P=0.252	(e)	(e)
POLY 1.5	P=0.387N	P=0.246	(e)	(e)
POLY 6	P=0.358N	P=0.258	(e)	(e)
RAO-SCOTT	P=0.483N	P=0.372	(e)	(e)
LITTER C-A/FISHERS	P=0.403N	P=0.239	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney: Pelvis, Urothelium Hyperplasia				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.31	0/71.88	0/79.19
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney: Renal Tubule Cyst				
LESION RATES				
OVERALL (a)	3/90 (3%)	2/90 (2%)	0/90 (0%)	0/89 (0%)
LITTERS (b)	3/35 (9%)	2/34 (6%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	3/70.88	2/74.84	0/71.88	0/79.19
POLY-3 PERCENT (g)	4.2%	2.7%	0%	0%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	464	407	---	---
STATISTICAL TESTS				
POLY 3	P=0.037N*	P=0.475N	P=0.118N	P=0.103N
POLY 1.5	P=0.038N*	P=0.486N	P=0.120N	P=0.110N
POLY 6	P=0.035N*	P=0.466N	P=0.116N	P=0.095N
RAO-SCOTT	P=0.077N	P=0.507N	P=0.184N	P=0.173N
LITTER C-A/FISHERS	P=0.038N*	P=0.514N	P=0.120N	P=0.120N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney: Renal Tubule Hyperplasia Atypical				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.19
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Kidney: Renal Tubule Hyperplasia Oncocytic				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.19
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lacrimal Gland				
Metaplasia Harderian Gland				
LESION RATES				
OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
LITTERS (b)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (c)	0/0.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Angiectasis**				
LESION RATES				
OVERALL (a)	6/90 (7%)	3/90 (3%)	9/90 (10%)	3/90 (3%)
LITTERS (b)	6/35 (17%)	3/34 (9%)	9/35 (26%)	3/35 (9%)
POLY-3 RATE (c)	6/70.04	3/73.34	9/71.88	3/79.63
POLY-3 PERCENT (g)	8.6%	4.1%	12.5%	3.8%
TERMINAL (d)	5/48 (10%)	2/45 (4%)	9/50 (18%)	3/61 (5%)
FIRST INCIDENCE	550	729	737 (T)	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.253N	P=0.223N	P=0.311	P=0.188N
POLY 1.5	P=0.282N	P=0.234N	P=0.302	P=0.209N
POLY 6	P=0.222N	P=0.214N	P=0.322	P=0.167N
RAO-SCOTT	P=0.276N	P=0.224N	P=0.309	P=0.193N
LITTER C-A/FISHERS	P=0.324N	P=0.253N	P=0.281	P=0.239N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Basophilic Focus**				
LESION RATES				
OVERALL (a)	11/90 (12%)	11/90 (12%)	7/90 (8%)	15/90 (17%)
LITTERS (b)	9/35 (26%)	10/34 (29%)	7/35 (20%)	13/35 (37%)
POLY-3 RATE (c)	11/71.04	11/74.05	7/72.25	15/80.59
POLY-3 PERCENT (g)	15.5%	14.9%	9.7%	18.6%
TERMINAL (d)	8/48 (17%)	9/45 (20%)	5/50 (10%)	13/61 (21%)
FIRST INCIDENCE	524	628	678	557
STATISTICAL TESTS				
POLY 3	P=0.309	P=0.550N	P=0.212N	P=0.384
POLY 1.5	P=0.275	P=0.568N	P=0.221N	P=0.337
POLY 6	P=0.349	P=0.533N	P=0.202N	P=0.437
RAO-SCOTT	P=0.337	P=0.539N	P=0.219N	P=0.386
LITTER C-A/FISHERS	P=0.203	P=0.470	P=0.388N	P=0.220

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

Females

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Liver				
Clear Cell Focus				
LESION RATES				
OVERALL (a)	2/90 (2%)	4/90 (4%)	7/90 (8%)	3/90 (3%)
LITTERS (b)	2/35 (6%)	4/34 (12%)	7/35 (20%)	3/35 (9%)
POLY-3 RATE (c)	2/69.46	4/73.31	7/71.88	3/79.63
POLY-3 PERCENT (g)	2.9%	5.5%	9.7%	3.8%
TERMINAL (d)	2/48 (4%)	4/45 (9%)	7/50 (14%)	3/61 (5%)
FIRST INCIDENCE	737 (T)	737 (T)	737 (T)	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.543	P=0.364	P=0.091	P=0.561
POLY 1.5	P=0.501	P=0.353	P=0.088	P=0.538
POLY 6	P=0.562N	P=0.374	P=0.096	P=0.586
RAO-SCOTT	P=0.506	P=0.349	P=0.095	P=0.542
LITTER C-A/FISHERS	P=0.435	P=0.323	P=0.075	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Eosinophilic Focus**				
LESION RATES				
OVERALL (a)	9/90 (10%)	17/90 (19%)	10/90 (11%)	9/90 (10%)
LITTERS (b)	9/35 (26%)	16/34 (47%)	8/35 (23%)	9/35 (26%)
POLY-3 RATE (c)	9/71.34	17/74.13	10/75.08	9/80.11
POLY-3 PERCENT (g)	12.6%	22.9%	13.3%	11.2%
TERMINAL (d)	6/48 (13%)	13/45 (29%)	4/50 (8%)	8/61 (13%)
FIRST INCIDENCE	492	550	493	593
STATISTICAL TESTS				
POLY 3	P=0.194N	P=0.077	P=0.548	P=0.496N
POLY 1.5	P=0.232N	P=0.073	P=0.525	P=0.534N
POLY 6	P=0.157N	P=0.082	P=0.576	P=0.455N
RAO-SCOTT	P=0.213N	P=0.082	P=0.533	P=0.485N
LITTER C-A/FISHERS	P=0.278N	P=0.055	P=0.500N	P=0.607

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Extramedullary Hematopoiesis**				
LESION RATES				
OVERALL (a)	15/90 (17%)	11/90 (12%)	13/90 (14%)	13/90 (14%)
LITTERS (b)	12/35 (34%)	11/34 (32%)	12/35 (34%)	12/35 (34%)
POLY-3 RATE (c)	15/74.85	11/76.72	13/75.77	13/83.00
POLY-3 PERCENT (g)	20%	14.3%	17.2%	15.7%
TERMINAL (d)	4/48 (8%)	2/45 (4%)	3/50 (6%)	3/61 (5%)
FIRST INCIDENCE	268	300	416	305
STATISTICAL TESTS				
POLY 3	P=0.352N	P=0.236N	P=0.403N	P=0.305N
POLY 1.5	P=0.392N	P=0.247N	P=0.416N	P=0.347N
POLY 6	P=0.306N	P=0.228N	P=0.385N	P=0.263N
RAO-SCOTT	P=0.352N	P=0.238N	P=0.398N	P=0.306N
LITTER C-A/FISHERS	P=0.524	P=0.534N	P=0.599	P=0.599

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Hepatodiaphragmatic Nodule**				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	0/90 (0%)	3/90 (3%)
LITTERS (b)	1/35 (3%)	0/34 (0%)	0/35 (0%)	2/35 (6%)
POLY-3 RATE (c)	1/69.46	0/73.31	0/71.88	3/79.73
POLY-3 PERCENT (g)	1.4%	0%	0%	3.8%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	0/50 (0%)	2/61 (3%)
FIRST INCIDENCE	737 (T)	---	---	711
STATISTICAL TESTS				
POLY 3	P=0.093	P=0.489N	P=0.493N	P=0.357
POLY 1.5	P=0.090	P=0.494N	P=0.497N	P=0.338
POLY 6	P=0.097	P=0.485N	P=0.489N	P=0.379
RAO-SCOTT	P=0.233	P=0.640N	P=0.639N	P=0.479
LITTER C-A/FISHERS	P=0.247	P=0.507N	P=0.500N	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Infiltration Cellular Mixed Cell**				
LESION RATES				
OVERALL (a)	1/90 (1%)	2/90 (2%)	4/90 (4%)	2/90 (2%)
LITTERS (b)	1/35 (3%)	2/34 (6%)	4/35 (11%)	2/35 (6%)
POLY-3 RATE (c)	1/69.53	2/74.53	4/73.76	2/80.28
POLY-3 PERCENT (g)	1.4%	2.7%	5.4%	2.5%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	1/61 (2%)
FIRST INCIDENCE	719	493	450	522
STATISTICAL TESTS				
POLY 3	P=0.472	P=0.524	P=0.199	P=0.550
POLY 1.5	P=0.441	P=0.514	P=0.191	P=0.531
POLY 6	P=0.506	P=0.535	P=0.210	P=0.569
RAO-SCOTT	P=0.452	P=0.505	P=0.205	P=0.535
LITTER C-A/FISHERS	P=0.390	P=0.489	P=0.178	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver **Mixed Cell Focus**				
LESION RATES				
OVERALL (a)	29/90 (32%)	17/90 (19%)	29/90 (32%)	35/90 (39%)
LITTERS (b)	23/35 (66%)	15/34 (44%)	19/35 (54%)	25/35 (71%)
POLY-3 RATE (c)	29/75.33	17/74.71	29/74.41	35/81.16
POLY-3 PERCENT (g)	38.5%	22.8%	39%	43.1%
TERMINAL (d)	19/48 (40%)	11/45 (24%)	23/50 (46%)	31/61 (51%)
FIRST INCIDENCE	464	612	493	492
STATISTICAL TESTS				
POLY 3	P=0.082	P=0.025N*	P=0.544	P=0.332
POLY 1.5	P=0.068	P=0.027N*	P=0.547	P=0.290
POLY 6	P=0.099	P=0.023N*	P=0.544	P=0.376
RAO-SCOTT	P=0.105	P=0.034N*	P=0.536	P=0.342
LITTER C-A/FISHERS	P=0.174	P=0.059N	P=0.232N	P=0.399

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Bile Duct Cyst				
LESION RATES				
OVERALL (a)	11/90 (12%)	14/90 (16%)	6/90 (7%)	9/90 (10%)
LITTERS (b)	8/35 (23%)	13/34 (38%)	6/35 (17%)	9/35 (26%)
POLY-3 RATE (c)	11/70.09	14/74.22	6/72.65	9/79.80
POLY-3 PERCENT (g)	15.7%	18.9%	8.3%	11.3%
TERMINAL (d)	9/48 (19%)	10/45 (22%)	5/50 (10%)	7/61 (12%)
FIRST INCIDENCE	641	649	450	711
STATISTICAL TESTS				
POLY 3	P=0.137N	P=0.388	P=0.131N	P=0.291N
POLY 1.5	P=0.163N	P=0.363	P=0.141N	P=0.332N
POLY 6	P=0.113N	P=0.415	P=0.121N	P=0.250N
RAO-SCOTT	P=0.158N	P=0.392	P=0.148N	P=0.303N
LITTER C-A/FISHERS	P=0.438N	P=0.130	P=0.383N	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Bile Duct Fibrosis				
LESION RATES				
OVERALL (a)	1/90 (1%)	1/90 (1%)	4/90 (4%)	0/90 (0%)
LITTERS (b)	1/35 (3%)	1/34 (3%)	4/35 (11%)	0/35 (0%)
POLY-3 RATE (c)	1/69.46	1/73.31	4/71.88	0/79.63
POLY-3 PERCENT (g)	1.4%	1.4%	5.6%	0%
TERMINAL (d)	1/48 (2%)	1/45 (2%)	4/50 (8%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	737 (T)	737 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.375N	P=0.749N	P=0.191	P=0.473N
POLY 1.5	P=0.400N	P=0.754N	P=0.187	P=0.483N
POLY 6	P=0.348N	P=0.743N	P=0.198	P=0.462N
RAO-SCOTT	P=0.431N	P=0.732N	P=0.232	P=0.511N
LITTER C-A/FISHERS	P=0.440N	P=0.746	P=0.178	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Bile Duct Hyperplasia				
LESION RATES				
OVERALL (a)	9/90 (10%)	10/90 (11%)	12/90 (13%)	7/90 (8%)
LITTERS (b)	9/35 (26%)	10/34 (29%)	9/35 (26%)	6/35 (17%)
POLY-3 RATE (c)	9/71.23	10/75.92	12/73.27	7/80.07
POLY-3 PERCENT (g)	12.6%	13.2%	16.4%	8.7%
TERMINAL (d)	4/48 (8%)	3/45 (7%)	9/50 (18%)	5/61 (8%)
FIRST INCIDENCE	492	464	493	663
STATISTICAL TESTS				
POLY 3	P=0.244N	P=0.559	P=0.343	P=0.305N
POLY 1.5	P=0.277N	P=0.534	P=0.332	P=0.337N
POLY 6	P=0.212N	P=0.584	P=0.355	P=0.274N
RAO-SCOTT	P=0.278N	P=0.553	P=0.355	P=0.321N
LITTER C-A/FISHERS	P=0.187N	P=0.470	P=0.607	P=0.281N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Hepatocyte Hypertrophy				
LESION RATES				
OVERALL (a)	2/90 (2%)	2/90 (2%)	1/90 (1%)	1/90 (1%)
LITTERS (b)	2/35 (6%)	2/34 (6%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	2/69.46	2/73.36	1/72.26	1/80.13
POLY-3 PERCENT (g)	2.9%	2.7%	1.4%	1.3%
TERMINAL (d)	2/48 (4%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	724	627	587
STATISTICAL TESTS				
POLY 3	P=0.304N	P=0.674N	P=0.486N	P=0.451N
POLY 1.5	P=0.317N	P=0.682N	P=0.493N	P=0.469N
POLY 6	P=0.289N	P=0.665N	P=0.477N	P=0.430N
RAO-SCOTT	P=0.315N	P=0.649N	P=0.470N	P=0.446N
LITTER C-A/FISHERS	P=0.333N	P=0.682	P=0.500N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Hepatocyte Increased mitoses				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	2.9%	0%	0%	0%
TERMINAL (d)	2/48 (4%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.122N	P=0.226N	P=0.230N	P=0.209N
POLY 1.5	P=0.119N	P=0.232N	P=0.234N	P=0.220N
POLY 6	P=0.124N	P=0.221N	P=0.226N	P=0.199N
RAO-SCOTT	P=0.235N	P=0.368N	P=0.370N	P=0.362N
LITTER C-A/FISHERS	P=0.114N	P=0.254N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Hepatocyte Necrosis				
LESION RATES				
OVERALL (a)	4/90 (4%)	9/90 (10%)	7/90 (8%)	4/90 (4%)
LITTERS (b)	4/35 (11%)	7/34 (21%)	7/35 (20%)	4/35 (11%)
POLY-3 RATE (c)	4/69.92	9/75.93	7/73.64	4/80.68
POLY-3 PERCENT (g)	5.7%	11.9%	9.5%	5%
TERMINAL (d)	1/48 (2%)	1/45 (2%)	2/50 (4%)	1/61 (2%)
FIRST INCIDENCE	668	407	545	579
STATISTICAL TESTS				
POLY 3	P=0.276N	P=0.156	P=0.295	P=0.562N
POLY 1.5	P=0.316N	P=0.142	P=0.281	P=0.592N
POLY 6	P=0.236N	P=0.173	P=0.315	P=0.529N
RAO-SCOTT	P=0.323N	P=0.179	P=0.310	P=0.557N
LITTER C-A/FISHERS	P=0.461N	P=0.239	P=0.256	P=0.645

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Hepatocyte Vacuolation, Cytoplasmic				
LESION RATES				
OVERALL (a)	1/90 (1%)	5/90 (6%)	5/90 (6%)	9/90 (10%)
LITTERS (b)	1/35 (3%)	5/34 (15%)	4/35 (11%)	8/35 (23%)
POLY-3 RATE (c)	1/70.01	5/74.00	5/72.94	9/80.16
POLY-3 PERCENT (g)	1.4%	6.8%	6.9%	11.2%
TERMINAL (d)	0/48 (0%)	3/45 (7%)	1/50 (2%)	7/61 (12%)
FIRST INCIDENCE	565	623	559	633
STATISTICAL TESTS				
POLY 3	P=0.017*	P=0.118	P=0.114	P=0.018*
POLY 1.5	P=0.014*	P=0.112	P=0.110	P=0.015*
POLY 6	P=0.022*	P=0.124	P=0.121	P=0.023*
RAO-SCOTT	P=0.032*	P=0.148	P=0.143	P=0.034*
LITTER C-A/FISHERS	P=0.017*	P=0.092	P=0.178	P=0.014*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Kupffer Cell Hyperplasia				
LESION RATES				
OVERALL (a)	3/90 (3%)	0/90 (0%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	3/35 (9%)	0/34 (0%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	3/69.56	0/73.31	0/71.88	1/79.63
POLY-3 PERCENT (g)	4.3%	0%	0%	1.3%
TERMINAL (d)	2/48 (4%)	0/45 (0%)	0/50 (0%)	1/61 (2%)
FIRST INCIDENCE	711	---	---	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.253N	P=0.112N	P=0.115N	P=0.260N
POLY 1.5	P=0.251N	P=0.116N	P=0.118N	P=0.277N
POLY 6	P=0.255N	P=0.108N	P=0.111N	P=0.243N
RAO-SCOTT	P=0.298N	P=0.185N	P=0.188N	P=0.335N
LITTER C-A/FISHERS	P=0.245N	P=0.125N	P=0.120N	P=0.307N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Kupffer Cell Hypertrophy				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	2.9%	0%	0%	0%
TERMINAL (d)	2/48 (4%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.122N	P=0.226N	P=0.230N	P=0.209N
POLY 1.5	P=0.119N	P=0.232N	P=0.234N	P=0.220N
POLY 6	P=0.124N	P=0.221N	P=0.226N	P=0.199N
RAO-SCOTT	P=0.236N	P=0.369N	P=0.370N	P=0.363N
LITTER C-A/FISHERS	P=0.114N	P=0.254N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Liver: Periductal Cholangiofibrosis				
LESION RATES				
OVERALL (a)	1/90 (1%)	1/90 (1%)	1/90 (1%)	1/90 (1%)
LITTERS (b)	1/35 (3%)	1/34 (3%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	1/69.46	1/73.63	1/71.88	1/79.77
POLY-3 PERCENT (g)	1.4%	1.4%	1.4%	1.3%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	1/50 (2%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	647	737 (T)	702
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung **Congestion**				
LESION RATES				
OVERALL (a)	3/90 (3%)	12/90 (13%)	9/90 (10%)	5/90 (6%)
LITTERS (b)	2/35 (6%)	12/34 (35%)	9/35 (26%)	5/35 (14%)
POLY-3 RATE (c)	3/70.43	12/75.70	9/75.16	5/81.34
POLY-3 PERCENT (g)	4.3%	15.9%	12%	6.2%
TERMINAL (d)	1/48 (2%)	1/45 (2%)	3/50 (6%)	0/61 (0%)
FIRST INCIDENCE	547	623	417	536
STATISTICAL TESTS				
POLY 3	P=0.362N	P=0.020*	P=0.081	P=0.439
POLY 1.5	P=0.418N	P=0.017*	P=0.074	P=0.408
POLY 6	P=0.304N	P=0.024*	P=0.090	P=0.474
RAO-SCOTT	P=0.400N	P=0.018*	P=0.074	P=0.415
LITTER C-A/FISHERS	P=0.509	P=0.002**	P=0.023*	P=0.214

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung **Foreign Body**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	1/73.31	0/71.88	1/79.63
POLY-3 PERCENT (g)	0%	1.4%	0%	1.3%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	1/61 (2%)
FIRST INCIDENCE	---	737 (T)	---	737 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung **Hemorrhage**				
LESION RATES				
OVERALL (a)	1/90 (1%)	6/90 (7%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	1/35 (3%)	5/34 (15%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	1/69.46	6/74.87	0/71.88	1/80.13
POLY-3 PERCENT (g)	1.4%	8%	0%	1.3%
TERMINAL (d)	1/48 (2%)	2/45 (4%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	550	---	587
STATISTICAL TESTS				
POLY 3	P=0.181N	P=0.073	P=0.493N	P=0.728N
POLY 1.5	P=0.201N	P=0.067	P=0.497N	P=0.740N
POLY 6	P=0.161N	P=0.080	P=0.489N	P=0.713N
RAO-SCOTT	P=0.284N	P=0.152	P=0.587N	P=0.750N
LITTER C-A/FISHERS	P=0.275N	P=0.092	P=0.500N	P=0.754

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung **Inflammation**				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/90 (0%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	2/35 (6%)	0/34 (0%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	2/69.74	0/73.31	0/71.88	1/79.63
POLY-3 PERCENT (g)	2.9%	0%	0%	1.3%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	0/50 (0%)	1/61 (2%)
FIRST INCIDENCE	660	---	---	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.468N	P=0.227N	P=0.231N	P=0.454N
POLY 1.5	P=0.466N	P=0.232N	P=0.235N	P=0.471N
POLY 6	P=0.470N	P=0.223N	P=0.227N	P=0.436N
RAO-SCOTT	P=0.486N	P=0.312N	P=0.313N	P=0.509N
LITTER C-A/FISHERS	P=0.458N	P=0.254N	P=0.246N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung **Inflammation Acute**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	6/90 (7%)	6/90 (7%)	6/90 (7%)	11/90 (12%)
LITTERS (b)	6/35 (17%)	5/34 (15%)	6/35 (17%)	10/35 (29%)
POLY-3 RATE (c)	6/70.20	6/76.50	6/74.17	11/81.11
POLY-3 PERCENT (g)	8.6%	7.8%	8.1%	13.6%
TERMINAL (d)	4/48 (8%)	0/45 (0%)	3/50 (6%)	6/61 (10%)
FIRST INCIDENCE	531	319	416	560
STATISTICAL TESTS				
POLY 3	P=0.132	P=0.558N	P=0.580N	P=0.238
POLY 1.5	P=0.115	P=0.582N	P=0.596N	P=0.203
POLY 6	P=0.154	P=0.532N	P=0.562N	P=0.281
RAO-SCOTT	P=0.153	P=0.544N	P=0.563N	P=0.242
LITTER C-A/FISHERS	P=0.107	P=0.521N	P=0.624	P=0.197

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung				
Inflammation Granulomatous				
LESION RATES				
OVERALL (a)	1/90 (1%)	5/90 (6%)	1/90 (1%)	2/90 (2%)
LITTERS (b)	1/35 (3%)	5/34 (15%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	1/69.85	5/73.31	1/72.48	2/79.63
POLY-3 PERCENT (g)	1.4%	6.8%	1.4%	2.5%
TERMINAL (d)	0/48 (0%)	5/45 (11%)	0/50 (0%)	2/61 (3%)
FIRST INCIDENCE	622	737 (T)	545	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.460N	P=0.116	P=0.753N	P=0.545
POLY 1.5	P=0.484N	P=0.111	P=0.756N	P=0.529
POLY 6	P=0.435N	P=0.120	P=0.748N	P=0.563
RAO-SCOTT	P=0.495N	P=0.175	P=0.744N	P=0.576
LITTER C-A/FISHERS	P=0.308N	P=0.092	P=0.754	P=0.754

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung: Alveolar Epithelium Metaplasia				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	2/90 (2%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	2/35 (6%)
POLY-3 RATE (c)	0/69.46	1/73.31	0/71.88	2/79.63
POLY-3 PERCENT (g)	0%	1.4%	0%	2.5%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	2/61 (3%)
FIRST INCIDENCE	---	737 (T)	---	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.161	P=0.511	(e)	P=0.270
POLY 1.5	P=0.153	P=0.506	(e)	P=0.258
POLY 6	P=0.171	P=0.515	(e)	P=0.283
RAO-SCOTT	P=0.230	P=0.552	(e)	P=0.339
LITTER C-A/FISHERS	P=0.141	P=0.493	(e)	P=0.246

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung: Alveolus **Infiltration Cellular Histiocyte**				
LESION RATES				
OVERALL (a)	71/90 (79%)	77/90 (86%)	84/90 (93%)	81/90 (90%)
LITTERS (b)	33/35 (94%)	33/34 (97%)	35/35 (100%)	35/35 (100%)
POLY-3 RATE (c)	71/85.53	77/86.57	84/87.62	81/88.77
POLY-3 PERCENT (g)	83%	89%	95.9%	91.3%
TERMINAL (d)	39/48 (81%)	39/45 (87%)	47/50 (94%)	55/61 (90%)
FIRST INCIDENCE	202	300	268	305
STATISTICAL TESTS				
POLY 3	P=0.040*	P=0.170	P=0.003**	P=0.070
POLY 1.5	P=0.027*	P=0.162	P=0.002**	P=0.052
POLY 6	P=0.065	P=0.194	P=0.006**	P=0.101
RAO-SCOTT	P=0.065	P=0.211	P=0.011*	P=0.104
LITTER C-A/FISHERS	P=0.099	P=0.511	P=0.246	P=0.246

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung: Artery **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	1/35 (3%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	1/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	1.4%	0%	0%	0%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung: Artery, Mediastinum **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung: Epithelium Alveolus Hyperplasia				
LESION RATES				
OVERALL (a)	2/90 (2%)	2/90 (2%)	3/90 (3%)	1/90 (1%)
LITTERS (b)	2/35 (6%)	2/34 (6%)	3/35 (9%)	1/35 (3%)
POLY-3 RATE (c)	2/69.46	2/73.83	3/71.88	1/79.63
POLY-3 PERCENT (g)	2.9%	2.7%	4.2%	1.3%
TERMINAL (d)	2/48 (4%)	1/45 (2%)	3/50 (6%)	1/61 (2%)
FIRST INCIDENCE	737 (T)	578	737 (T)	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.348N	P=0.671N	P=0.516	P=0.453N
POLY 1.5	P=0.369N	P=0.681N	P=0.508	P=0.470N
POLY 6	P=0.327N	P=0.661N	P=0.525	P=0.434N
RAO-SCOTT	P=0.364N	P=0.644N	P=0.495	P=0.439N
LITTER C-A/FISHERS	P=0.399N	P=0.682	P=0.500	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lung: Interstitium **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mandibular **Congestion**				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/90 (2%)	0/89 (0%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	2/34 (6%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	2/73.99	0/71.48	1/79.79
POLY-3 PERCENT (g)	0%	2.7%	0%	1.3%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	635	---	696
STATISTICAL TESTS				
POLY 3	P=0.590	P=0.252	(e)	P=0.528
POLY 1.5	P=0.570	P=0.246	(e)	P=0.517
POLY 6	P=0.611	P=0.259	(e)	P=0.539
RAO-SCOTT	P=0.595	P=0.320	(e)	P=0.585
LITTER C-A/FISHERS	P=0.542	P=0.239	(e)	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mandibular **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	2/89 (2%)	3/90 (3%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	2/35 (6%)	3/35 (9%)
POLY-3 RATE (c)	0/69.46	1/73.71	2/71.48	3/79.79
POLY-3 PERCENT (g)	0%	1.4%	2.8%	3.8%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	2/50 (4%)	2/61 (3%)
FIRST INCIDENCE	---	623	737 (T)	695
STATISTICAL TESTS				
POLY 3	P=0.084	P=0.512	P=0.244	P=0.148
POLY 1.5	P=0.076	P=0.507	P=0.240	P=0.137
POLY 6	P=0.094	P=0.517	P=0.250	P=0.160
RAO-SCOTT	P=0.115	P=0.518	P=0.273	P=0.185
LITTER C-A/FISHERS	P=0.062	P=0.493	P=0.246	P=0.120

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mandibular **Hyperplasia Lymphocyte**				
LESION RATES				
OVERALL (a)	46/90 (51%)	49/90 (54%)	45/89 (51%)	43/90 (48%)
LITTERS (b)	27/35 (77%)	28/34 (82%)	30/35 (86%)	25/35 (71%)
POLY-3 RATE (c)	46/75.41	49/79.76	45/74.56	43/82.05
POLY-3 PERCENT (g)	61%	61.4%	60.4%	52.4%
TERMINAL (d)	31/48 (65%)	28/45 (62%)	33/50 (66%)	33/61 (54%)
FIRST INCIDENCE	489	319	531	579
STATISTICAL TESTS				
POLY 3	P=0.111N	P=0.545	P=0.536N	P=0.169N
POLY 1.5	P=0.160N	P=0.477	P=0.540N	P=0.236N
POLY 6	P=0.074N	P=0.535N	P=0.536N	P=0.119N
RAO-SCOTT	P=0.127N	P=0.536	P=0.525N	P=0.177N
LITTER C-A/FISHERS	P=0.282N	P=0.406	P=0.270	P=0.393N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mandibular **Infiltration Cellular Histiocyte**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/89 (0%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.48	1/80.19
POLY-3 PERCENT (g)	0%	0%	0%	1.3%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	560
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

Females

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Lymph Node, Mandibular **Infiltration Cellular Polymorphonuclear**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/89 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.48	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mandibular **Proliferation Plasma Cell**				
LESION RATES				
OVERALL (a)	68/90 (76%)	68/90 (76%)	58/89 (65%)	56/90 (62%)
LITTERS (b)	33/35 (94%)	32/34 (94%)	33/35 (94%)	28/35 (80%)
POLY-3 RATE (c)	68/83.72	68/82.80	58/79.03	56/85.76
POLY-3 PERCENT (g)	81.2%	82.1%	73.4%	65.3%
TERMINAL (d)	37/48 (77%)	36/45 (80%)	35/50 (70%)	38/61 (62%)
FIRST INCIDENCE	464	464	464	492
STATISTICAL TESTS				
POLY 3	P=0.002N**	P=0.521	P=0.146N	P=0.012N*
POLY 1.5	P=0.003N**	P=0.533	P=0.115N	P=0.016N*
POLY 6	P=0.002N**	P=0.513	P=0.192N	P=0.012N*
RAO-SCOTT	P=0.005N**	P=0.519	P=0.166N	P=0.019N*
LITTER C-A/FISHERS	P=0.023N*	P=0.682N	P=0.693	P=0.075N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mandibular: Lymphatic Sinus Ectasia				
LESION RATES				
OVERALL (a)	1/90 (1%)	2/90 (2%)	2/89 (2%)	3/90 (3%)
LITTERS (b)	1/35 (3%)	2/34 (6%)	2/35 (6%)	3/35 (9%)
POLY-3 RATE (c)	1/69.46	2/73.31	2/71.61	3/80.20
POLY-3 PERCENT (g)	1.4%	2.7%	2.8%	3.7%
TERMINAL (d)	1/48 (2%)	2/45 (4%)	1/50 (2%)	2/61 (3%)
FIRST INCIDENCE	737 (T)	737 (T)	702	557
STATISTICAL TESTS				
POLY 3	P=0.289	P=0.519	P=0.511	P=0.360
POLY 1.5	P=0.268	P=0.511	P=0.503	P=0.339
POLY 6	P=0.314	P=0.527	P=0.520	P=0.382
RAO-SCOTT	P=0.288	P=0.486	P=0.477	P=0.344
LITTER C-A/FISHERS	P=0.234	P=0.489	P=0.500	P=0.307

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mesenteric **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	1/90 (1%)	3/90 (3%)	2/90 (2%)	0/89 (0%)
LITTERS (b)	1/35 (3%)	3/34 (9%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	1/69.57	3/73.31	2/71.88	0/79.19
POLY-3 PERCENT (g)	1.4%	4.1%	2.8%	0%
TERMINAL (d)	0/48 (0%)	3/45 (7%)	2/50 (4%)	0/61 (0%)
FIRST INCIDENCE	709	737 (T)	737 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.197N	P=0.325	P=0.511	P=0.474N
POLY 1.5	P=0.215N	P=0.317	P=0.506	P=0.485N
POLY 6	P=0.178N	P=0.333	P=0.518	P=0.463N
RAO-SCOTT	P=0.259N	P=0.355	P=0.519	P=0.510N
LITTER C-A/FISHERS	P=0.238N	P=0.296	P=0.500	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mesenteric **Hyperplasia Lymphocyte**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	1/90 (1%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	1/71.88	0/79.19
POLY-3 PERCENT (g)	0%	0%	1.4%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	1/50 (2%)	0/61 (0%)
FIRST INCIDENCE	---	---	737 (T)	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mesenteric **Infiltration Cellular Histiocyte**				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/90 (0%)	0/90 (0%)	1/89 (1%)
LITTERS (b)	2/35 (6%)	0/34 (0%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	2/71.16	0/73.31	0/71.88	1/79.19
POLY-3 PERCENT (g)	2.8%	0%	0%	1.3%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	1/61 (2%)
FIRST INCIDENCE	268	---	---	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.469N	P=0.231N	P=0.236N	P=0.463N
POLY 1.5	P=0.467N	P=0.235N	P=0.238N	P=0.479N
POLY 6	P=0.470N	P=0.228N	P=0.232N	P=0.445N
RAO-SCOTT	P=0.489N	P=0.313N	P=0.315N	P=0.516N
LITTER C-A/FISHERS	P=0.458N	P=0.254N	P=0.246N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

Females

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Lymph Node, Mesenteric **Infiltration Cellular Polymorphonuclear**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.19
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mesenteric: Lymphatic Sinus Ectasia				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	1/90 (1%)	1/89 (1%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	0/73.31	1/71.88	1/79.19
POLY-3 PERCENT (g)	0%	0%	1.4%	1.3%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	1/50 (2%)	1/61 (2%)
FIRST INCIDENCE	---	---	737 (T)	737 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node, Mesenteric: Lymphocyte Depletion				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.19
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Bronchial **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	0/13 (0%)	0/8 (0%)	1/11 (9%)	0/20 (0%)
LITTERS (b)	0/13 (0%)	0/8 (0%)	1/11 (9%)	0/17 (0%)
POLY-3 RATE (c)	0/11.27	0/6.39	1/9.36	0/18.85
POLY-3 PERCENT (g)	0%	0%	10.7%	0%
TERMINAL (d)	0/6 (0%)	0/5 (0%)	1/8 (13%)	0/15 (0%)
FIRST INCIDENCE	---	---	737 (T)	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Iliac **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	3/13 (23%)	3/8 (38%)	1/11 (9%)	3/20 (15%)
LITTERS (b)	3/13 (23%)	3/8 (38%)	1/11 (9%)	3/17 (18%)
POLY-3 RATE (c)	3/11.27	3/6.77	1/9.36	3/18.85
POLY-3 PERCENT (g)	26.6%	44.3%	10.7%	15.9%
TERMINAL (d)	3/6 (50%)	2/5 (40%)	1/8 (13%)	3/15 (20%)
FIRST INCIDENCE	737 (T)	628	737 (T)	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.209N	P=0.401	P=0.365N	P=0.408N
POLY 1.5	P=0.227N	P=0.400	P=0.373N	P=0.428N
POLY 6	P=0.185N	P=0.424	P=0.339N	P=0.376N
RAO-SCOTT	P=0.232N	P=0.412	P=0.380N	P=0.425N
LITTER C-A/FISHERS	P=0.330N	P=0.410	P=0.363N	P=0.531N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Iliac **Hyperplasia Lymphocyte**				
LESION RATES				
OVERALL (a)	1/13 (8%)	0/8 (0%)	1/11 (9%)	6/20 (30%)
LITTERS (b)	1/13 (8%)	0/8 (0%)	1/11 (9%)	5/17 (29%)
POLY-3 RATE (c)	1/11.55	0/6.39	1/9.36	6/18.95
POLY-3 PERCENT (g)	8.7%	0%	10.7%	31.7%
TERMINAL (d)	0/6 (0%)	0/5 (0%)	1/8 (13%)	5/15 (33%)
FIRST INCIDENCE	662	---	737 (T)	711
STATISTICAL TESTS				
POLY 3	P=0.035*	P=0.616N	P=0.715	P=0.153
POLY 1.5	P=0.032*	P=0.609N	P=0.713	P=0.145
POLY 6	P=0.040*	P=0.619N	P=0.724	P=0.167
RAO-SCOTT	P=0.063	P=0.628N	P=0.723	P=0.200
LITTER C-A/FISHERS	P=0.039*	P=0.619N	P=0.717	P=0.156

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Iliac **Infiltration Cellular Histiocyte**				
LESION RATES				
OVERALL (a)	0/13 (0%)	0/8 (0%)	0/11 (0%)	1/20 (5%)
LITTERS (b)	0/13 (0%)	0/8 (0%)	0/11 (0%)	1/17 (6%)
POLY-3 RATE (c)	0/11.27	0/6.39	0/9.36	1/18.85
POLY-3 PERCENT (g)	0%	0%	0%	5.3%
TERMINAL (d)	0/6 (0%)	0/5 (0%)	0/8 (0%)	1/15 (7%)
FIRST INCIDENCE	---	---	---	737 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Iliac **Pigment**				
LESION RATES				
OVERALL (a)	1/13 (8%)	0/8 (0%)	0/11 (0%)	3/20 (15%)
LITTERS (b)	1/13 (8%)	0/8 (0%)	0/11 (0%)	3/17 (18%)
POLY-3 RATE (c)	1/11.65	0/6.39	0/9.36	3/18.85
POLY-3 PERCENT (g)	8.6%	0%	0%	15.9%
TERMINAL (d)	0/6 (0%)	0/5 (0%)	0/8 (0%)	3/15 (20%)
FIRST INCIDENCE	629	---	---	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.236	P=0.617N	P=0.544N	P=0.488
POLY 1.5	P=0.227	P=0.610N	P=0.544N	P=0.479
POLY 6	P=0.247	P=0.622N	P=0.537N	P=0.502
RAO-SCOTT	P=0.271	P=0.622N	P=0.569N	P=0.515
LITTER C-A/FISHERS	P=0.166	P=0.619N	P=0.542N	P=0.409

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Iliac **Proliferation Plasma Cell**				
LESION RATES				
OVERALL (a)	6/13 (46%)	1/8 (13%)	2/11 (18%)	5/20 (25%)
LITTERS (b)	6/13 (46%)	1/8 (13%)	2/11 (18%)	5/17 (29%)
POLY-3 RATE (c)	6/12.11	1/6.39	2/10.31	5/19.26
POLY-3 PERCENT (g)	49.6%	15.7%	19.4%	26%
TERMINAL (d)	3/6 (50%)	1/5 (20%)	1/8 (13%)	3/15 (20%)
FIRST INCIDENCE	629	737 (T)	268	651
STATISTICAL TESTS				
POLY 3	P=0.194N	P=0.178N	P=0.144N	P=0.167N
POLY 1.5	P=0.213N	P=0.159N	P=0.149N	P=0.177N
POLY 6	P=0.174N	P=0.199N	P=0.137N	P=0.154N
RAO-SCOTT	P=0.212N	P=0.171N	P=0.155N	P=0.175N
LITTER C-A/FISHERS	P=0.348N	P=0.133N	P=0.156N	P=0.287N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

Females

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Lymph Node: Iliac, Lymphatic Sinus Ectasia				
LESION RATES				
OVERALL (a)	0/13 (0%)	1/8 (13%)	1/11 (9%)	5/20 (25%)
LITTERS (b)	0/13 (0%)	1/8 (13%)	1/11 (9%)	5/17 (29%)
POLY-3 RATE (c)	0/11.27	1/6.39	1/9.36	5/18.95
POLY-3 PERCENT (g)	0%	15.7%	10.7%	26.4%
TERMINAL (d)	0/6 (0%)	1/5 (20%)	1/8 (13%)	4/15 (27%)
FIRST INCIDENCE	---	737 (T)	737 (T)	711
STATISTICAL TESTS				
POLY 3	P=0.047*	P=0.385	P=0.462	P=0.079
POLY 1.5	P=0.042*	P=0.390	P=0.459	P=0.073
POLY 6	P=0.055	P=0.385	P=0.474	P=0.091
RAO-SCOTT	P=0.066	P=0.377	P=0.465	P=0.104
LITTER C-A/FISHERS	P=0.022*	P=0.381	P=0.458	P=0.043*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Lumbar **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	1/13 (8%)	2/8 (25%)	0/11 (0%)	0/20 (0%)
LITTERS (b)	1/13 (8%)	2/8 (25%)	0/11 (0%)	0/17 (0%)
POLY-3 RATE (c)	1/11.86	2/7.60	0/9.36	0/18.85
POLY-3 PERCENT (g)	8.4%	26.3%	0%	0%
TERMINAL (d)	0/6 (0%)	0/5 (0%)	0/8 (0%)	0/15 (0%)
FIRST INCIDENCE	550	407	---	---
STATISTICAL TESTS				
POLY 3	P=0.095N	P=0.338	P=0.547N	P=0.407N
POLY 1.5	P=0.099N	P=0.332	P=0.546N	P=0.410N
POLY 6	P=0.089N	P=0.352	P=0.541N	P=0.400N
RAO-SCOTT	P=0.229N	P=0.502	P=0.700N	P=0.628N
LITTER C-A/FISHERS	P=0.134N	P=0.316	P=0.542N	P=0.433N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Lumbar, Lymphatic Sinus Ectasia				
LESION RATES				
OVERALL (a)	0/13 (0%)	0/8 (0%)	0/11 (0%)	1/20 (5%)
LITTERS (b)	0/13 (0%)	0/8 (0%)	0/11 (0%)	1/17 (6%)
POLY-3 RATE (c)	0/11.27	0/6.39	0/9.36	1/18.85
POLY-3 PERCENT (g)	0%	0%	0%	5.3%
TERMINAL (d)	0/6 (0%)	0/5 (0%)	0/8 (0%)	1/15 (7%)
FIRST INCIDENCE	---	---	---	737 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Mediastinal **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	0/13 (0%)	2/8 (25%)	4/11 (36%)	4/20 (20%)
LITTERS (b)	0/13 (0%)	2/8 (25%)	4/11 (36%)	4/17 (24%)
POLY-3 RATE (c)	0/11.27	2/6.79	4/9.36	4/18.85
POLY-3 PERCENT (g)	0%	29.5%	42.8%	21.2%
TERMINAL (d)	0/6 (0%)	1/5 (20%)	4/8 (50%)	4/15 (27%)
FIRST INCIDENCE	---	623	737 (T)	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.250	P=0.111	P=0.018*	P=0.133
POLY 1.5	P=0.226	P=0.112	P=0.018*	P=0.125
POLY 6	P=0.291	P=0.117	P=0.020*	P=0.146
RAO-SCOTT	P=0.275	P=0.156	P=0.047*	P=0.171
LITTER C-A/FISHERS	P=0.136	P=0.133	P=0.031*	P=0.087

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Pancreatic **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	1/13 (8%)	0/8 (0%)	1/11 (9%)	0/20 (0%)
LITTERS (b)	1/13 (8%)	0/8 (0%)	1/11 (9%)	0/17 (0%)
POLY-3 RATE (c)	1/11.27	0/6.39	1/9.36	0/18.85
POLY-3 PERCENT (g)	8.9%	0%	10.7%	0%
TERMINAL (d)	1/6 (17%)	0/5 (0%)	1/8 (13%)	0/15 (0%)
FIRST INCIDENCE	737 (T)	---	737 (T)	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Renal **Erythrophagocytosis**				
LESION RATES				
OVERALL (a)	0/13 (0%)	2/8 (25%)	0/11 (0%)	0/20 (0%)
LITTERS (b)	0/13 (0%)	2/8 (25%)	0/11 (0%)	0/17 (0%)
POLY-3 RATE (c)	0/11.27	2/6.77	0/9.36	0/18.85
POLY-3 PERCENT (g)	0%	29.5%	0%	0%
TERMINAL (d)	0/6 (0%)	1/5 (20%)	0/8 (0%)	0/15 (0%)
FIRST INCIDENCE	---	628	---	---
STATISTICAL TESTS				
POLY 3	P=0.263N	P=0.111	(e)	(e)
POLY 1.5	P=0.273N	P=0.112	(e)	(e)
POLY 6	P=0.242N	P=0.117	(e)	(e)
RAO-SCOTT	P=0.457N	P=0.364	(e)	(e)
LITTER C-A/FISHERS	P=0.328N	P=0.133	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Renal **Proliferation Plasma Cell**				
LESION RATES				
OVERALL (a)	0/13 (0%)	0/8 (0%)	0/11 (0%)	0/20 (0%)
LITTERS (b)	0/13 (0%)	0/8 (0%)	0/11 (0%)	0/17 (0%)
POLY-3 RATE (c)	0/11.27	0/6.39	0/9.36	0/18.85
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/6 (0%)	0/5 (0%)	0/8 (0%)	0/15 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Lymph Node: Renal, Lymphatic Sinus Ectasia				
LESION RATES				
OVERALL (a)	0/13 (0%)	1/8 (13%)	0/11 (0%)	0/20 (0%)
LITTERS (b)	0/13 (0%)	1/8 (13%)	0/11 (0%)	0/17 (0%)
POLY-3 RATE (c)	0/11.27	1/6.77	0/9.36	0/18.85
POLY-3 PERCENT (g)	0%	14.8%	0%	0%
TERMINAL (d)	0/6 (0%)	0/5 (0%)	0/8 (0%)	0/15 (0%)
FIRST INCIDENCE	---	628	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mammary Gland **Atrophy**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mammary Gland **Galactocele**				
LESION RATES				
OVERALL (a)	24/90 (27%)	17/90 (19%)	17/90 (19%)	10/90 (11%)
LITTERS (b)	17/35 (49%)	14/34 (41%)	13/35 (37%)	10/35 (29%)
POLY-3 RATE (c)	24/74.46	17/75.82	17/76.47	10/80.24
POLY-3 PERCENT (g)	32.2%	22.4%	22.2%	12.5%
TERMINAL (d)	13/48 (27%)	9/45 (20%)	6/50 (12%)	8/61 (13%)
FIRST INCIDENCE	464	532	483	638
STATISTICAL TESTS				
POLY 3	P=0.003N**	P=0.118N	P=0.112N	P=0.002N**
POLY 1.5	P=0.004N**	P=0.128N	P=0.126N	P=0.003N**
POLY 6	P=0.002N**	P=0.110N	P=0.099N	P=0.002N**
RAO-SCOTT	P=0.006N**	P=0.143N	P=0.137N	P=0.006N**
LITTER C-A/FISHERS	P=0.053N	P=0.354N	P=0.235N	P=0.070N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mammary Gland Hyperplasia				
LESION RATES				
OVERALL (a)	49/90 (54%)	50/90 (56%)	46/90 (51%)	34/90 (38%)
LITTERS (b)	29/35 (83%)	31/34 (91%)	28/35 (80%)	25/35 (71%)
POLY-3 RATE (c)	49/80.49	50/81.10	46/79.64	34/82.46
POLY-3 PERCENT (g)	60.9%	61.7%	57.8%	41.2%
TERMINAL (d)	25/48 (52%)	26/45 (58%)	28/50 (56%)	24/61 (39%)
FIRST INCIDENCE	464	319	416	492
STATISTICAL TESTS				
POLY 3	P=0.002N**	P=0.525	P=0.402N	P=0.007N**
POLY 1.5	P=0.003N**	P=0.514	P=0.395N	P=0.009N**
POLY 6	P=0.002N**	P=0.531	P=0.421N	P=0.007N**
RAO-SCOTT	P=0.003N**	P=0.519	P=0.401N	P=0.010N**
LITTER C-A/FISHERS	P=0.064N	P=0.253	P=0.500N	P=0.197N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mammary Gland **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	2/90 (2%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	2/35 (6%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	0/73.31	2/73.60	1/80.33
POLY-3 PERCENT (g)	0%	0%	2.7%	1.2%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	268	492
STATISTICAL TESTS				
POLY 3	P=0.299	(e)	P=0.251	P=0.529
POLY 1.5	P=0.279	(e)	P=0.246	P=0.518
POLY 6	P=0.322	(e)	P=0.257	P=0.540
RAO-SCOTT	P=0.347	(e)	P=0.321	P=0.589
LITTER C-A/FISHERS	P=0.247	(e)	P=0.246	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mammary Gland **Inflammation Granulomatous**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	2/90 (2%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	2/72.51	0/79.63
POLY-3 PERCENT (g)	0%	0%	2.8%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	1/50 (2%)	0/61 (0%)
FIRST INCIDENCE	---	---	531	---
STATISTICAL TESTS				
POLY 3	P=0.660	(e)	P=0.248	(e)
POLY 1.5	P=0.637	(e)	P=0.243	(e)
POLY 6	P=0.683	(e)	P=0.254	(e)
RAO-SCOTT	P=0.664	(e)	P=0.372	(e)
LITTER C-A/FISHERS	P=0.597	(e)	P=0.246	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mammary Gland: Duct Dilation				
LESION RATES				
OVERALL (a)	56/90 (62%)	61/90 (68%)	51/90 (57%)	70/90 (78%)
LITTERS (b)	32/35 (91%)	30/34 (88%)	29/35 (83%)	34/35 (97%)
POLY-3 RATE (c)	56/79.66	61/82.51	51/79.12	70/85.60
POLY-3 PERCENT (g)	70.3%	73.9%	64.5%	81.8%
TERMINAL (d)	33/48 (69%)	30/45 (67%)	29/50 (58%)	52/61 (85%)
FIRST INCIDENCE	464	407	417	492
STATISTICAL TESTS				
POLY 3	P=0.059	P=0.362	P=0.261N	P=0.051
POLY 1.5	P=0.046*	P=0.309	P=0.268N	P=0.035*
POLY 6	P=0.067	P=0.434	P=0.254N	P=0.066
RAO-SCOTT	P=0.082	P=0.370	P=0.274N	P=0.068
LITTER C-A/FISHERS	P=0.248	P=0.483N	P=0.239N	P=0.307

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mesentery **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	1/4 (25%)	0/3 (0%)	0/11 (0%)	1/4 (25%)
LITTERS (b)	1/4 (25%)	0/2 (0%)	0/11 (0%)	1/4 (25%)
POLY-3 RATE (c)	1/3.66	0/2.85	0/8.19	1/3.12
POLY-3 PERCENT (g)	27.3%	0%	0%	32.1%
TERMINAL (d)	0/2 (0%)	0/2 (0%)	0/5 (0%)	1/2 (50%)
FIRST INCIDENCE	690	---	---	737 (T)
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mesentery **Necrosis**				
LESION RATES				
OVERALL (a)	1/4 (25%)	1/3 (33%)	5/11 (45%)	2/4 (50%)
LITTERS (b)	1/4 (25%)	1/2 (50%)	5/11 (45%)	2/4 (50%)
POLY-3 RATE (c)	1/3.48	1/2.85	5/8.79	2/3.36
POLY-3 PERCENT (g)	28.8%	35.1%	56.9%	59.6%
TERMINAL (d)	1/2 (50%)	1/2 (50%)	3/5 (60%)	1/2 (50%)
FIRST INCIDENCE	737 (T)	737 (T)	598	674
STATISTICAL TESTS				
POLY 3	P=0.288	P=0.725	P=0.396	P=0.484
POLY 1.5	P=0.307	P=0.711	P=0.415	P=0.486
POLY 6	P=0.290	P=0.748	P=0.400	P=0.503
RAO-SCOTT	P=0.339	P=0.783	P=0.452	P=0.535
LITTER C-A/FISHERS	P=0.383	P=0.600	P=0.462	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mesentery Neovascularization				
LESION RATES				
OVERALL (a)	0/4 (0%)	0/3 (0%)	0/11 (0%)	0/4 (0%)
LITTERS (b)	0/4 (0%)	0/2 (0%)	0/11 (0%)	0/4 (0%)
POLY-3 RATE (c)	0/3.48	0/2.85	0/8.19	0/3.12
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/2 (0%)	0/2 (0%)	0/5 (0%)	0/2 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mesentery: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/4 (0%)	2/3 (67%)	2/11 (18%)	0/4 (0%)
LITTERS (b)	0/4 (0%)	1/2 (50%)	2/11 (18%)	0/4 (0%)
POLY-3 RATE (c)	0/3.48	2/3.00	2/8.19	0/3.12
POLY-3 PERCENT (g)	0%	66.7%	24.4%	0%
TERMINAL (d)	0/2 (0%)	1/2 (50%)	2/5 (40%)	0/2 (0%)
FIRST INCIDENCE	---	699	737 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.450N	P=0.117	P=0.434	(e)
POLY 1.5	P=0.435N	P=0.103	P=0.451	(e)
POLY 6	P=0.458N	P=0.146	P=0.420	(e)
RAO-SCOTT	P=0.516N	P=0.338	P=0.541	(e)
LITTER C-A/FISHERS	P=0.556N	P=0.333	P=0.524	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mesentery: Artery Mineral				
LESION RATES				
OVERALL (a)	0/4 (0%)	0/3 (0%)	0/11 (0%)	0/4 (0%)
LITTERS (b)	0/4 (0%)	0/2 (0%)	0/11 (0%)	0/4 (0%)
POLY-3 RATE (c)	0/3.48	0/2.85	0/8.19	0/3.12
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/2 (0%)	0/2 (0%)	0/5 (0%)	0/2 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Mesentery: Vein **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	0/4 (0%)	0/3 (0%)	1/11 (9%)	1/4 (25%)
LITTERS (b)	0/4 (0%)	0/2 (0%)	1/11 (9%)	1/4 (25%)
POLY-3 RATE (c)	0/3.48	0/2.85	1/8.78	1/3.77
POLY-3 PERCENT (g)	0%	0%	11.4%	26.6%
TERMINAL (d)	0/2 (0%)	0/2 (0%)	0/5 (0%)	0/2 (0%)
FIRST INCIDENCE	---	---	545	522
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nerve Trigeminal Degeneration				
LESION RATES				
OVERALL (a)	64/84 (76%)	70/84 (83%)	64/85 (75%)	72/84 (86%)
LITTERS (b)	33/35 (94%)	33/34 (97%)	33/35 (94%)	34/35 (97%)
POLY-3 RATE (c)	64/74.62	70/77.22	64/73.31	72/79.58
POLY-3 PERCENT (g)	85.8%	90.7%	87.3%	90.5%
TERMINAL (d)	41/45 (91%)	42/44 (96%)	42/46 (91%)	53/56 (95%)
FIRST INCIDENCE	464	493	516	492
STATISTICAL TESTS				
POLY 3	P=0.261	P=0.217	P=0.485	P=0.227
POLY 1.5	P=0.191	P=0.173	P=0.523	P=0.151
POLY 6	P=0.353	P=0.309	P=0.466	P=0.342
RAO-SCOTT	P=0.287	P=0.241	P=0.475	P=0.250
LITTER C-A/FISHERS	P=0.440	P=0.511	P=0.693	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose				
Foreign Body				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/89 (1%)	1/90 (1%)	2/89 (2%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	1/35 (3%)	2/35 (6%)
POLY-3 RATE (c)	0/69.46	1/72.79	1/71.88	2/79.16
POLY-3 PERCENT (g)	0%	1.4%	1.4%	2.5%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	1/50 (2%)	1/61 (2%)
FIRST INCIDENCE	---	635	737 (T)	695
STATISTICAL TESTS				
POLY 3	P=0.186	P=0.509	P=0.507	P=0.268
POLY 1.5	P=0.173	P=0.504	P=0.503	P=0.256
POLY 6	P=0.201	P=0.515	P=0.511	P=0.283
RAO-SCOTT	P=0.209	P=0.494	P=0.488	P=0.286
LITTER C-A/FISHERS	P=0.154	P=0.493	P=0.500	P=0.246

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose **Inflammation**				
LESION RATES				
OVERALL (a)	1/90 (1%)	3/89 (3%)	1/90 (1%)	3/89 (3%)
LITTERS (b)	1/35 (3%)	3/34 (9%)	1/35 (3%)	3/35 (9%)
POLY-3 RATE (c)	1/69.46	3/73.09	1/71.88	3/79.16
POLY-3 PERCENT (g)	1.4%	4.1%	1.4%	3.8%
TERMINAL (d)	1/48 (2%)	1/45 (2%)	1/50 (2%)	2/61 (3%)
FIRST INCIDENCE	737 (T)	635	737 (T)	695
STATISTICAL TESTS				
POLY 3	P=0.368	P=0.325	P=0.753N	P=0.355
POLY 1.5	P=0.346	P=0.315	P=0.757N	P=0.335
POLY 6	P=0.394	P=0.336	P=0.748N	P=0.378
RAO-SCOTT	P=0.378	P=0.327	P=0.721N	P=0.360
LITTER C-A/FISHERS	P=0.315	P=0.296	P=0.754	P=0.307

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose				
Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/89 (1%)	0/90 (0%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/72.58	0/71.88	0/79.00
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	699	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose: Olfactory Epithelium Accumulation, Hyaline Droplet				
LESION RATES				
OVERALL (a)	89/90 (99%)	89/89 (100%)	86/90 (96%)	86/89 (97%)
LITTERS (b)	35/35 (100%)	34/34 (100%)	35/35 (100%)	35/35 (100%)
POLY-3 RATE (c)	89/89.02	89/89.00	86/87.46	86/89.00
POLY-3 PERCENT (g)	100%	100%	98.3%	96.6%
TERMINAL (d)	48/48 (100%)	45/45 (100%)	49/50 (98%)	58/61 (95%)
FIRST INCIDENCE	268	300	268	305
STATISTICAL TESTS				
POLY 3	P=0.020N*	P=1.000	P=0.333N	P=0.124N
POLY 1.5	P=0.027N*	P=1.000	P=0.247N	P=0.140N
POLY 6	P=0.020N*	P=1.000	P=0.451N	P=0.121N
RAO-SCOTT	P=0.059N	P=1.000	P=0.469N	P=0.212N
LITTER C-A/FISHERS	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose: Olfactory Epithelium Metaplasia Respiratory				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/89 (0%)	0/90 (0%)	2/89 (2%)
LITTERS (b)	1/35 (3%)	0/34 (0%)	0/35 (0%)	2/35 (6%)
POLY-3 RATE (c)	1/69.46	0/72.43	0/71.88	2/79.16
POLY-3 PERCENT (g)	1.4%	0%	0%	2.5%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	0/50 (0%)	1/61 (2%)
FIRST INCIDENCE	737 (T)	---	---	695
STATISTICAL TESTS				
POLY 3	P=0.258	P=0.492N	P=0.493N	P=0.545
POLY 1.5	P=0.253	P=0.496N	P=0.497N	P=0.527
POLY 6	P=0.265	P=0.487N	P=0.489N	P=0.566
RAO-SCOTT	P=0.342	P=0.539N	P=0.537N	P=0.573
LITTER C-A/FISHERS	P=0.247	P=0.507N	P=0.500N	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose: Respiratory Epithelium Accumulation, Hyaline Droplet				
LESION RATES				
OVERALL (a)	12/90 (13%)	19/89 (21%)	22/90 (24%)	11/89 (12%)
LITTERS (b)	10/35 (29%)	15/34 (44%)	17/35 (49%)	9/35 (26%)
POLY-3 RATE (c)	12/73.72	19/79.12	22/76.73	11/82.82
POLY-3 PERCENT (g)	16.3%	24%	28.7%	13.3%
TERMINAL (d)	4/48 (8%)	4/45 (9%)	9/50 (18%)	5/61 (8%)
FIRST INCIDENCE	464	300	416	305
STATISTICAL TESTS				
POLY 3	P=0.205N	P=0.160	P=0.050*	P=0.382N
POLY 1.5	P=0.256N	P=0.141	P=0.045*	P=0.426N
POLY 6	P=0.162N	P=0.179	P=0.058	P=0.340N
RAO-SCOTT	P=0.252N	P=0.171	P=0.060	P=0.384N
LITTER C-A/FISHERS	P=0.338N	P=0.137	P=0.070	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Nose: Respiratory Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/89 (1%)	0/90 (0%)	3/89 (3%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	3/35 (9%)
POLY-3 RATE (c)	0/69.46	1/72.73	0/71.88	3/79.16
POLY-3 PERCENT (g)	0%	1.4%	0%	3.8%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	2/61 (3%)
FIRST INCIDENCE	---	656	---	695
STATISTICAL TESTS				
POLY 3	P=0.052	P=0.509	(e)	P=0.146
POLY 1.5	P=0.048*	P=0.504	(e)	P=0.135
POLY 6	P=0.057	P=0.515	(e)	P=0.159
RAO-SCOTT	P=0.102	P=0.545	(e)	P=0.207
LITTER C-A/FISHERS	P=0.044*	P=0.493	(e)	P=0.120

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Ovary **Atrophy**				
LESION RATES				
OVERALL (a)	72/90 (80%)	69/90 (77%)	56/89 (63%)	77/90 (86%)
LITTERS (b)	35/35 (100%)	33/34 (97%)	30/35 (86%)	35/35 (100%)
POLY-3 RATE (c)	72/83.26	69/86.15	56/80.26	77/87.84
POLY-3 PERCENT (g)	86.5%	80.1%	69.8%	87.7%
TERMINAL (d)	42/48 (88%)	34/45 (76%)	32/49 (65%)	53/61 (87%)
FIRST INCIDENCE	353	300	268	492
STATISTICAL TESTS				
POLY 3	P=0.378	P=0.170N	P=0.005N**	P=0.499
POLY 1.5	P=0.319	P=0.221N	P=0.005N**	P=0.388
POLY 6	P=0.441	P=0.136N	P=0.006N**	P=0.596N
RAO-SCOTT	P=0.420	P=0.208N	P=0.014N*	P=0.509
LITTER C-A/FISHERS	P=0.560N	P=0.493N	P=0.027N*	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Ovary				
Cyst				
LESION RATES				
OVERALL (a)	22/90 (24%)	27/90 (30%)	23/89 (26%)	34/90 (38%)
LITTERS (b)	17/35 (49%)	20/34 (59%)	21/35 (60%)	27/35 (77%)
POLY-3 RATE (c)	22/73.62	27/76.78	23/75.87	34/81.28
POLY-3 PERCENT (g)	29.9%	35.2%	30.3%	41.8%
TERMINAL (d)	13/48 (27%)	17/45 (38%)	11/49 (22%)	28/61 (46%)
FIRST INCIDENCE	508	339	268	587
STATISTICAL TESTS				
POLY 3	P=0.077	P=0.300	P=0.548	P=0.080
POLY 1.5	P=0.061	P=0.280	P=0.520	P=0.062
POLY 6	P=0.098	P=0.317	P=0.564N	P=0.103
RAO-SCOTT	P=0.085	P=0.295	P=0.537	P=0.083
LITTER C-A/FISHERS	P=0.010**	P=0.270	P=0.236	P=0.013*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Ovary				
Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	2/89 (2%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.31	2/70.88	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	2.8%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	2/49 (4%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	737 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.562N	P=0.511	P=0.243	(e)
POLY 1.5	P=0.583N	P=0.506	P=0.239	(e)
POLY 6	P=0.540N	P=0.515	P=0.247	(e)
RAO-SCOTT	P=0.611N	P=0.575	P=0.325	(e)
LITTER C-A/FISHERS	P=0.614N	P=0.493	P=0.246	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Ovary: Bursa Dilation				
LESION RATES				
OVERALL (a)	4/90 (4%)	4/90 (4%)	2/89 (2%)	1/90 (1%)
LITTERS (b)	4/35 (11%)	4/34 (12%)	2/35 (6%)	1/35 (3%)
POLY-3 RATE (c)	4/69.85	4/73.93	2/70.98	1/80.25
POLY-3 PERCENT (g)	5.7%	5.4%	2.8%	1.3%
TERMINAL (d)	3/48 (6%)	0/45 (0%)	1/49 (2%)	0/61 (0%)
FIRST INCIDENCE	622	657	711	536
STATISTICAL TESTS				
POLY 3	P=0.075N	P=0.610N	P=0.331N	P=0.143N
POLY 1.5	P=0.083N	P=0.624N	P=0.338N	P=0.157N
POLY 6	P=0.066N	P=0.596N	P=0.323N	P=0.129N
RAO-SCOTT	P=0.096N	P=0.595N	P=0.335N	P=0.161N
LITTER C-A/FISHERS	P=0.091N	P=0.629	P=0.337N	P=0.178N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Ovary: Rete Ovarii Hyperplasia				
LESION RATES				
OVERALL (a)	15/90 (17%)	17/90 (19%)	14/89 (16%)	11/90 (12%)
LITTERS (b)	13/35 (37%)	14/34 (41%)	12/35 (34%)	9/35 (26%)
POLY-3 RATE (c)	15/70.79	17/74.18	14/72.00	11/80.42
POLY-3 PERCENT (g)	21.2%	22.9%	19.5%	13.7%
TERMINAL (d)	11/48 (23%)	12/45 (27%)	7/49 (14%)	8/61 (13%)
FIRST INCIDENCE	608	605	631	587
STATISTICAL TESTS				
POLY 3	P=0.086N	P=0.480	P=0.479N	P=0.157N
POLY 1.5	P=0.113N	P=0.455	P=0.497N	P=0.192N
POLY 6	P=0.062N	P=0.504	P=0.455N	P=0.125N
RAO-SCOTT	P=0.107N	P=0.474	P=0.473N	P=0.169N
LITTER C-A/FISHERS	P=0.133N	P=0.462	P=0.500N	P=0.220N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pancreas **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	0/90 (0%)	3/89 (3%)
LITTERS (b)	1/35 (3%)	0/34 (0%)	0/35 (0%)	3/35 (9%)
POLY-3 RATE (c)	1/69.64	0/73.31	0/71.88	3/79.19
POLY-3 PERCENT (g)	1.4%	0%	0%	3.8%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	3/61 (5%)
FIRST INCIDENCE	690	---	---	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.092	P=0.490N	P=0.494N	P=0.354
POLY 1.5	P=0.089	P=0.494N	P=0.497N	P=0.334
POLY 6	P=0.095	P=0.486N	P=0.490N	P=0.375
RAO-SCOTT	P=0.164	P=0.534N	P=0.534N	P=0.404
LITTER C-A/FISHERS	P=0.087	P=0.507N	P=0.500N	P=0.307

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pancreas: Acinus Atrophy				
LESION RATES				
OVERALL (a)	5/90 (6%)	2/90 (2%)	6/90 (7%)	2/89 (2%)
LITTERS (b)	5/35 (14%)	2/34 (6%)	6/35 (17%)	2/35 (6%)
POLY-3 RATE (c)	5/70.16	2/73.34	6/72.36	2/79.47
POLY-3 PERCENT (g)	7.1%	2.7%	8.3%	2.5%
TERMINAL (d)	4/48 (8%)	1/45 (2%)	4/50 (8%)	0/61 (0%)
FIRST INCIDENCE	492	731	631	702
STATISTICAL TESTS				
POLY 3	P=0.222N	P=0.202N	P=0.521	P=0.173N
POLY 1.5	P=0.245N	P=0.210N	P=0.510	P=0.192N
POLY 6	P=0.197N	P=0.194N	P=0.537	P=0.154N
RAO-SCOTT	P=0.247N	P=0.212N	P=0.510	P=0.187N
LITTER C-A/FISHERS	P=0.270N	P=0.226N	P=0.500	P=0.214N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pancreas: Acinus Hyperplasia				
LESION RATES				
OVERALL (a)	1/90 (1%)	4/90 (4%)	2/90 (2%)	2/89 (2%)
LITTERS (b)	1/35 (3%)	4/34 (12%)	2/35 (6%)	2/35 (6%)
POLY-3 RATE (c)	1/69.46	4/73.43	2/71.88	2/79.19
POLY-3 PERCENT (g)	1.4%	5.5%	2.8%	2.5%
TERMINAL (d)	1/48 (2%)	3/45 (7%)	2/50 (4%)	2/61 (3%)
FIRST INCIDENCE	737 (T)	706	737 (T)	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.549N	P=0.198	P=0.512	P=0.545
POLY 1.5	P=0.576N	P=0.191	P=0.506	P=0.527
POLY 6	P=0.519N	P=0.206	P=0.520	P=0.565
RAO-SCOTT	P=0.559N	P=0.212	P=0.497	P=0.537
LITTER C-A/FISHERS	P=0.574	P=0.169	P=0.500	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pancreas: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/90 (0%)	5/90 (6%)	0/90 (0%)	1/89 (1%)
LITTERS (b)	0/35 (0%)	3/34 (9%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	5/74.04	0/71.88	1/79.19
POLY-3 PERCENT (g)	0%	6.8%	0%	1.3%
TERMINAL (d)	0/48 (0%)	2/45 (4%)	0/50 (0%)	1/61 (2%)
FIRST INCIDENCE	---	656	---	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.384N	P=0.039*	(e)	P=0.526
POLY 1.5	P=0.410N	P=0.036*	(e)	P=0.515
POLY 6	P=0.356N	P=0.042*	(e)	P=0.538
RAO-SCOTT	P=0.523N	P=0.204	(e)	P=0.760
LITTER C-A/FISHERS	P=0.631N	P=0.114	(e)	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pancreas: Artery Mineral				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/89 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.19
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pancreas: Periductal Cholangiofibrosis				
LESION RATES				
OVERALL (a)	0/90 (0%)	3/90 (3%)	2/90 (2%)	1/89 (1%)
LITTERS (b)	0/35 (0%)	3/34 (9%)	2/35 (6%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	3/73.95	2/71.88	1/79.19
POLY-3 PERCENT (g)	0%	4.1%	2.8%	1.3%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	2/50 (4%)	1/61 (2%)
FIRST INCIDENCE	---	570	737 (T)	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.600N	P=0.132	P=0.246	P=0.526
POLY 1.5	P=0.603	P=0.127	P=0.242	P=0.515
POLY 6	P=0.571N	P=0.138	P=0.250	P=0.538
RAO-SCOTT	P=0.601	P=0.169	P=0.278	P=0.548
LITTER C-A/FISHERS	P=0.560	P=0.114	P=0.246	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Parathyroid Gland **Cyst**				
LESION RATES				
OVERALL (a)	0/87 (0%)	0/80 (0%)	2/85 (2%)	0/85 (0%)
LITTERS (b)	0/35 (0%)	0/33 (0%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	0/66.85	0/65.54	2/68.73	0/75.03
POLY-3 PERCENT (g)	0%	0%	2.9%	0%
TERMINAL (d)	0/46 (0%)	0/40 (0%)	1/48 (2%)	0/58 (0%)
FIRST INCIDENCE	---	---	493	---
STATISTICAL TESTS				
POLY 3	P=0.659	(e)	P=0.244	(e)
POLY 1.5	P=0.636	(e)	P=0.239	(e)
POLY 6	P=0.683	(e)	P=0.251	(e)
RAO-SCOTT	P=0.661	(e)	P=0.363	(e)
LITTER C-A/FISHERS	P=0.599	(e)	P=0.246	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Parathyroid Gland **Fibrosis**				
LESION RATES				
OVERALL (a)	13/87 (15%)	11/80 (14%)	6/85 (7%)	10/85 (12%)
LITTERS (b)	11/35 (31%)	9/33 (27%)	5/35 (14%)	9/35 (26%)
POLY-3 RATE (c)	13/68.73	11/66.12	6/69.07	10/75.03
POLY-3 PERCENT (g)	18.9%	16.6%	8.7%	13.3%
TERMINAL (d)	8/46 (17%)	8/40 (20%)	3/48 (6%)	10/58 (17%)
FIRST INCIDENCE	547	647	493	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.180N	P=0.452N	P=0.066N	P=0.246N
POLY 1.5	P=0.203N	P=0.471N	P=0.071N	P=0.281N
POLY 6	P=0.159N	P=0.437N	P=0.060N	P=0.216N
RAO-SCOTT	P=0.194N	P=0.452N	P=0.083N	P=0.263N
LITTER C-A/FISHERS	P=0.304N	P=0.457N	P=0.077N	P=0.396N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Parathyroid Gland Hyperplasia				
LESION RATES				
OVERALL (a)	0/87 (0%)	2/80 (3%)	0/85 (0%)	3/85 (4%)
LITTERS (b)	0/35 (0%)	2/33 (6%)	0/35 (0%)	3/35 (9%)
POLY-3 RATE (c)	0/66.85	2/65.69	0/68.03	3/75.03
POLY-3 PERCENT (g)	0%	3%	0%	4%
TERMINAL (d)	0/46 (0%)	1/40 (3%)	0/48 (0%)	3/58 (5%)
FIRST INCIDENCE	---	699	---	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.120	P=0.234	(e)	P=0.143
POLY 1.5	P=0.112	P=0.228	(e)	P=0.133
POLY 6	P=0.131	P=0.240	(e)	P=0.155
RAO-SCOTT	P=0.180	P=0.297	(e)	P=0.207
LITTER C-A/FISHERS	P=0.099	P=0.232	(e)	P=0.120

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Parathyroid Gland **Hyperplasia Focal**				
LESION RATES				
OVERALL (a)	3/87 (3%)	0/80 (0%)	2/85 (2%)	0/85 (0%)
LITTERS (b)	3/35 (9%)	0/33 (0%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	3/67.45	0/65.54	2/68.03	0/75.03
POLY-3 PERCENT (g)	4.5%	0%	2.9%	0%
TERMINAL (d)	2/46 (4%)	0/40 (0%)	2/48 (4%)	0/58 (0%)
FIRST INCIDENCE	547	---	737 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.114N	P=0.125N	P=0.496N	P=0.103N
POLY 1.5	P=0.119N	P=0.130N	P=0.503N	P=0.111N
POLY 6	P=0.109N	P=0.122N	P=0.487N	P=0.095N
RAO-SCOTT	P=0.170N	P=0.189N	P=0.517N	P=0.168N
LITTER C-A/FISHERS	P=0.122N	P=0.131N	P=0.500N	P=0.120N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Peripheral Nerve, Sciatic Degeneration				
LESION RATES				
OVERALL (a)	80/90 (89%)	83/90 (92%)	83/90 (92%)	89/90 (99%)
LITTERS (b)	35/35 (100%)	34/34 (100%)	35/35 (100%)	35/35 (100%)
POLY-3 RATE (c)	80/84.63	83/84.61	83/85.56	89/89.44
POLY-3 PERCENT (g)	94.5%	98.1%	97%	99.5%
TERMINAL (d)	47/48 (98%)	45/45 (100%)	49/50 (98%)	61/61 (100%)
FIRST INCIDENCE	202	300	268	305
STATISTICAL TESTS				
POLY 3	P=0.021*	P=0.140	P=0.300	P=0.026*
POLY 1.5	P=0.009**	P=0.160	P=0.247	P=0.012*
POLY 6	P=0.074	P=0.211	P=0.453	P=0.088
RAO-SCOTT	P=0.062	P=0.203	P=0.334	P=0.068
LITTER C-A/FISHERS	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Peripheral Nerve, Tibial Degeneration				
LESION RATES				
OVERALL (a)	77/90 (86%)	77/90 (86%)	83/89 (93%)	86/89 (97%)
LITTERS (b)	35/35 (100%)	34/34 (100%)	35/35 (100%)	35/35 (100%)
POLY-3 RATE (c)	77/81.42	77/81.17	83/84.87	86/86.89
POLY-3 PERCENT (g)	94.6%	94.9%	97.8%	99%
TERMINAL (d)	48/48 (100%)	45/45 (100%)	49/50 (98%)	61/61 (100%)
FIRST INCIDENCE	353	550	464	492
STATISTICAL TESTS				
POLY 3	P=0.013*	P=0.646	P=0.169	P=0.035*
POLY 1.5	P=0.004**	P=0.577	P=0.081	P=0.016*
POLY 6	P=0.087	P=0.731N	P=0.564	P=0.191
RAO-SCOTT	P=0.056	P=0.592	P=0.239	P=0.113
LITTER C-A/FISHERS	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pituitary Gland **Pigment**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/89 (0%)	2/89 (2%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.06	2/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	2.8%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	2/50 (4%)	0/61 (0%)
FIRST INCIDENCE	---	---	737 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.659	(e)	P=0.246	(e)
POLY 1.5	P=0.636	(e)	P=0.242	(e)
POLY 6	P=0.682	(e)	P=0.251	(e)
RAO-SCOTT	P=0.664	(e)	P=0.372	(e)
LITTER C-A/FISHERS	P=0.597	(e)	P=0.246	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pituitary Gland: Pars Distalis **Angiectasis**				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/89 (0%)	0/89 (0%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/69.46	0/73.06	0/71.88	0/79.63
POLY-3 PERCENT (g)	2.9%	0%	0%	0%
TERMINAL (d)	2/48 (4%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.122N	P=0.227N	P=0.231N	P=0.209N
POLY 1.5	P=0.119N	P=0.233N	P=0.234N	P=0.220N
POLY 6	P=0.126N	P=0.221N	P=0.226N	P=0.199N
RAO-SCOTT	P=0.228N	P=0.362N	P=0.363N	P=0.353N
LITTER C-A/FISHERS	P=0.114N	P=0.254N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pituitary Gland: Pars Distalis **Cyst**				
LESION RATES				
OVERALL (a)	7/90 (8%)	5/89 (6%)	3/89 (3%)	1/90 (1%)
LITTERS (b)	6/35 (17%)	4/34 (12%)	3/35 (9%)	1/35 (3%)
POLY-3 RATE (c)	7/69.46	5/74.54	3/72.48	1/79.63
POLY-3 PERCENT (g)	10.1%	6.7%	4.1%	1.3%
TERMINAL (d)	7/48 (15%)	2/45 (4%)	2/50 (4%)	1/61 (2%)
FIRST INCIDENCE	737 (T)	300	545	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.012N*	P=0.334N	P=0.145N	P=0.021N*
POLY 1.5	P=0.014N*	P=0.357N	P=0.154N	P=0.025N*
POLY 6	P=0.010N**	P=0.311N	P=0.134N	P=0.017N*
RAO-SCOTT	P=0.032N*	P=0.372N	P=0.197N	P=0.049N*
LITTER C-A/FISHERS	P=0.034N*	P=0.386N	P=0.239N	P=0.053N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pituitary Gland: Pars Distalis Hyperplasia				
LESION RATES				
OVERALL (a)	20/90 (22%)	22/89 (25%)	26/89 (29%)	22/90 (24%)
LITTERS (b)	18/35 (51%)	17/34 (50%)	18/35 (51%)	17/35 (49%)
POLY-3 RATE (c)	20/72.39	22/75.70	26/74.41	22/81.28
POLY-3 PERCENT (g)	27.6%	29.1%	34.9%	27.1%
TERMINAL (d)	13/48 (27%)	15/45 (33%)	19/50 (38%)	18/61 (30%)
FIRST INCIDENCE	513	532	450	522
STATISTICAL TESTS				
POLY 3	P=0.493N	P=0.495	P=0.215	P=0.541N
POLY 1.5	P=0.511	P=0.460	P=0.203	P=0.540
POLY 6	P=0.428N	P=0.531	P=0.231	P=0.480N
RAO-SCOTT	P=0.506N	P=0.492	P=0.230	P=0.536N
LITTER C-A/FISHERS	P=0.460N	P=0.549N	P=0.594	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pituitary Gland: Pars Intermedia Cyst				
LESION RATES				
OVERALL (a)	3/90 (3%)	3/89 (3%)	1/89 (1%)	3/90 (3%)
LITTERS (b)	3/35 (9%)	3/34 (9%)	1/35 (3%)	3/35 (9%)
POLY-3 RATE (c)	3/70.08	3/73.31	1/71.88	3/79.77
POLY-3 PERCENT (g)	4.3%	4.1%	1.4%	3.8%
TERMINAL (d)	2/48 (4%)	1/45 (2%)	1/50 (2%)	2/61 (3%)
FIRST INCIDENCE	531	699	737 (T)	702
STATISTICAL TESTS				
POLY 3	P=0.502N	P=0.640N	P=0.297N	P=0.600N
POLY 1.5	P=0.517N	P=0.651N	P=0.302N	P=0.623N
POLY 6	P=0.485N	P=0.629N	P=0.291N	P=0.575N
RAO-SCOTT	P=0.485N	P=0.617N	P=0.285N	P=0.583N
LITTER C-A/FISHERS	P=0.539N	P=0.649	P=0.307N	P=0.663

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Pituitary Gland: Pars Intermedia Hyperplasia				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/89 (0%)	1/89 (1%)	0/90 (0%)
LITTERS (b)	1/35 (3%)	0/34 (0%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	1/70.08	0/73.06	1/71.88	0/79.63
POLY-3 PERCENT (g)	1.4%	0%	1.4%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	1/50 (2%)	0/61 (0%)
FIRST INCIDENCE	531	---	737 (T)	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/90 (0%)	3/90 (3%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	2/34 (6%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	3/73.46	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	4.1%	0%	0%
TERMINAL (d)	0/48 (0%)	2/45 (4%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	699	---	---
STATISTICAL TESTS				
POLY 3	P=0.271N	P=0.131	(e)	(e)
POLY 1.5	P=0.287N	P=0.127	(e)	(e)
POLY 6	P=0.254N	P=0.136	(e)	(e)
RAO-SCOTT	P=0.465N	P=0.348	(e)	(e)
LITTER C-A/FISHERS	P=0.403N	P=0.239	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Artery Mineral				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Duct, Parotid Gland Dilation				
LESION RATES				
OVERALL (a)	1/90 (1%)	1/90 (1%)	2/90 (2%)	0/90 (0%)
LITTERS (b)	1/35 (3%)	1/34 (3%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	1/69.53	1/73.31	2/72.05	0/79.63
POLY-3 PERCENT (g)	1.4%	1.4%	2.8%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	719	737 (T)	702	---
STATISTICAL TESTS				
POLY 3	P=0.324N	P=0.749N	P=0.512	P=0.473N
POLY 1.5	P=0.340N	P=0.754N	P=0.506	P=0.483N
POLY 6	P=0.308N	P=0.744N	P=0.520	P=0.462N
RAO-SCOTT	P=0.366N	P=0.727N	P=0.511	P=0.491N
LITTER C-A/FISHERS	P=0.363N	P=0.746	P=0.500	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Parotid Gland Atrophy				
LESION RATES				
OVERALL (a)	4/90 (4%)	7/90 (8%)	9/90 (10%)	1/90 (1%)
LITTERS (b)	4/35 (11%)	7/34 (21%)	8/35 (23%)	1/35 (3%)
POLY-3 RATE (c)	4/69.53	7/73.67	9/75.14	1/80.13
POLY-3 PERCENT (g)	5.8%	9.5%	12%	1.3%
TERMINAL (d)	3/48 (6%)	3/45 (7%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	719	696	464	587
STATISTICAL TESTS				
POLY 3	P=0.085N	P=0.299	P=0.154	P=0.142N
POLY 1.5	P=0.106N	P=0.285	P=0.139	P=0.156N
POLY 6	P=0.065N	P=0.315	P=0.176	P=0.128N
RAO-SCOTT	P=0.137N	P=0.322	P=0.186	P=0.177N
LITTER C-A/FISHERS	P=0.123N	P=0.239	P=0.171	P=0.178N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Parotid Gland Fibrosis				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	2/90 (2%)	3/90 (3%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	2/35 (6%)	3/35 (9%)
POLY-3 RATE (c)	0/69.46	0/73.31	2/72.88	3/79.73
POLY-3 PERCENT (g)	0%	0%	2.7%	3.8%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	2/61 (3%)
FIRST INCIDENCE	---	---	464	711
STATISTICAL TESTS				
POLY 3	P=0.038*	(e)	P=0.249	P=0.148
POLY 1.5	P=0.034*	(e)	P=0.244	P=0.137
POLY 6	P=0.043*	(e)	P=0.255	P=0.160
RAO-SCOTT	P=0.082	(e)	P=0.321	P=0.222
LITTER C-A/FISHERS	P=0.028*	(e)	P=0.246	P=0.120

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Parotid Gland Inflammation Acute				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	1/90 (1%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.31	1/72.02	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	1.4%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	702	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Parotid Gland **Vacuolation, Cytoplasmic**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	1/90 (1%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	1/72.51	0/79.63
POLY-3 PERCENT (g)	0%	0%	1.4%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	531	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

Females

DOSE	0.0W/kg(CDMA)chr	1.5W/kg(CDMA)chr	3.0W/kg(CDMA)chr	6.0W/kg(CDMA)chr
Salivary Glands: Sublingual Gland Atrophy				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/90 (2%)	3/90 (3%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	2/34 (6%)	3/35 (9%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	2/73.61	3/72.51	0/79.63
POLY-3 PERCENT (g)	0%	2.7%	4.1%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	2/50 (4%)	0/61 (0%)
FIRST INCIDENCE	---	656	531	---
STATISTICAL TESTS				
POLY 3	P=0.456N	P=0.251	P=0.129	(e)
POLY 1.5	P=0.484N	P=0.245	P=0.125	(e)
POLY 6	P=0.426N	P=0.257	P=0.133	(e)
RAO-SCOTT	P=0.519N	P=0.320	P=0.192	(e)
LITTER C-A/FISHERS	P=0.527N	P=0.239	P=0.120	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Salivary Glands: Submandibular Gland Atrophy				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	1/90 (1%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	0/73.31	1/71.88	1/80.13
POLY-3 PERCENT (g)	0%	0%	1.4%	1.3%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	1/50 (2%)	0/61 (0%)
FIRST INCIDENCE	---	---	737 (T)	587
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skeletal Muscle Degeneration				
LESION RATES				
OVERALL (a)	3/90 (3%)	7/90 (8%)	10/90 (11%)	2/90 (2%)
LITTERS (b)	3/35 (9%)	7/34 (21%)	10/35 (29%)	2/35 (6%)
POLY-3 RATE (c)	3/69.80	7/74.97	10/73.70	2/79.63
POLY-3 PERCENT (g)	4.3%	9.3%	13.6%	2.5%
TERMINAL (d)	2/48 (4%)	2/45 (4%)	3/50 (6%)	2/61 (3%)
FIRST INCIDENCE	641	300	559	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.243N	P=0.193	P=0.049*	P=0.441N
POLY 1.5	P=0.282N	P=0.181	P=0.044*	P=0.463N
POLY 6	P=0.206N	P=0.206	P=0.056	P=0.418N
RAO-SCOTT	P=0.290N	P=0.196	P=0.056	P=0.429N
LITTER C-A/FISHERS	P=0.341N	P=0.141	P=0.031*	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skeletal Muscle **Mineral**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin **Cyst Epithelial Inclusion**				
LESION RATES				
OVERALL (a)	1/90 (1%)	1/90 (1%)	3/90 (3%)	1/90 (1%)
LITTERS (b)	1/35 (3%)	1/34 (3%)	3/35 (9%)	1/35 (3%)
POLY-3 RATE (c)	1/69.46	1/73.43	3/72.18	1/79.63
POLY-3 PERCENT (g)	1.4%	1.4%	4.2%	1.3%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	2/50 (4%)	1/61 (2%)
FIRST INCIDENCE	737 (T)	706	656	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.608N	P=0.748N	P=0.320	P=0.729N
POLY 1.5	P=0.599	P=0.754N	P=0.313	P=0.741N
POLY 6	P=0.586N	P=0.743N	P=0.329	P=0.716N
RAO-SCOTT	P=0.600	P=0.724N	P=0.334	P=0.714N
LITTER C-A/FISHERS	P=0.560	P=0.746	P=0.307	P=0.754

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin **Inflammation**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	0/90 (0%)	1/90 (1%)
LITTERS (b)	1/35 (3%)	0/34 (0%)	0/35 (0%)	1/35 (3%)
POLY-3 RATE (c)	1/69.74	0/73.31	0/71.88	1/80.33
POLY-3 PERCENT (g)	1.4%	0%	0%	1.2%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	660	---	---	492
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin **Ulcer**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	1/90 (1%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	1/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	1.4%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	1/50 (2%)	0/61 (0%)
FIRST INCIDENCE	---	---	737 (T)	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin: Epidermis **Hyperplasia**				
LESION RATES				
OVERALL (a)	2/90 (2%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/69.86	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	2.9%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	660	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.121N	P=0.228N	P=0.232N	P=0.211N
POLY 1.5	P=0.119N	P=0.232N	P=0.235N	P=0.221N
POLY 6	P=0.123N	P=0.224N	P=0.228N	P=0.201N
RAO-SCOTT	P=0.242N	P=0.379N	P=0.380N	P=0.373N
LITTER C-A/FISHERS	P=0.114N	P=0.254N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin: Prepuce **Hyperplasia**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin: Prepuce				
Ulcer				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin: Subcutaneous Tissue Inflammation				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Skin: Subcutaneous Tissue **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spinal Cord, Cervical Degeneration				
LESION RATES				
OVERALL (a)	24/90 (27%)	29/90 (32%)	22/90 (24%)	35/90 (39%)
LITTERS (b)	18/35 (51%)	21/34 (62%)	21/35 (60%)	27/35 (77%)
POLY-3 RATE (c)	24/70.99	29/76.00	22/74.70	35/81.16
POLY-3 PERCENT (g)	33.8%	38.2%	29.5%	43.1%
TERMINAL (d)	18/48 (38%)	17/45 (38%)	13/50 (26%)	30/61 (49%)
FIRST INCIDENCE	578	464	464	522
STATISTICAL TESTS				
POLY 3	P=0.150	P=0.350	P=0.347N	P=0.152
POLY 1.5	P=0.112	P=0.306	P=0.387N	P=0.107
POLY 6	P=0.196	P=0.405	P=0.299N	P=0.210
RAO-SCOTT	P=0.168	P=0.346	P=0.342N	P=0.156
LITTER C-A/FISHERS	P=0.021*	P=0.267	P=0.315	P=0.022*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spinal Cord, Lumbar Degeneration				
LESION RATES				
OVERALL (a)	10/90 (11%)	11/90 (12%)	15/89 (17%)	12/90 (13%)
LITTERS (b)	10/35 (29%)	11/34 (32%)	15/35 (43%)	12/35 (34%)
POLY-3 RATE (c)	10/72.25	11/75.94	15/76.02	12/81.87
POLY-3 PERCENT (g)	13.8%	14.5%	19.7%	14.7%
TERMINAL (d)	3/48 (6%)	4/45 (9%)	4/50 (8%)	6/61 (10%)
FIRST INCIDENCE	531	493	545	536
STATISTICAL TESTS				
POLY 3	P=0.477	P=0.549	P=0.229	P=0.534
POLY 1.5	P=0.425	P=0.528	P=0.211	P=0.489
POLY 6	P=0.531	P=0.568	P=0.256	P=0.579
RAO-SCOTT	P=0.459	P=0.532	P=0.219	P=0.520
LITTER C-A/FISHERS	P=0.326	P=0.468	P=0.159	P=0.399

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spinal Cord, Lumbar: Nerve Degeneration				
LESION RATES				
OVERALL (a)	74/90 (82%)	77/90 (86%)	77/89 (87%)	80/90 (89%)
LITTERS (b)	34/35 (97%)	34/34 (100%)	34/35 (97%)	35/35 (100%)
POLY-3 RATE (c)	74/79.49	77/80.91	77/81.18	80/86.40
POLY-3 PERCENT (g)	93.1%	95.2%	94.9%	92.6%
TERMINAL (d)	47/48 (98%)	45/45 (100%)	50/50 (100%)	58/61 (95%)
FIRST INCIDENCE	492	493	493	492
STATISTICAL TESTS				
POLY 3	P=0.415N	P=0.377	P=0.424	P=0.584N
POLY 1.5	P=0.426	P=0.334	P=0.354	P=0.429
POLY 6	P=0.138N	P=0.498	P=0.544	P=0.348N
RAO-SCOTT	P=0.437N	P=0.397	P=0.432	P=0.561N
LITTER C-A/FISHERS	P=0.403	P=0.507	P=0.754	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spinal Cord, Thoracic **Degeneration**				
LESION RATES				
OVERALL (a)	59/90 (66%)	64/90 (71%)	59/90 (66%)	70/90 (78%)
LITTERS (b)	31/35 (89%)	32/34 (94%)	31/35 (89%)	34/35 (97%)
POLY-3 RATE (c)	59/72.42	64/76.67	59/75.47	70/81.12
POLY-3 PERCENT (g)	81.5%	83.5%	78.2%	86.3%
TERMINAL (d)	47/48 (98%)	44/45 (98%)	45/50 (90%)	61/61 (100%)
FIRST INCIDENCE	608	579	559	638
STATISTICAL TESTS				
POLY 3	P=0.232	P=0.448	P=0.365N	P=0.232
POLY 1.5	P=0.139	P=0.334	P=0.480N	P=0.126
POLY 6	P=0.376	P=0.620N	P=0.196N	P=0.438
RAO-SCOTT	P=0.281	P=0.448	P=0.378N	P=0.274
LITTER C-A/FISHERS	P=0.181	P=0.351	P=0.645	P=0.178

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spleen **Extramedullary Hematopoiesis**				
LESION RATES				
OVERALL (a)	80/90 (89%)	74/90 (82%)	79/90 (88%)	82/90 (91%)
LITTERS (b)	34/35 (97%)	33/34 (97%)	35/35 (100%)	35/35 (100%)
POLY-3 RATE (c)	80/86.77	74/87.36	79/85.53	82/88.03
POLY-3 PERCENT (g)	92.2%	84.7%	92.4%	93.2%
TERMINAL (d)	47/48 (98%)	42/45 (93%)	49/50 (98%)	60/61 (98%)
FIRST INCIDENCE	202	300	16	305
STATISTICAL TESTS				
POLY 3	P=0.208	P=0.077N	P=0.609	P=0.521
POLY 1.5	P=0.202	P=0.100N	P=0.589N	P=0.467
POLY 6	P=0.227	P=0.060N	P=0.602	P=0.593
RAO-SCOTT	P=0.246	P=0.108N	P=0.597	P=0.525
LITTER C-A/FISHERS	P=0.234	P=0.746N	P=0.500	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spleen **Hyperplasia Lymphocyte**				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.74	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	612	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spleen **Necrosis**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spleen **Pigment**				
LESION RATES				
OVERALL (a)	74/90 (82%)	79/90 (88%)	77/90 (86%)	79/90 (88%)
LITTERS (b)	35/35 (100%)	34/34 (100%)	34/35 (97%)	33/35 (94%)
POLY-3 RATE (c)	74/86.29	79/87.10	77/85.15	79/88.69
POLY-3 PERCENT (g)	85.8%	90.7%	90.4%	89.1%
TERMINAL (d)	43/48 (90%)	43/45 (96%)	48/50 (96%)	56/61 (92%)
FIRST INCIDENCE	202	300	268	305
STATISTICAL TESTS				
POLY 3	P=0.347	P=0.202	P=0.220	P=0.323
POLY 1.5	P=0.288	P=0.197	P=0.244	P=0.267
POLY 6	P=0.435	P=0.215	P=0.198	P=0.405
RAO-SCOTT	P=0.354	P=0.217	P=0.236	P=0.330
LITTER C-A/FISHERS	P=0.071N	(e)	P=0.500N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spleen: Red Pulp Atrophy				
LESION RATES				
OVERALL (a)	7/90 (8%)	11/90 (12%)	13/90 (14%)	6/90 (7%)
LITTERS (b)	7/35 (20%)	11/34 (32%)	11/35 (31%)	6/35 (17%)
POLY-3 RATE (c)	7/71.42	11/75.01	13/74.10	6/80.92
POLY-3 PERCENT (g)	9.8%	14.7%	17.5%	7.4%
TERMINAL (d)	1/48 (2%)	3/45 (7%)	5/50 (10%)	1/61 (2%)
FIRST INCIDENCE	547	635	417	557
STATISTICAL TESTS				
POLY 3	P=0.248N	P=0.259	P=0.131	P=0.407N
POLY 1.5	P=0.291N	P=0.245	P=0.124	P=0.441N
POLY 6	P=0.207N	P=0.275	P=0.140	P=0.374N
RAO-SCOTT	P=0.284N	P=0.262	P=0.139	P=0.404N
LITTER C-A/FISHERS	P=0.325N	P=0.186	P=0.206	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Spleen: White Pulp Atrophy				
LESION RATES				
OVERALL (a)	3/90 (3%)	3/90 (3%)	4/90 (4%)	1/90 (1%)
LITTERS (b)	3/35 (9%)	3/34 (9%)	4/35 (11%)	1/35 (3%)
POLY-3 RATE (c)	3/69.82	3/73.61	4/73.58	1/79.79
POLY-3 PERCENT (g)	4.3%	4.1%	5.4%	1.3%
TERMINAL (d)	0/48 (0%)	2/45 (4%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	690	656	417	696
STATISTICAL TESTS				
POLY 3	P=0.197N	P=0.637N	P=0.528	P=0.261N
POLY 1.5	P=0.216N	P=0.647N	P=0.515	P=0.278N
POLY 6	P=0.178N	P=0.627N	P=0.544	P=0.245N
RAO-SCOTT	P=0.220N	P=0.615N	P=0.512	P=0.262N
LITTER C-A/FISHERS	P=0.242N	P=0.649	P=0.500	P=0.307N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Forestomach **Edema**				
LESION RATES				
OVERALL (a)	2/90 (2%)	2/90 (2%)	2/90 (2%)	3/90 (3%)
LITTERS (b)	2/35 (6%)	2/34 (6%)	2/35 (6%)	3/35 (9%)
POLY-3 RATE (c)	2/70.17	2/73.77	2/72.12	3/79.63
POLY-3 PERCENT (g)	2.9%	2.7%	2.8%	3.8%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	3/61 (5%)
FIRST INCIDENCE	524	675	702	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.441	P=0.675N	P=0.683N	P=0.557
POLY 1.5	P=0.421	P=0.683N	P=0.688N	P=0.536
POLY 6	P=0.462	P=0.667N	P=0.677N	P=0.579
RAO-SCOTT	P=0.435	P=0.642N	P=0.649N	P=0.532
LITTER C-A/FISHERS	P=0.390	P=0.682	P=0.693	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Forestomach **Erosion**				
LESION RATES				
OVERALL (a)	2/90 (2%)	1/90 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	2/35 (6%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	2/69.89	1/73.67	0/71.88	0/79.63
POLY-3 PERCENT (g)	2.9%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	634	635	---	---
STATISTICAL TESTS				
POLY 3	P=0.099N	P=0.482N	P=0.232N	P=0.211N
POLY 1.5	P=0.100N	P=0.490N	P=0.235N	P=0.221N
POLY 6	P=0.097N	P=0.474N	P=0.228N	P=0.201N
RAO-SCOTT	P=0.168N	P=0.528N	P=0.320N	P=0.311N
LITTER C-A/FISHERS	P=0.099N	P=0.511N	P=0.246N	P=0.246N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Forestomach **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	4/90 (4%)	5/90 (6%)	2/90 (2%)	1/90 (1%)
LITTERS (b)	4/35 (11%)	5/34 (15%)	2/35 (6%)	1/35 (3%)
POLY-3 RATE (c)	4/70.16	5/74.17	2/72.48	1/79.63
POLY-3 PERCENT (g)	5.7%	6.7%	2.8%	1.3%
TERMINAL (d)	2/48 (4%)	1/45 (2%)	1/50 (2%)	1/61 (2%)
FIRST INCIDENCE	634	656	545	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.061N	P=0.534	P=0.324N	P=0.146N
POLY 1.5	P=0.068N	P=0.519	P=0.331N	P=0.159N
POLY 6	P=0.054N	P=0.550	P=0.315N	P=0.134N
RAO-SCOTT	P=0.084N	P=0.527	P=0.333N	P=0.168N
LITTER C-A/FISHERS	P=0.075N	P=0.481	P=0.337N	P=0.178N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Forestomach **Ulcer**				
LESION RATES				
OVERALL (a)	1/90 (1%)	3/90 (3%)	3/90 (3%)	3/90 (3%)
LITTERS (b)	1/35 (3%)	3/34 (9%)	3/35 (9%)	3/35 (9%)
POLY-3 RATE (c)	1/69.73	3/73.96	3/72.95	3/79.80
POLY-3 PERCENT (g)	1.4%	4.1%	4.1%	3.8%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	2/61 (3%)
FIRST INCIDENCE	662	657	559	694
STATISTICAL TESTS				
POLY 3	P=0.364	P=0.328	P=0.323	P=0.356
POLY 1.5	P=0.338	P=0.318	P=0.315	P=0.337
POLY 6	P=0.394	P=0.338	P=0.333	P=0.377
RAO-SCOTT	P=0.354	P=0.315	P=0.310	P=0.347
LITTER C-A/FISHERS	P=0.294	P=0.296	P=0.307	P=0.307

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Forestomach: Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	10/90 (11%)	11/90 (12%)	8/90 (9%)	8/90 (9%)
LITTERS (b)	10/35 (29%)	8/34 (24%)	8/35 (23%)	8/35 (23%)
POLY-3 RATE (c)	10/70.91	11/75.45	8/74.13	8/81.19
POLY-3 PERCENT (g)	14.1%	14.6%	10.8%	9.9%
TERMINAL (d)	5/48 (10%)	2/45 (4%)	2/50 (4%)	4/61 (7%)
FIRST INCIDENCE	629	579	516	522
STATISTICAL TESTS				
POLY 3	P=0.196N	P=0.561	P=0.362N	P=0.289N
POLY 1.5	P=0.228N	P=0.534	P=0.381N	P=0.329N
POLY 6	P=0.168N	P=0.590	P=0.341N	P=0.252N
RAO-SCOTT	P=0.215N	P=0.551	P=0.365N	P=0.299N
LITTER C-A/FISHERS	P=0.361N	P=0.420N	P=0.393N	P=0.393N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Forestomach: Epithelium Hyperplasia Basal Cell				
LESION RATES				
OVERALL (a)	1/90 (1%)	1/90 (1%)	2/90 (2%)	0/90 (0%)
LITTERS (b)	1/35 (3%)	1/34 (3%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	1/69.46	1/73.31	2/71.98	0/79.63
POLY-3 PERCENT (g)	1.4%	1.4%	2.8%	0%
TERMINAL (d)	1/48 (2%)	1/45 (2%)	1/50 (2%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	737 (T)	711	---
STATISTICAL TESTS				
POLY 3	P=0.324N	P=0.749N	P=0.512	P=0.473N
POLY 1.5	P=0.340N	P=0.754N	P=0.506	P=0.483N
POLY 6	P=0.307N	P=0.743N	P=0.521	P=0.462N
RAO-SCOTT	P=0.368N	P=0.727N	P=0.513	P=0.494N
LITTER C-A/FISHERS	P=0.363N	P=0.746	P=0.500	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Glandular Erosion				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	1/89 (1%)	1/88 (1%)
LITTERS (b)	1/35 (3%)	0/34 (0%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	1/69.46	0/73.31	1/71.83	1/79.05
POLY-3 PERCENT (g)	1.4%	0%	1.4%	1.3%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	---	704	587
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Glandular **Mineral**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/89 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.70	0/78.56
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Glandular **Necrosis**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	0/89 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	0/73.31	0/71.70	0/78.56
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Stomach, Glandular: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/90 (0%)	1/90 (1%)	0/89 (0%)	0/88 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	1/73.31	0/71.70	0/78.56
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thymus **Atrophy**				
LESION RATES				
OVERALL (a)	75/87 (86%)	67/83 (81%)	74/87 (85%)	63/87 (72%)
LITTERS (b)	34/35 (97%)	34/34 (100%)	34/34 (100%)	34/35 (97%)
POLY-3 RATE (c)	75/81.62	67/78.59	74/82.81	63/83.34
POLY-3 PERCENT (g)	91.9%	85.3%	89.4%	75.6%
TERMINAL (d)	42/46 (91%)	36/43 (84%)	45/50 (90%)	44/60 (73%)
FIRST INCIDENCE	464	300	268	492
STATISTICAL TESTS				
POLY 3	P=0.002N**	P=0.126N	P=0.378N	P=0.003N**
POLY 1.5	P=0.003N**	P=0.149N	P=0.412N	P=0.004N**
POLY 6	P<0.001N**	P=0.109N	P=0.386N	P=0.002N**
RAO-SCOTT	P=0.005N**	P=0.159N	P=0.399N	P=0.007N**
LITTER C-A/FISHERS	P=0.596N	P=0.507	P=0.507	P=0.754

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thymus **Cyst**				
LESION RATES				
OVERALL (a)	39/87 (45%)	34/83 (41%)	34/87 (39%)	45/87 (52%)
LITTERS (b)	27/35 (77%)	27/34 (79%)	25/34 (74%)	31/35 (89%)
POLY-3 RATE (c)	39/72.83	34/72.13	34/73.95	45/78.82
POLY-3 PERCENT (g)	53.6%	47.1%	46%	57.1%
TERMINAL (d)	24/46 (52%)	21/43 (49%)	23/50 (46%)	38/60 (63%)
FIRST INCIDENCE	489	300	268	593
STATISTICAL TESTS				
POLY 3	P=0.256	P=0.266N	P=0.219N	P=0.389
POLY 1.5	P=0.221	P=0.300N	P=0.238N	P=0.328
POLY 6	P=0.289	P=0.244N	P=0.204N	P=0.440
RAO-SCOTT	P=0.273	P=0.264N	P=0.218N	P=0.384
LITTER C-A/FISHERS	P=0.156	P=0.526	P=0.472N	P=0.171

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thymus **Ectopic Parathyroid Gland**				
LESION RATES				
OVERALL (a)	1/87 (1%)	2/83 (2%)	2/87 (2%)	2/87 (2%)
LITTERS (b)	1/35 (3%)	2/34 (6%)	2/34 (6%)	2/35 (6%)
POLY-3 RATE (c)	1/66.89	2/67.54	2/70.28	2/77.40
POLY-3 PERCENT (g)	1.5%	3%	2.9%	2.6%
TERMINAL (d)	0/46 (0%)	2/43 (5%)	2/50 (4%)	2/60 (3%)
FIRST INCIDENCE	690	737 (T)	737 (T)	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.500	P=0.503	P=0.517	P=0.550
POLY 1.5	P=0.474	P=0.495	P=0.509	P=0.531
POLY 6	P=0.528	P=0.512	P=0.527	P=0.570
RAO-SCOTT	P=0.481	P=0.469	P=0.482	P=0.522
LITTER C-A/FISHERS	P=0.425	P=0.489	P=0.489	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thymus **Hemorrhage**				
LESION RATES				
OVERALL (a)	2/87 (2%)	5/83 (6%)	5/87 (6%)	3/87 (3%)
LITTERS (b)	2/35 (6%)	5/34 (15%)	4/34 (12%)	3/35 (9%)
POLY-3 RATE (c)	2/67.68	5/68.38	5/73.32	3/78.28
POLY-3 PERCENT (g)	3%	7.3%	6.8%	3.8%
TERMINAL (d)	0/46 (0%)	0/43 (0%)	0/50 (0%)	0/60 (0%)
FIRST INCIDENCE	547	635	16	633
STATISTICAL TESTS				
POLY 3	P=0.513N	P=0.223	P=0.253	P=0.565
POLY 1.5	P=0.551N	P=0.213	P=0.240	P=0.541
POLY 6	P=0.471N	P=0.235	P=0.269	P=0.592
RAO-SCOTT	P=0.537N	P=0.248	P=0.277	P=0.565
LITTER C-A/FISHERS	P=0.542	P=0.202	P=0.323	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thymus **Hyperplasia Epithelial**				
LESION RATES				
OVERALL (a)	55/87 (63%)	59/83 (71%)	54/87 (62%)	38/87 (44%)
LITTERS (b)	32/35 (91%)	31/34 (91%)	30/34 (88%)	28/35 (80%)
POLY-3 RATE (c)	55/74.67	59/76.10	54/78.54	38/78.66
POLY-3 PERCENT (g)	73.7%	77.5%	68.8%	48.3%
TERMINAL (d)	38/46 (83%)	36/43 (84%)	33/50 (66%)	33/60 (55%)
FIRST INCIDENCE	464	300	450	492
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.349	P=0.302N	P<0.001N**
POLY 1.5	P<0.001N**	P=0.255	P=0.393N	P<0.001N**
POLY 6	P<0.001N**	P=0.493	P=0.206N	P<0.001N**
RAO-SCOTT	P<0.001N**	P=0.365	P=0.321N	P=0.002N**
LITTER C-A/FISHERS	P=0.077N	P=0.649N	P=0.483N	P=0.153N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thymus: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/87 (0%)	2/83 (2%)	1/87 (1%)	0/87 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	1/34 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/66.71	2/67.69	1/70.28	0/77.40
POLY-3 PERCENT (g)	0%	3%	1.4%	0%
TERMINAL (d)	0/46 (0%)	1/43 (2%)	1/50 (2%)	0/60 (0%)
FIRST INCIDENCE	---	699	737 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.402N	P=0.241	P=0.510	(e)
POLY 1.5	P=0.424N	P=0.235	P=0.505	(e)
POLY 6	P=0.380N	P=0.248	P=0.517	(e)
RAO-SCOTT	P=0.549N	P=0.455	P=0.698	(e)
LITTER C-A/FISHERS	P=0.593N	P=0.493	P=0.493	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thyroid Gland: C-Cell Hyperplasia				
LESION RATES				
OVERALL (a)	28/90 (31%)	30/90 (33%)	34/90 (38%)	38/89 (43%)
LITTERS (b)	24/35 (69%)	22/34 (65%)	25/35 (71%)	23/35 (66%)
POLY-3 RATE (c)	28/70.55	30/76.15	34/76.28	38/80.92
POLY-3 PERCENT (g)	39.7%	39.4%	44.6%	47%
TERMINAL (d)	25/48 (52%)	20/45 (44%)	23/50 (46%)	34/61 (56%)
FIRST INCIDENCE	531	550	450	492
STATISTICAL TESTS				
POLY 3	P=0.154	P=0.554N	P=0.329	P=0.226
POLY 1.5	P=0.103	P=0.515	P=0.271	P=0.151
POLY 6	P=0.226	P=0.474N	P=0.413	P=0.332
RAO-SCOTT	P=0.175	P=0.544N	P=0.336	P=0.240
LITTER C-A/FISHERS	P=0.500N	P=0.466N	P=0.500	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Thyroid Gland: Follicle Cyst				
LESION RATES				
OVERALL (a)	1/90 (1%)	0/90 (0%)	1/90 (1%)	0/89 (0%)
LITTERS (b)	1/35 (3%)	0/34 (0%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	1/69.46	0/73.31	1/71.88	0/79.19
POLY-3 PERCENT (g)	1.4%	0%	1.4%	0%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	1/50 (2%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	---	737 (T)	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Tissue NOS: Abdominal, Fat Necrosis				
LESION RATES				
OVERALL (a)	0/8 (0%)	5/11 (45%)	3/8 (38%)	2/6 (33%)
LITTERS (b)	0/7 (0%)	5/11 (45%)	3/7 (43%)	2/6 (33%)
POLY-3 RATE (c)	0/5.74	5/10.29	3/8.00	2/6.00
POLY-3 PERCENT (g)	0%	48.6%	37.5%	33.3%
TERMINAL (d)	0/3 (0%)	2/6 (33%)	2/7 (29%)	1/5 (20%)
FIRST INCIDENCE	---	578	516	720
STATISTICAL TESTS				
POLY 3	P=0.453	P=0.065	P=0.157	P=0.224
POLY 1.5	P=0.366	P=0.050*	P=0.126	P=0.192
POLY 6	P=0.555	P=0.083	P=0.199	P=0.266
RAO-SCOTT	P=0.375	P=0.072	P=0.154	P=0.220
LITTER C-A/FISHERS	P=0.268	P=0.054	P=0.096	P=0.192

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Tissue NOS: Fat Necrosis				
LESION RATES				
OVERALL (a)	6/8 (75%)	4/11 (36%)	4/8 (50%)	3/6 (50%)
LITTERS (b)	6/7 (86%)	4/11 (36%)	4/7 (57%)	3/6 (50%)
POLY-3 RATE (c)	6/7.64	4/9.69	4/7.34	3/5.93
POLY-3 PERCENT (g)	78.6%	41.3%	54.5%	50.6%
TERMINAL (d)	3/3 (100%)	4/6 (67%)	4/7 (57%)	3/5 (60%)
FIRST INCIDENCE	353	737 (T)	737 (T)	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.319N	P=0.126N	P=0.329N	P=0.307N
POLY 1.5	P=0.345N	P=0.118N	P=0.325N	P=0.328N
POLY 6	P=0.276N	P=0.137N	P=0.314N	P=0.272N
RAO-SCOTT	P=0.334N	P=0.146N	P=0.331N	P=0.317N
LITTER C-A/FISHERS	P=0.310N	P=0.057N	P=0.280N	P=0.217N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Trachea: Glands **Cyst**				
LESION RATES				
OVERALL (a)	1/89 (1%)	1/88 (1%)	0/89 (0%)	2/89 (2%)
LITTERS (b)	1/35 (3%)	1/34 (3%)	0/35 (0%)	2/35 (6%)
POLY-3 RATE (c)	1/68.83	1/71.90	0/71.70	2/79.00
POLY-3 PERCENT (g)	1.5%	1.4%	0%	2.5%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	0/50 (0%)	2/61 (3%)
FIRST INCIDENCE	737 (T)	699	---	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.397	P=0.751N	P=0.492N	P=0.548
POLY 1.5	P=0.386	P=0.756N	P=0.496N	P=0.530
POLY 6	P=0.409	P=0.745N	P=0.488N	P=0.566
RAO-SCOTT	P=0.425	P=0.725N	P=0.479N	P=0.544
LITTER C-A/FISHERS	P=0.369	P=0.746	P=0.500N	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Trigeminal Ganglion Degeneration				
LESION RATES				
OVERALL (a)	33/81 (41%)	21/77 (27%)	22/81 (27%)	28/75 (37%)
LITTERS (b)	23/35 (66%)	18/34 (53%)	18/35 (51%)	20/34 (59%)
POLY-3 RATE (c)	33/64.84	21/64.71	22/66.14	28/66.47
POLY-3 PERCENT (g)	50.9%	32.5%	33.3%	42.1%
TERMINAL (d)	26/43 (61%)	14/40 (35%)	14/43 (33%)	25/49 (51%)
FIRST INCIDENCE	634	628	493	626
STATISTICAL TESTS				
POLY 3	P=0.340N	P=0.021N*	P=0.026N*	P=0.195N
POLY 1.5	P=0.392N	P=0.032N*	P=0.035N*	P=0.264N
POLY 6	P=0.295N	P=0.013N*	P=0.018N*	P=0.139N
RAO-SCOTT	P=0.318N	P=0.027N*	P=0.032N*	P=0.202N
LITTER C-A/FISHERS	P=0.390N	P=0.202N	P=0.166N	P=0.366N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Urinary Bladder **Edema**				
LESION RATES				
OVERALL (a)	0/88 (0%)	3/88 (3%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	3/34 (9%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/67.74	3/71.90	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	4.2%	0%	0%
TERMINAL (d)	0/48 (0%)	2/45 (4%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	699	---	---
STATISTICAL TESTS				
POLY 3	P=0.264N	P=0.132	(e)	(e)
POLY 1.5	P=0.280N	P=0.127	(e)	(e)
POLY 6	P=0.248N	P=0.137	(e)	(e)
RAO-SCOTT	P=0.384N	P=0.242	(e)	(e)
LITTER C-A/FISHERS	P=0.309N	P=0.114	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Urinary Bladder Hemorrhage				
LESION RATES				
OVERALL (a)	0/88 (0%)	1/88 (1%)	1/90 (1%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	1/35 (3%)	0/35 (0%)
POLY-3 RATE (c)	0/67.74	1/71.75	1/72.70	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	1.4%	0%
TERMINAL (d)	0/48 (0%)	1/45 (2%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	417	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Urinary Bladder **Inflammation Acute**				
LESION RATES				
OVERALL (a)	3/88 (3%)	2/88 (2%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	3/35 (9%)	2/34 (6%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	3/68.27	2/71.75	0/71.88	0/79.63
POLY-3 PERCENT (g)	4.4%	2.8%	0%	0%
TERMINAL (d)	1/48 (2%)	2/45 (4%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	662	737 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.034N*	P=0.478N	P=0.112N	P=0.096N
POLY 1.5	P=0.035N*	P=0.487N	P=0.114N	P=0.103N
POLY 6	P=0.033N*	P=0.469N	P=0.109N	P=0.089N
RAO-SCOTT	P=0.076N	P=0.510N	P=0.182N	P=0.169N
LITTER C-A/FISHERS	P=0.038N*	P=0.514N	P=0.120N	P=0.120N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Urinary Bladder **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	0/88 (0%)	1/88 (1%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	1/34 (3%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	0/67.74	1/71.90	0/71.88	0/79.63
POLY-3 PERCENT (g)	0%	1.4%	0%	0%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	699	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Urinary Bladder: Urothelium Hyperplasia				
LESION RATES				
OVERALL (a)	1/88 (1%)	0/88 (0%)	0/90 (0%)	0/90 (0%)
LITTERS (b)	1/35 (3%)	0/34 (0%)	0/35 (0%)	0/35 (0%)
POLY-3 RATE (c)	1/67.74	0/71.75	0/71.88	0/79.63
POLY-3 PERCENT (g)	1.5%	0%	0%	0%
TERMINAL (d)	1/48 (2%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	737 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
RAO-SCOTT	(n)	(n)	(n)	(n)
LITTER C-A/FISHERS	(n)	(n)	(n)	(n)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Uterus **Adenomyosis**				
LESION RATES				
OVERALL (a)	0/90 (0%)	2/90 (2%)	2/90 (2%)	0/90 (0%)
LITTERS (b)	0/35 (0%)	2/34 (6%)	2/35 (6%)	0/35 (0%)
POLY-3 RATE (c)	0/69.46	2/73.31	2/71.88	0/79.63
POLY-3 PERCENT (g)	0%	2.7%	2.8%	0%
TERMINAL (d)	0/48 (0%)	2/45 (4%)	2/50 (4%)	0/61 (0%)
FIRST INCIDENCE	---	737 (T)	737 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.437N	P=0.250	P=0.246	(e)
POLY 1.5	P=0.461N	P=0.245	P=0.242	(e)
POLY 6	P=0.411N	P=0.255	P=0.250	(e)
RAO-SCOTT	P=0.506N	P=0.329	P=0.323	(e)
LITTER C-A/FISHERS	P=0.497N	P=0.239	P=0.246	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Uterus				
Cyst				
LESION RATES				
OVERALL (a)	5/90 (6%)	6/90 (7%)	7/90 (8%)	11/90 (12%)
LITTERS (b)	4/35 (11%)	4/34 (12%)	6/35 (17%)	9/35 (26%)
POLY-3 RATE (c)	5/69.46	6/73.47	7/71.88	11/79.87
POLY-3 PERCENT (g)	7.2%	8.2%	9.7%	13.8%
TERMINAL (d)	5/48 (10%)	5/45 (11%)	7/50 (14%)	10/61 (16%)
FIRST INCIDENCE	737 (T)	696	737 (T)	674
STATISTICAL TESTS				
POLY 3	P=0.089	P=0.539	P=0.405	P=0.152
POLY 1.5	P=0.074	P=0.522	P=0.394	P=0.128
POLY 6	P=0.108	P=0.556	P=0.420	P=0.181
RAO-SCOTT	P=0.134	P=0.543	P=0.427	P=0.198
LITTER C-A/FISHERS	P=0.051	P=0.629	P=0.367	P=0.109

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Uterus **Dilation**				
LESION RATES				
OVERALL (a)	8/90 (9%)	10/90 (11%)	11/90 (12%)	8/90 (9%)
LITTERS (b)	7/35 (20%)	10/34 (29%)	9/35 (26%)	8/35 (23%)
POLY-3 RATE (c)	8/70.44	10/75.46	11/74.41	8/82.15
POLY-3 PERCENT (g)	11.4%	13.3%	14.8%	9.7%
TERMINAL (d)	7/48 (15%)	5/45 (11%)	3/50 (6%)	2/61 (3%)
FIRST INCIDENCE	202	407	417	522
STATISTICAL TESTS				
POLY 3	P=0.364N	P=0.462	P=0.358	P=0.476N
POLY 1.5	P=0.422N	P=0.433	P=0.333	P=0.528N
POLY 6	P=0.300N	P=0.495	P=0.393	P=0.417N
RAO-SCOTT	P=0.388N	P=0.457	P=0.359	P=0.473N
LITTER C-A/FISHERS	P=0.536	P=0.265	P=0.388	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Uterus **Hemorrhage**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	1/90 (1%)	4/90 (4%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	1/35 (3%)	4/35 (11%)
POLY-3 RATE (c)	0/69.46	0/73.31	1/72.19	4/81.61
POLY-3 PERCENT (g)	0%	0%	1.4%	4.9%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	0/50 (0%)	0/61 (0%)
FIRST INCIDENCE	---	---	652	522
STATISTICAL TESTS				
POLY 3	P=0.008**	(e)	P=0.508	P=0.087
POLY 1.5	P=0.007**	(e)	P=0.504	P=0.077
POLY 6	P=0.009**	(e)	P=0.513	P=0.099
RAO-SCOTT	P=0.029*	(e)	P=0.544	P=0.142
LITTER C-A/FISHERS	P=0.006**	(e)	P=0.500	P=0.057

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Uterus **Inflammation**				
LESION RATES				
OVERALL (a)	4/90 (4%)	11/90 (12%)	8/90 (9%)	12/90 (13%)
LITTERS (b)	4/35 (11%)	9/34 (26%)	7/35 (20%)	11/35 (31%)
POLY-3 RATE (c)	4/69.64	11/75.87	8/72.88	12/80.82
POLY-3 PERCENT (g)	5.7%	14.5%	11%	14.9%
TERMINAL (d)	3/48 (6%)	6/45 (13%)	6/50 (12%)	8/61 (13%)
FIRST INCIDENCE	690	407	503	587
STATISTICAL TESTS				
POLY 3	P=0.115	P=0.071	P=0.205	P=0.061
POLY 1.5	P=0.091	P=0.062	P=0.195	P=0.048*
POLY 6	P=0.146	P=0.081	P=0.218	P=0.079
RAO-SCOTT	P=0.128	P=0.086	P=0.217	P=0.076
LITTER C-A/FISHERS	P=0.056	P=0.098	P=0.256	P=0.039*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Uterus **Inflammation Chronic**				
LESION RATES				
OVERALL (a)	0/90 (0%)	0/90 (0%)	4/90 (4%)	1/90 (1%)
LITTERS (b)	0/35 (0%)	0/34 (0%)	4/35 (11%)	1/35 (3%)
POLY-3 RATE (c)	0/69.46	0/73.31	4/72.70	1/79.63
POLY-3 PERCENT (g)	0%	0%	5.5%	1.3%
TERMINAL (d)	0/48 (0%)	0/45 (0%)	3/50 (6%)	1/61 (2%)
FIRST INCIDENCE	---	---	417	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.314	(e)	P=0.069	P=0.527
POLY 1.5	P=0.288	(e)	P=0.066	P=0.517
POLY 6	P=0.343	(e)	P=0.072	P=0.538
RAO-SCOTT	P=0.352	(e)	P=0.131	P=0.600
LITTER C-A/FISHERS	P=0.247	(e)	P=0.057	P=0.500

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Uterus: Cervix **Hyperplasia Stromal**				
LESION RATES				
OVERALL (a)	2/90 (2%)	1/90 (1%)	1/90 (1%)	1/90 (1%)
LITTERS (b)	2/35 (6%)	1/34 (3%)	1/35 (3%)	1/35 (3%)
POLY-3 RATE (c)	2/70.04	1/73.31	1/71.88	1/79.63
POLY-3 PERCENT (g)	2.9%	1.4%	1.4%	1.3%
TERMINAL (d)	1/48 (2%)	1/45 (2%)	1/50 (2%)	1/61 (2%)
FIRST INCIDENCE	550	737 (T)	737 (T)	737 (T)
STATISTICAL TESTS				
POLY 3	P=0.386N	P=0.484N	P=0.491N	P=0.456N
POLY 1.5	P=0.395N	P=0.491N	P=0.496N	P=0.472N
POLY 6	P=0.376N	P=0.478N	P=0.485N	P=0.438N
RAO-SCOTT	P=0.385N	P=0.469N	P=0.473N	P=0.449N
LITTER C-A/FISHERS	P=0.406N	P=0.511N	P=0.500N	P=0.500N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Uterus: Endometrium **Hyperplasia Cystic**				
LESION RATES				
OVERALL (a)	37/90 (41%)	43/90 (48%)	35/90 (39%)	46/90 (51%)
LITTERS (b)	28/35 (80%)	25/34 (74%)	23/35 (66%)	30/35 (86%)
POLY-3 RATE (c)	37/73.57	43/79.08	35/75.90	46/81.91
POLY-3 PERCENT (g)	50.3%	54.4%	46.1%	56.2%
TERMINAL (d)	28/48 (58%)	26/45 (58%)	23/50 (46%)	39/61 (64%)
FIRST INCIDENCE	489	300	503	492
STATISTICAL TESTS				
POLY 3	P=0.303	P=0.362	P=0.360N	P=0.278
POLY 1.5	P=0.242	P=0.297	P=0.401N	P=0.207
POLY 6	P=0.367	P=0.446	P=0.307N	P=0.362
RAO-SCOTT	P=0.323	P=0.370	P=0.366N	P=0.292
LITTER C-A/FISHERS	P=0.299	P=0.363N	P=0.141N	P=0.376

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD)
TERMINAL SACRIFICE AT 106 WEEKS

	Females			
DOSE	**0.0W/kg(CDMA)chr**	**1.5W/kg(CDMA)chr**	**3.0W/kg(CDMA)chr**	**6.0W/kg(CDMA)chr**
Uterus: Epithelium **Metaplasia**				
LESION RATES				
OVERALL (a)	48/90 (53%)	39/90 (43%)	28/90 (31%)	46/90 (51%)
LITTERS (b)	31/35 (89%)	25/34 (74%)	18/35 (51%)	28/35 (80%)
POLY-3 RATE (c)	48/81.10	39/80.96	28/75.37	46/85.20
POLY-3 PERCENT (g)	59.2%	48.2%	37.2%	54%
TERMINAL (d)	26/48 (54%)	21/45 (47%)	19/50 (38%)	33/61 (54%)
FIRST INCIDENCE	353	300	450	492
STATISTICAL TESTS				
POLY 3	P=0.350N	P=0.100N	P=0.003N**	P=0.298N
POLY 1.5	P=0.385N	P=0.102N	P=0.002N**	P=0.342N
POLY 6	P=0.317N	P=0.103N	P=0.005N**	P=0.264N
RAO-SCOTT	P=0.349N	P=0.122N	P=0.008N**	P=0.316N
LITTER C-A/FISHERS	P=0.257N	P=0.098N	P<0.001N**	P=0.256N

LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.
(b)	Number of litters with tumor-bearing animals/number of litters examined at site
(c)	Number of tumor-bearing animals/Poly-3 number
(d)	Observed incidence at terminal kill.
(e)	Value of statistic cannot be computed.
(f)	Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
(g)	Poly-3 adjusted lifetime tumor incidence.
(n)	No statistics are calculated if all dose groups have fewer than two tumors.
(I)	Interim sacrifice
(T)	Terminal sacrifice
#	Tumor rates based on numbers of animals necropsied.
*	To the right of any statistical result, indicates significance at (P<=0.05).
**	To the right of any statistical result, indicates significance at (P<=0.01).
N	Indicates a negative trend for all tests
	The Rao-Scott statistic performs the Poly-3 test with an adjustment for within-litter correlation.
	The Litter C-A/Fishers statistic compare directly the litter incidence rates.

*** END OF REPORT ***